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Identifying regulators of cytotoxic T cell function through molecular and genetic screening
Katharina Strege
Cytotoxic T lymphocytes (CTL) are crucial components of the adaptive immune system
that kill infected and tumourigenic cells. CTL killing requires focused secretion of cytotoxic
compounds from lytic granules. This process is known as degranulation. In this study, I
aimed to establish the CRISPR-Cas9 gene editing technology in primary T cells and to
optimise screening approaches to identify regulators of CTL killing.
The first half of the thesis focuses on primary mouse CTL. The CRISPR technology
was successfully optimised in CTL using Cas9-ribonucleoprotein complexes resulting in
efficient CRISPR-mediated loss of target proteins. Genes encoding known mediators of
CTL cytotoxicity, Rab27a, Munc13-4 and Prf1, were targeted using CRISPR. The resulting
samples were used to establish a flow cytometry-based assay that simultaneously measures
CTL degranulation and target cell death.
This assay enabled me to screen for mediators of CTL killing, while providing mechanistic
insight by detecting degranulation. The screen was informed by a transcriptomic study that
compared naive and effector CD8 T cells. 1803 significantly upregulated differentially
expressed genes [log2(fold change)>2] were identified. Functional annotation analysis
and literature research were used to select genes for the targeted CRISPR screen, which
highlighted the importance of HIF-1a and NFIL3 in CTL killing.
The second half of the thesis focuses on primary human CTL. The combined degranulation
and killing assay was further validated using patient-derived CTL, indicating its potential as
a diagnostic test. I showed that the assay is suitable for mid-sized screens using a library of
64 compounds targeting the NF-kB signalling pathway. Further opportunities for increasing
the scale of this screening technique are discussed.
viii
Finally, I successfully tested CRISPR using Cas9-ribonucleoprotein complexes in the
human system. Additionally, stable Cas9 expression through lentiviral transduction was
explored in primary CTL and related cell lines. This has the potential to allow selection of
cells expressing the CRISPR machinery, providing a cleaner experimental system and the
possibility of large-scale screening approaches.
In summary, the techniques established in this thesis will be valuable for studying
the genetics underlying CTL killing and the combined degranulation and killing assay
furthermore shows great potential for diagnostic purposes.
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1.1 Cytotoxic cells in the immune system
Our immune system protects us from disease and fights infections. It can broadly be
separated into two arms, the innate and the adaptive immune system. The innate immune
system immediately responds to defend the host, while the adaptive immune system launches
a highly specific and long-lasting response that takes several days to develop (Lowry and
Zehring, 2017; Pennock et al., 2013). Cytotoxic lymphocytes are found across the innate
and adaptive arms of the immune system (Russell and Ley, 2002). Natural killer (NK) cells
are part of the innate immune system, while cytotoxic T lymphocytes (CTL) are part of the
adaptive immune system (Russell and Ley, 2002; Topham and Hewitt, 2009). Activated T
cells that express the cluster of differentiation (CD) 8 co-receptor on their surface will be
referred to as CTLs throughout this thesis. However, it is important to note that CD4 T cells,
which are usually known for cytokine production, can also show cytotoxic activity (Jellison
et al., 2005; Pennock et al., 2013). Additionally, NK cells have been reported to develop
memory to antigens, a quality usually attributed to the adaptive immune system (Lowry and
Zehring, 2017).
CTLs recognise antigens presented in complex with major histocompatibility complex
(MHC) class I molecules on the cell surface (de la Roche et al., 2016). MHC class I surface
expression can be decreased in virally infected and tumour cells to prevent CTL mediated
cytotoxicity. However, cells lacking MHC class I surface expression can be recognised
and eliminated by NK cells (Mandal and Viswanathan, 2015; Topham and Hewitt, 2009).
Both NK cells and CTLs kill their target cells through the focused secretion of cytotoxic
compounds, which are stored in secretory lysosomes, referred to as lytic granules. Thereby
cytotoxic cells can kill infected and cancerous cells, protecting the body from disease (de la
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Roche et al., 2016; Topham and Hewitt, 2009). Defects in CTL and NK cell cytotoxicity
cause immunodeficiency disorders, which are discussed in detail in section 1.4.3. One of
the infections that affected patients frequently present with are Epstein-Barr virus infections,
indicating that CTL and NK cells are particularly important for effective responses to this
pathogen (Janka and Lehmberg, 2014). Additionally, cytotoxic T cells were shown to be
effective in the treatment of metastatic melanoma (Rosenberg et al., 2008).
1.2 The role of CTLs in the immune response
Each T cell expresses numerous copies of a unique T cell receptor (TCR) on its surface,
which recognises a specific peptide (antigen) presented by an MHC class I molecule. The
TCR is a heterodimer and associates with CD3e , g , d and z (Wucherpfennig et al., 2010).
Selection in the thymus gives rise to T cells that express TCRs that react to non-self peptides
displayed by MHC class I molecules (Harty and Badovinac, 2008). TCR variability is
mediated by rearrangement of the genes that encode them. It is estimated that up to 1018
different ab heterodimer TCRs can be produced (Cantrell, 2015). Due to the large repertoire
of naive T cells that are generated, T cells that recognise a particular peptide are rare, and
therefore need to undergo vast proliferation when they encounter their antigen in order to
destroy all diseased cells (Harty and Badovinac, 2008).
Naive CD8 T cells travel between the blood and secondary lymphoid organs, such as the
lymph nodes and spleen, where they interact with antigen presenting cells (APCs), such as
dendritic cells (Harty and Badovinac, 2008; Zhang and Bevan, 2011). If, for example, an
individual is infected by a virus, APCs acquire viral peptides at the site of infection. The
APCs then travel from the infected tissue to the secondary lymphoid organs to present the
antigens from the infectious agent to CD8 T cells (Harty and Badovinac, 2008). As each
naive CD8 T cell expresses a unique TCR, APCs may have to interact with many T cells
until they find one that recognises their antigen (Cooper and Herrin, 2010).
Three signals have to be received for naive T cell activation to occur (Mescher et al.,
2006). Firstly, the TCR of the naive CD8 T cell has to recognise the specific peptide presented
by the MHC class I molecule on the surface of the APCs (signal 1) (Brownlie and Zamoyska,
2013; Harty and Badovinac, 2008). In response to recognition, signalling molecules are
recruited to the TCR complex. The molecular effects of signal 1 will be discussed in more
detail in section 1.3. The naive T cell also has to receive co-stimulatory signals in order to be
activated (Signal 2). Receptors on the APCs interact with co-stimulatory receptors on the
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T cells. The best studied interaction is between CD28 on the T cells and B7.1 or B7.2 on
APCs (Williams and Bevan, 2007). This interaction stimulates survival, proliferation and
production of cytokines, such as interleukin (IL) 2 (Williams and Bevan, 2007). Cytokines,
such as IL-12 and type 1 interferons (IFNs) provide the third signal. They contribute to T cell
survival and expression of effector molecules, such as granzyme B (Harty and Badovinac,
2008; Mescher et al., 2006; Williams and Bevan, 2007).
Naive CD8 T cells that receive all three signals are triggered to differentiate into effector
CTL and proliferate extensively (Harty and Badovinac, 2008; Williams and Bevan, 2007).
Numerous transcription factors are activated downstream of TCR signalling. These induce a
transcriptional program that results in immense changes, including a doubling in cell size
(from 5 µm to 10 µm) (de la Roche et al., 2016), changes in metabolism (MacIver et al.,
2013) and proliferation status (Best et al., 2013; Brownlie and Zamoyska, 2013). In total, the
differentiation and clonal expansion processes are estimated to take 4-5 days (de la Roche
et al., 2016). The differences between naive and effector cells will be explored in more detail
in chapter 4.
Mature effector CTL leave the lymph node and enter peripheral tissues to kill diseased
cells at the site of infection (Zhang and Bevan, 2011). In the periphery, intracellular peptides
are continuously degraded by the proteasome inside the cell and the resulting peptides are
loaded into the peptide binding groove of MHC class I proteins in the endoplasmic reticulum
(Neefjes et al., 2011). Peptide-MHC class I complexes are then displayed on the cell surface.
This process happens in all nucleated cells of the body (Neefjes et al., 2011). The constant
monitoring of intracellular antigens by effector CTLs provides a crucial control mechanism
to ensure that the cells of the body are healthy. CTLs that recognise a peptide-MHC complex
eliminate the infected cell through the secretion of cytotoxic compounds, described in detail
in section 1.4, and also release cytokines such as IFNg and tumour necrosis factor (TNF)
(Harty and Badovinac, 2008; Parish and Kaech, 2009; Williams and Bevan, 2007).
The antigen-specific CTLs proliferate and kill target cells, normally resulting in the
elimination of the infection. After 5-8 days, CTL numbers decline in a ’contraction’ phase,
driven by apoptosis (Harty and Badovinac, 2008; Parish and Kaech, 2009). It is estimated
that CTL numbers are reduced by 90-95% (Harty and Badovinac, 2008; Williams and Bevan,
2007). This is important, as the immune response has to be terminated to limit damage to the
body (Brownlie and Zamoyska, 2013).
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However, some cells survive the contraction phase as interaction with antigen also results
in the formation of memory T cells (Harty and Badovinac, 2008; Williams and Bevan, 2007).
Memory T cells reside in secondary lymphoid organs and peripheral tissues and provide
long term protection against the disease. In response to re-stimulation by encountering the
antigen for a second time, memory cells can respond rapidly, producing larger amounts of
effector cells than during the first immune response (Parish and Kaech, 2009). This ability
of the adaptive immune system to form long-lasting memory cells is crucial for the concept
of vaccination (Harty and Badovinac, 2008). Memory T cells were found 75 years post
vaccination in humans, demonstrating the longevity of this response (Williams and Bevan,
2007).
It is therefore clear that CTLs are crucial to protect us from diseases. This is also
demonstrated by disorders that are caused when these lymphocytes are not functioning
properly, as discussed in detail in section 1.4.2 and 1.4.3. The following section outlines the
intricate mechanism underlying T cell activation.
1.3 TCR signalling
When naive T cells in the secondary lymphoid organs recognise a peptide-MHC complex on
APCs, or an effector CTL encounters a target cell in the periphery, binding of the TCR to
the peptide MHC complex triggers a complex signalling response (Brownlie and Zamoyska,
2013).
The main signalling events triggered by TCR engagement are outlined in Figure 1.1.
The lymphocyte-specific protein tyrosine kinase (Lck) is activated downstream of the TCR
and CD3 (Brownlie and Zamoyska, 2013). The TCR depends on Lck, which binds to
the cytoplasmic portion of the CD8 co-receptor, to initiate a complex signalling cascade
(Brownlie and Zamoyska, 2013). Lck phosphorylates tyrosine residues in immunoreceptor
tyrosine-based activation motifs (ITAMS) of the cytoplasmic portions of CD3 g , d , e
and z chains (Brownlie and Zamoyska, 2013). z -chain-associated protein kinase of 70
kDa (Zap70) binds to phosphorylated ITAMs, and Lck also phosphorylates Zap70 (Smith-
Garvin et al., 2009). Zap70 is activated by phosphorylation and undergoes conformational
change. Subsequently, Zap70 is able to phosphorylate target molecules, such as the linker for
activation of T cells (LAT) (Brownlie and Zamoyska, 2013) and Src homology 2 domain-
containing leukocyte protein of 76 kDa (SLP76) (Smith-Garvin et al., 2009).






































Fig. 1.1 TCR signalling. When the TCR recognises a peptide in the context of MHC class
I, Lck phosphorylates CD3 chains, as well as Zap70. This triggers the formation of the
LAT signalosome, which consists of several molecules, including SLP76, ITK, VAV1 and
PLCg1. The conversion of PI(4,5)P2 to DAG and IP3 by PLCg1 is required for the activation
of several signalling molecules and transcription factors, including NFAT, ERK1/2 and
NF-kB. This extensive transcription factor activation results in drastic changes in gene
expression that are crucial for the differentiation of naive T cells to effector CTL (Brownlie
and Zamoyska, 2013; Cantrell, 2015; Navarro and Cantrell, 2014).
Phosphorylated LAT allows recruitment of further signalling molecules, forming the LAT
signalosome, which is crucial for the production of downstream signals (Figure 1.1). ZAP70
phosphorylates SLP76, which subsequently forms a complex with LAT, phospholipase Cg1
(PLCg1), interleukin-2-inducible T cell kinase (ITK) and Vav Guanine Nucleotide Exchange
Factor 1 (VAV1) (Brownlie and Zamoyska, 2013; Smith-Garvin et al., 2009). This complex
is crucial for rearrangement of the actin cytoskeleton. Furthermore, PLCg1 activation drives
conversion of phosphatidylinositol-(4,5)-biphosphate (PI(4,5)P2) from the plasma membrane
to the second messenger molecules inositol-(1,4,5)-triphosphate (IP3) and diacylglycerol
(DAG), which triggers complex downstream events (Brownlie and Zamoyska, 2013; Macian,
2005).
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Production of IP3 results in the release of Ca2+ from the endoplasmic reticulum into the
cytosol, which in turn leads to the activation of the nuclear factor of activated T cells (NFAT)
transcription factor (Hogan et al., 2003; Macian, 2005). Meanwhile, DAG activates Ras and
members of the protein kinase D (PKD) and protein kinase C (PKC) families, resulting in
the activation of transcription factors (Navarro and Cantrell, 2014).
PKCq interacts with CARMA1, which leads to activation of the IKK complex, that in
turn can induce nuclear factor-kB (NF-kB) transcriptional activity (Matsumoto et al., 2005;
Navarro and Cantrell, 2014; Paul and Schaefer, 2013). The NF-kB signalling pathway is
outlined in more detail in chapter 5. Additionally, PKCs were found to be important for cell
adhesion in effector CTL and centrosome polarisation to the contact site between the CTL and
its target (Letschka et al., 2008; Quann et al., 2009). PKD2, which is phosphorylated by PKCs,
is needed for transcriptional upregulation of IL-2 and IFNg (Navarro and Cantrell, 2014).
Production of DAG also triggers RAS activation through RAS guanine nucleotide exchange
factor RAS guanyl-releasing protein 1 (RAS-GRP1) (Brownlie and Zamoyska, 2013). RAS,
in turn, leads to activation of the mitogen-activated protein kinase (MAPK) cascade and
subsequent activation of the extracellular signal-regulated kinase (ERK) (Brownlie and
Zamoyska, 2013).
In its entirety, this signalling network results in complex intracellular events and changes
in gene transcription. In naive T cells this drives differentiation to effectors. In CTL, TCR
signalling induces cytoskeletal rearrangements, secretion of lytic granules and cytokine
production (Brownlie and Zamoyska, 2013; de la Roche et al., 2016). TCR signalling has
furthermore been speculated to be important for re-filling the cytotoxic content of the lytic
granules, ensuring that pre-formed granules are available continuously (Isaaz et al., 1995).
1.4 CTL effector function
In response to TCR signalling naive T cells undergo proliferation, metabolic changes and
differentiate into effector CTL over several days. In effector CTLs, peptide-MHC complex
recognition leads to the rapid polarisation of lytic granules to the contact site between the
CTL and the target cell. Within 20 minutes (min) of target cell recognition, the CTL has
secreted the cytotoxic proteins contained within lytic granules, resulting in target cell death,
and detached from the dying target cell to find its next target (Ritter et al., 2015). CTLs
are therefore serial killers that can eliminate one target after another within a short period
of time. Some of the intracellular events typically associated with the CTL killing process
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are outlined in brief in Figure 1.2. The precise molecular steps underlying this process are







Fig. 1.2 CTL killing process. CTL travel around the body, searching for cells that present
their specific peptide in complex with MHC class I. As the CTL searches for target cells it
adapts a migratory shape with a protruding leading edge and a uropod. Lytic granules and
the centrosome are mostly found at the back of the cell. Upon recognition of a target cell,
the CTL forms a tight cell-to-cell contact with the target cell. Subsequently, the centrosome
polarises towards the contact site, delivering the lytic granules to the immunological synapse.
The lytic granule membrane fuses with the plasma membrane, secreting the cytotoxic contents
which trigger apoptosis of the target cell. The entire process from target cell recognition to
detachment of the CTL takes around 20 min. The CTL can immediately interact with another
target, acting as a serial killer (Ritter et al., 2015; Stinchcombe et al., 2001b).
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1.4.1 Formation of the immunological synapse
Both naive T cells and effector CTL form a tight contact with their APCs and target cells,
respectively. This contact is known as the immunological synapse (IS) and has a highly
organised structure (Figure 1.3). Actin depletes from the centre of the synapse forming an
outer ring around the IS, known as the distal supramolecular activation complex (dSMAC)
(Carisey et al., 2018; Ritter et al., 2015; Stinchcombe et al., 2001b, 2006). The actin
depletion is suggested to be of functional significance as it removes the actin barrier for
granule secretion (Ritter et al., 2017). A ring of adhesion molecules, also referred to as the
peripheral SMAC (pSMAC), lies within the dSMAC. The pSMAC is reported to contain
adhesion molecules such as LFA-1 and talin (Grakoui et al., 1999; Monks et al., 1998;
Potter et al., 2001; Stinchcombe et al., 2001b). TCRs and associated signalling molecules,
such as Lck and PKCq can be found at the centre of the IS, also referred to as the central
SMAC (cSMAC) (Grakoui et al., 1999; Monks et al., 1998; Stinchcombe et al., 2001b).
TCRs are internalised for recycling from the cSMAC (Das et al., 2004). The secretory zone,
where the centrosome docks and cytolytic components are released, lies adjacent to the
cSMAC (Ritter et al., 2015; Stinchcombe et al., 2006). The polarisation of the centrosome,
which is the microtubule organising centre in CTL, is thought to be crucial for the focused
delivery of lytic granules to the IS (Stinchcombe and Griffiths, 2007; Stinchcombe et al.,
2006). Granule polarisation happens within 6-10 min of target cell recognition (Ritter et al.,
2015). The importance of centrosome polarisation during this process was demonstrated by
knockdown of Cep83, a distal appendage protein necessary for the centrosome to dock at the
plasma membrane (Tanos et al., 2013). Cep83 knockdown decreases lytic granule secretion
(Stinchcombe et al., 2015). Additionally, other organelles have been reported to polarise
towards the IS, such as the Golgi apparatus (Stinchcombe et al., 2006).
Recently, actin depletion was found to be mediated by changes in the composition of
the plasma membrane as the IS forms. As explained in section 1.3, PLCg1 is recruited
to the plasma membrane upon TCR signalling, and hydrolyses PI(4,5)P2 to DAG and IP3.
It has been observed that loss of PI(4,5)P2 correlates with actin depletion at the centre
of the IS (Gawden-Bone et al., 2018; Ritter et al., 2015, 2017). In the absence of a TCR
stimulus, phosphatidylinositol 4-phosphate 5-kinase type I (PIP5K), which controls PI(4,5)P2
formation, and actin were found at the plasma membrane. Upon TCR engagement, PLCg1
conversion of PI(4,5)P2 to DAG leads to a reduction of negative charge in this area of the
plasma membrane, resulting in detachment of PIP5K. However, if PIP5K was modified so
that it was maintained across the IS membrane, actin depletion did not occur. Furthermore,
centrosome docking as well as lytic granule secretion was reduced, and target cell killing










Fig. 1.3 Structure of the IS. The en face view of a CTL in contact with its target shows the
formation of a ’bulls-eye configuration’ at the IS (Stinchcombe and Griffiths, 2007). TCRs
and associated signalling molecules form the cSMAC, which lies at the centre of the IS
together with the secretory domain, where the centrosome docks and the contents of lytic
granules are released (Ritter et al., 2015; Stinchcombe et al., 2006). Centrosome polarisation
is thought to be crucial for the delivery of lytic granules precisely to the contact site between
CTL and target. A ring of adhesion molecules (pSMAC) surrounds the cSMAC, containing
molecules such as LFA-1 and talin. Actin depletes from the centre of the IS and forms the
dSMAC (Ritter et al., 2015; Stinchcombe et al., 2006). Once granules are released, actin
depletion is reversed, preventing further lytic granule secretion (Ritter et al., 2017).
was impaired when PIP5K was maintained at the membrane (Gawden-Bone et al., 2018).
This demonstrates the importance of membrane composition for actin depletion, although
the precise molecular events linking PI(4,5)P2 to actin still remain to be elucidated.
1.4.2 Lytic granule contents
CTLs kill target cells through the release of lytic granules that contain cytotoxic proteins.
Polarisation of the centrosome precisely delivers the lytic granules to the contact site between
the CTL and the target cell (Stinchcombe and Griffiths, 2007; Stinchcombe et al., 2006).
Lytic granules contain granzymes, granulysin, perforin and Fas ligand (FasL), which are
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crucial for inducing apoptosis of target cells (Bossi and Griffiths, 2005). The content of the
lytic granules, and how they trigger target cell death, are described in detail below.
Perforin
The lytic granule component perforin multimerises to form pores in the target cell membrane
in order to allow cytotoxic proteins to enter target cells (Lopez et al., 2013a,b; Tschopp and
Nabholz, 1990). These pores are big enough to allow granzymes to pass into the cytosol
of the target cell (Law et al., 2010). Perforin contains a C2 domain that is required for
membrane binding via a calcium dependent mechanism (Uellner et al., 1997). While perforin
is active at high calcium concentrations and neutral pH in the extracellular environment upon
secretion, it was found to be inactive at the low pH within lytic granules (Kuta et al., 1989;
Young et al., 1987).
The importance of perforin for cytotoxicity was demonstrated by a study using a knockout
(KO) mouse model (Kägi et al., 1994a) and in patients, where perforin deficiency causes
an immunodeficiency disorder, familial hemophagocytic lymphohistiocytosis (FHL) type 2
(Kogawa et al., 2002; Stepp et al., 1999). Several other inherited genetic defects can cause
FHL, which has 5 subtypes (Janka and Lehmberg, 2014), covered in more detail in section
1.4.3. Patients affected by FHL present with hemophagocytic lymphohistiocytosis (HLH),
which is a clinical syndrome characterised by extremely high cytokine levels. This is the
result of continuous stimulation of the immune system due to an inability to resolve the
infection (Janka and Lehmberg, 2014).
Granzymes
Another component of the lytic granules are granzymes, a family of serine proteases, which
were shown to constitute 1-2% of the overall CTL proteome (Hukelmann et al., 2016).
Five granzymes have been identified in humans (granzyme A, B, H, K and M) and several
additional granzymes have been identified in mice (Bots and Medema, 2006; Masson and
Tschopp, 1987). Granzymes are made in an inactive form, and cleavage by cathepsin C in
the granules triggers enzymatic activation (Trapani, 2001). As granzymes are inactive at low
pH, CTLs likely store these potentially dangerous proteins in granules to avoid autolysis
(Masson et al., 1986). To enter the target cell, granzymes rely on perforin to form pores in
the plasma membrane (Bots and Medema, 2006; Lopez et al., 2013a,b; Trapani and Sutton,
2003). Interestingly, deficiency in individual granzymes does not cause severe phenotypes
in mice, in contrast to the effect observed in response to perforin deficiency, likely due to
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redundancy between granzymes (Trapani, 2001).
Granzyme B is the most widely studied granzyme and triggers caspase-dependent
apoptosis in target cells (Bots and Medema, 2006). CTLs derived from granzyme B deficient
mice showed a defect in their ability to trigger rapid apoptosis in target cells (Heusel et al.,
1994). Granzyme B cleaves the protein BID, which together with other proteins permeabilises
the outer membrane of mitochondria, triggering the release of pro-apoptotic proteins (Bots
and Medema, 2006; Trapani, 2001). Release of cytochrome c activates caspase-9, which
cleaves further caspases, triggering a cascade leading to apoptosis (Bots and Medema, 2006).
Granzyme B can additionally trigger apoptosis by cleaving members of the anti-apoptotic
BCL-2 protein family, as well as cleaving certain caspases, such as caspase 3 and caspase 8
(Bots and Medema, 2006). Granzyme B has been suggested to cleave several other molecular
targets, including cytoskeletal proteins and proteins in the nuclear membrane (Bots and
Medema, 2006; Trapani and Sutton, 2003). Granzyme A is reported to induce target cell
apoptosis by triggering loss of mitochondrial inner membrane potential, which results in
release of reactive oxygen species that induce DNA damage and impair DNA repair (Bots
and Medema, 2006). Granzyme A does not act via caspases, but is also reported to target
histone H1 and nuclear lamins (Bots and Medema, 2006).
Granulysin
Another cytotoxic protein found in lytic granules is granulysin (Peña et al., 1997; Peña and
Krensky, 1997). Granulysin triggers membrane damage and mitochondrial damage in target
cells, resulting in cytochrome c release and activation of caspases that trigger apoptosis
(Krensky and Clayberger, 2009). The acidic pH in the lytic granules is needed for the
processing of an inactive 15 kilodalton (kDa) version of granulysin to the lytic 9 kDa version
(Hanson et al., 1999; Peña and Krensky, 1997). Additionally, the lower molecular weight
(MW) version has reduced cytolytic activity at acidic granule pH (Hanson et al., 1999). This
again highlights the importance of lytic granules to store these potentially dangerous proteins
so no harm is caused to the CTL (Hanson et al., 1999).
Fas ligand
In addition to the perforin mediated pathway, CTLs can also trigger target cell death through
interaction between FasL (also known as CD95L), with Fas (also known as CD95 and APO-1)
on the surface of target cells (Krammer, 2000; Strasser et al., 2009). As FasL is also stored in
the lytic granules, the expression of FasL on the cell surface is carefully regulated by focused
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secretion of lytic granules in response to TCR signals (Bossi and Griffiths, 1999). Upon
interaction with FasL, the Fas receptor on target cells induces the formation of a signalling
complex containing, among others, caspase 8, which can trigger apoptosis upon activation
(Krammer, 2000; Strasser et al., 2009). Fas signalling can additionally trigger cell death
through the BCL-2 regulated apoptotic pathway involving release of pro-apoptotic molecules
from mitochondria (Krammer, 2000; Strasser et al., 2009). Experiments using CTL deficient
in FasL and perforin indicated that these two pathways are the main killing pathways used by
CTL (Kägi et al., 1994b).
All lytic granule components discussed here have in common that they need to be released
from the lytic granules in order to be exposed to the target cell and trigger apoptosis. Fusion
between the lytic granule membrane and the plasma membrane results in localisation of FasL
on the CTL plasma membrane and secretion of perforin, granzymes and granulysin. The
precise molecular mechanism underlying the fusion of these two membranes will be covered
in the next section.
1.4.3 Secretion of lytic granules
The lysosomal membrane fuses with the plasma membrane to release granule content. This
process is also referred to as degranulation (Betts et al., 2003). Through precise secretion
into the secretory cleft, lytic granules are delivered to the target cell without causing damage
to surrounding cells (Stinchcombe and Griffiths, 2003). The machinery required for CTL
degranulation was in large part identified through the study of patients suffering from
inheritable immunodeficiency conditions, where CTL and NK cells are unable to kill target
cells efficiently, such as FHL and Griscelli syndrome (GS) type 2 (de Saint Basile et al.,
2010; Janka and Lehmberg, 2014). These immunodeficiency conditions and their genetic
causes are summarised in Table 1.1.
FHL is divided into several subtypes according to the underlying genetic defect; mutations
in PRF1, encoding perforin, cause FHL2 (Stepp et al., 1999), mutations in MUNC13-4 cause
FHL3 (Feldmann et al., 2003), FHL4 is caused by defects in the gene encoding syntaxin-11
(STX11) (zur Stadt et al., 2005), FHL5 is caused by mutations in MUNC18-2 (Côte et al.,
2009; zur Stadt et al., 2009) and GS2 was found to be caused by mutations in RAB27A
(Ménasché et al., 2000). Mutations in these genes were found to result in a degranulation
defect in patient-derived CTL and NK cells, with the exception of mutations in PRF1,
which impairs target cell killing downstream of degranulation (de Saint Basile et al., 2010).
Therefore, despite having intact lytic granule content, cytotoxic lymphocytes from FHL3,
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FHL4, FHL5 and GS2 patients cannot kill target cells. This indicated that the proteins
encoded by the mutated genes are important for the secretion of lytic granule content (de
Saint Basile et al., 2010).
Table 1.1 List of genes and proteins associated with CTL-related immunodeficiencies.
HLH is a hyperinflammatory syndrome that is reported to lead to the following
clinical symptoms: fever, cytopenia, hepatosplenomegaly, hypertriglyceridemia and/or
hypofibrinogenemia, and hemophagocytosis in bone marrow, lymph nodes or spleen.
Additionally, patients can present with further symptoms, such as neurological
abnormalities (Henter et al., 2007; Janka and Lehmberg, 2014). HLH = hemophagocytic
lymphohistiocytosis, FHL = Familial hemophagocytic lymphohistiocytosis, GS = Griscelli
syndrome, CHS = Chediak-Higashi Syndrome and HSP = Hermansky-Pudlak Syndrome.
Disorder Gene/protein affected Symptoms Reference
FHL1 genetic locus = 9q22,gene/protein not known HLH (Ohadi et al., 1999)
FHL2 PRF1, PRF1 HLH (Stepp et al., 1999)
FHL3 MUNC13-4, MUNC13-4 HLH (Feldmann et al., 2003)
FHL4 STX11, STX11 HLH (zur Stadt et al., 2005)
FHL5 MUNC18-2, MUNC18-2 HLH (zur Stadt et al., 2009),(Côte et al., 2009)
GS2 RAB27A, RAB27A HLH,partial albinism
(Griscelli et al., 1978),





(Barbosa et al., 1996),
(Perou et al., 1996),
(Nagle et al., 1996),





(Hermansky and Pudlak, 1959),
(Dell’Angelica et al., 1999),





(Ammann et al., 2016)
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FHL and GS2 tend to have an early onset, usually within the first year of life. Patients
present with hyperinflammation caused by a highly activated but unsuccessful immune
response. Symptoms include fever, hepatosplenomegaly, cytopenia and these disorders
can be fatal in the absence of treatment. Currently, the treatment options are limited to
immunosuppressants and the only potential cure is hematopoietic stem cell transplantation
(Janka and Lehmberg, 2014). The fact that genetic defects in proteins involved in the
lytic granule secretion process, or lytic granule content in the case of perforin, cause
immunodeficiency disorders highlights how important the function of cytotoxic cells is
to maintain a healthy immune system.
Furthermore, other immunodeficiency disorders, such as Chediak-Higashi Syndrome
(CHS) and Hermansky-Pudlak Syndrome (HPS), enabled the identification of proteins
important in the maturation of lytic granules and their transport to the IS (de Saint Basile
et al., 2010; Janka and Lehmberg, 2014). CHS is caused by defects in LYST, which is
reported to cause a lysosome fission defect, resulting in granules that are too big to fuse at
the IS (Baetz et al., 1995; Durchfort et al., 2012). HPS type 2 is caused by defects in AP3b
(Dell’Angelica et al., 1999) and HPS type 10 is caused by defects in AP3d (Ammann et al.,
2016). Some mutations in AP3 have been shown to result in an inability of lysosomes to
move towards the centrosome (Clark and Griffiths, 2003; Clark et al., 2003).
Analysis of the mutations underlying immunodeficiency disorders has therefore been
crucial for the identification of the molecular machinery involved in lytic granule movement
to the IS, degranulation and target cell killing. Simultaneously, these disorders demonstrate
the devastating consequences of defective cytotoxic cells on an organismal level. Below I
focus on the key regulators of the final secretion steps at the IS and their point of action in
the secretion process is visualised in Figure 1.4.
RAB27A
In RAB27A depleted cells, granules can polarise to the IS but they can not dock at the plasma
membrane and fusion between the lytic granule membrane and the plasma membrane is
impaired (Stinchcombe et al., 2001a). RAB27A has also been implicated in the secretion of
granules from granulocytes (Munafó et al., 2007) and in pigment secretion in melanocytes
(Hume et al., 2001; Wu et al., 2001), indicating that RAB27A also regulates fusion between
vesicles and the plasma membranes in these biological settings. This explains why GS2
patients often present with albinism as well as immunodeficiency (Stinchcombe et al., 2004).















defective in RAB27A deficient cells (GS2)
Priming: 
defective in MUNC13-4 deficient cells (FHL3)
Fusion: 
defective in STX11 deficient cells (FHL4)
defective in MUNC18-2 deficient cells (FHL5)
Perforin pore formation: 
defective in PRF1 deficient cells (FHL2)
Fig. 1.4 Proteins crucial for lytic granule secretion at the IS. Lytic granule secretion
is an intricate process that involves fusion between the lytic granule membrane and the
plasma membrane. Key regulators of this process are RAB27A, MUNC13-4, MUNC18-2
and several SNARE proteins. Defects in some of the proteins highlighted in this figure
cause immunodeficiency diseases, indicated in brackets on the left. RAB27A interacts with
MUNC13-4 (Neeft et al., 2005; Shirakawa et al., 2004) and SLPs, which are located on the
plasma membrane in CTL (Holt et al., 2008; Kuroda et al., 2002b; Kurowska et al., 2012;
Ménasché et al., 2008). MUNC13-4 additionally interacts with STX11 and phospholipids
(Boswell et al., 2012; Elstak et al., 2011). MUNC18-2 and STX11 bind to one another (Cetica
et al., 2010; Côte et al., 2009; zur Stadt et al., 2009) and STX11 was found to form a SNARE
complex with the plasma membrane SNARE SNAP23 and one of the VAMP vesicle SNAREs
(Spessott et al., 2017; Ye et al., 2012).
RAB27A is a member of the Rab protein family, which control numerous cellular
processes by acting as molecular switches (Wennerberg et al., 2005). Rab proteins are known
to regulate vesicle trafficking, docking and fusion with target membranes by interacting with
certain effector molecules. RAB27A switches between its guanosine triphosphate (GTP)-
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bound active state and its guanosine diphosphate (GDP)-bound inactive state. The switch
is regulated by guanine nucleotide exchange factors (GEFs), which trigger GTP binding,
and GTPase-activating proteins (GAPs), which trigger GTP hydrolysis. The structure of the
"switch" regions in Rab proteins is altered depending on whether GDP or GTP is bound,
thereby affecting binding to effector proteins (Fukuda, 2013). Additionally, membrane
attachment, which is mediated by prenylation of Rab cysteine residues, is important for Rab
protein function (Pereira-Leal et al., 2001).
RAB27A can bind different effector proteins in different cell types in its active GTP-
bound form. Several RAB27A effector molecules have been identified, including Synaptotagmin-
like protein lacking C2 domains (SLACs), Synaptotagmin-like proteins (SLPs), and MUNC13-
4. SLAC2-a (also known as melanophilin) and SLP1-5 interact with GTP-bound RAB27A
via their SLP-homology domain (SHD) (Kuroda et al., 2002a,b). Melanophilin interacts with
both RAB27A and MYO5A in melanocytes, thereby mediating melanosome transport and
pigment secretion, but melanophilin is not expressed in CTLs and can therefore not mediate
lytic granule secretion (Fukuda et al., 2002; Hume et al., 2002; Nagashima et al., 2002;
Wu et al., 2002). In contrast, several SLPs were found to be expressed in CTLs, and the
expression of a dominant-negative SHD construct, interfering with binding of SHD-domain
containing proteins to RAB27A, reduced CTL killing capability (Holt et al., 2008; Ménasché
et al., 2008). CTLs derived from Slp1 and Slp2-a KO mice did not show reduced CTL
cytolytic activity, indicating that different SLP family members functioned as RAB27A
effectors in CTL (Holt et al., 2008). Subsequently, SLP3 was found to be important for
lytic granule secretion in CTL (Kurowska et al., 2012). MUNC13-4 has been shown to bind
GTP-bound RAB27A in hematopoietic cells, but in contrast to the other RAB27A effector
proteins mentioned above, MUNC13-4 does not contain an SHD domain (Neeft et al., 2005;
Shirakawa et al., 2004). The role of MUNC13-4 in lytic granule secretion will be covered in
more detail in the following subsection.
Missense mutations observed in GS2 patients have led to the identification of functionally
important RAB27A residues. For example, the Trp73Gly mutation was found to result in
RAB27A protein with reduced GTP hydrolysis and reduced binding to MUNC13-4 and
melanophilin, suggesting that residue 73 is important for binding to both of these effector
proteins (Menasche et al., 2003; Neeft et al., 2005). A further study investigating the
underlying mutations of GS2 patients that presented with immunodeficiency symptoms
but not albinism identified that mutations in Arg141, Tyr159 and Ser163 resulted in loss
of interaction of RAB27A with MUNC13-4, while interaction with melanophilin was
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maintained (Cetica et al., 2015). This demonstrates clearly that RAB27A is able to control
secretion in different cell types via interaction with cell-specific effector proteins.
MUNC13-4
In cells carrying mutations in MUNC13-4, granules can dock at the plasma membrane but
cannot secrete their contents, suggesting that MUNC13-4 is crucial for lytic granule priming
before fusion can occur (Elstak et al., 2011; Feldmann et al., 2003). MUNC13-4 contains
two MUNC13-homology domains (MHD1 and MHD2) with a C2 calcium binding domain
either side (C2A and C2B) (Feldmann et al., 2003). RAB27A and MUNC13-4 have been
shown to interact with one another in platelets, mast cells and CTL (Elstak et al., 2011; Neeft
et al., 2005; Shirakawa et al., 2004). MUNC13-4 binds to GTP-bound RAB27A, but not
GDP-bound RAB27A, and this binding required the N-terminal region between the C2A and
MHD1 domains of MUNC13-4 (Ménager et al., 2007; Neeft et al., 2005). A study using a
truncated construct comprised of MUNC13-4 residues 240-290 suggested that this region
is sufficient for binding to RAB27A (Elstak et al., 2011), however these findings should be
treated with caution as the truncated construct may not be folded correctly.
MUNC13-4 has additionally been shown to interact with soluble NSF attachment protein
receptor (SNARE) proteins, such as STX11, as well as syntaxin-1, -2 and -4, which are crucial
in membrane fusion (Boswell et al., 2012). While the C2A domain is important for binding
to SNAREs in a calcium dependent manner, the C2B domain binds to phosphatidylserine
containing membranes (Boswell et al., 2012). MUNC13-4 was furthermore shown to co-
immunoprecipitate with MUNC18-2 in platelets (Al Hawas et al., 2012). MUNC13-4 has
therefore been linked to both MUNC18-2 and STX11, two components thought to be required
for the final fusion between the lytic granule membrane and plasma membrane (Côte et al.,
2009; zur Stadt et al., 2009).
MUNC18-2 and STX11
Mutations that cause defects in STX11 and MUNC18-2 cause FHL4 and FHL5, respectively.
These two proteins bind to one another and loss of either protein results in a degranulation
defect (Bryceson et al., 2007; Cetica et al., 2010; Côte et al., 2009; zur Stadt et al., 2009,
2005).
STX11 belongs to the SNARE protein family but does not contain a C-terminal transmembrane
domain, instead it is thought to associate with membranes by palmitoylation of the C-terminus
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(Tang et al., 1998; Valdez et al., 1999). Studies in cells derived from FHL4 patients and Stx11
KO mice showed that STX11 controls CTL and NK cell degranulation (Arneson et al., 2007;
Bryceson et al., 2007; D’Orlando et al., 2013; zur Stadt et al., 2005).
MUNC18-2 is part of the Sec1/Munc18-like protein family, members of which function
in membrane fusion by interacting with SNAREs (Carr and Rizo, 2010; Südhof and Rothman,
2009). Members of the MUNC18 family of proteins have arch-shaped structures and their
cavity binds to syntaxins and SNARE complexes (Misura et al., 2000; Yu et al., 2013).
MUNC18-2 binds to the N-terminal peptide of STX11 and MUNC18-2 mutations that cause
FHL5 (Arg39Pro, Leu130Ser, Glu132Ala and Pro334Leu) mapped onto the surface of the
structure, indicating that these residues may be important for the interaction of MUNC18-2
with SNARE proteins (Hackmann et al., 2013).
In addition to showing that MUNC18-2 and STX11 interact, patient studies have shown
that MUNC18-2 deficient cells also show decreased STX11 levels, leading to the conclusion
that MUNC18-2 acts as a chaperone, stabilising STX11 (Bin et al., 2013; Cetica et al.,
2010; Côte et al., 2009; zur Stadt et al., 2009). Additionally, some mutations in MUNC18-2
(Arg65Gln/Trp) have been identified that do not lead to loss of protein or loss of STX11
binding (Spessott et al., 2015). Instead these mutant proteins seem to stabilise STX11, but
interfere with SNARE complex assembly, thereby still blocking secretion and still causing
FHL-symptoms in affected individuals (Spessott et al., 2015). In summary, MUNC18-2 is
both a chaperone of STX11 and may also be involved in membrane fusion as it can control
SNARE complex assembly (Spessott et al., 2017).
STX11 has been described to form a SNARE complex with synaptosome associated
protein (SNAP)23 and vesicle-associated membrane protein (VAMP)3 or VAMP8 to regulate
fusion between the vesicle membrane and the plasma membrane (Al Hawas et al., 2012;
Spessott et al., 2017; Valdez et al., 1999; Ye et al., 2012). Spessott et al. (2017) showed
that MUNC18-2 and STX11 interact with VAMP8 and SNAP23 in human CTL, and that
knockdown of VAMP8 reduces CTL cytotoxicity. However, different VAMPs may be able
to participate in CTL degranulation, and could be important during vesicle maturation, as
well as fusion at the IS. In addition to reduced degranulation and cytolytic activity observed
in CTL derived from Vamp8 KO mice, CTL derived from Vamp2 KO mice showed similar
phenotypes (Loo et al., 2009; Matti et al., 2013). Furthermore, VAMP7 knockdown in NK
cells decreased degranulation and cytotoxicity (Marcet-Palacios et al., 2008). These results
indicate partial redundancy between different VAMPs in the degranulation process.
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It is the intricate interaction of the proteins summarised in Figure 1.4, and perhaps further
unknown proteins, that leads to the final secretion of cytotoxic granule content into the
secretory cleft between the CTL and the target cell, which subsequently leads to target cell
death.
1.4.4 Detachment from target and serial killing
Upon degranulation, actin recovers forming a barrier for further lytic granule secretion
(Ritter et al., 2015, 2017). Detachment of CTLs from their target cells was shown to
depend on the CTL sensing target cell apoptosis (Jenkins et al., 2015). In the absence of
perforin, or if the caspase response in the target cell was inhibited, the time that CTLs and
targets remained conjugated was extended fivefold, from around 8 min to 40 min (Jenkins
et al., 2015). Furthermore, cytokine and chemokine secretion from CTLs was increased
in response to this continuing attachment. Sustained secretion of IFNg caused production
of proinflammatory cytokines from other immune cells, such as IL-6 from macrophages
(Jenkins et al., 2015). These findings provide a potential molecular mechanism for how
the dangerous hyperinflammatory state observed in FHL2 patients is generated. In healthy
individuals, the caspase-dependent signal prompts the CTL to detach from its target, so that
it can move on to kill the next target cell (Jenkins et al., 2015).
A crucial question that remains largely unanswered is how the secreted proteins damage
the membrane of the targets, but not the CTL plasma membrane. The CTL membrane is
not generally resistant to perforin, as CTLs could be used as targets and be killed by other
CTLs when loaded with appropriate peptide (Lopez et al., 2013a). Degranulation has been
suggested to protect from perforin pore formation (Lopez et al., 2013a). Additionally, CTLs
were found to strain the surface of their target cell (Basu et al., 2016). Perforin pore formation
and target killing were enhanced when target cell tension was increased (Basu et al., 2016).
Further studies will be necessary to explain this phenomenon fully.
1.5 Measuring CTL function with the degranulation assay
In addition to the secretion of lytic granule contents, transmembrane proteins of the granules
translocate to the cell surface when the lytic granule membrane fuses with the plasma
membrane (Betts et al., 2003; Peters et al., 1991). The transmembrane proteins include
lysosomal-associated membrane protein 1 (LAMP1, also known as CD107a), as well as
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LAMP2 (also known as CD107b) and LAMP3 (also known as CD63) (Peters et al., 1991).
These proteins are only found at low levels on the plasma membrane of unstimulated cytotoxic
lymphocytes. Upon lytic granule secretion, LAMP levels on the cell surface of CTLs and
NK cells are transiently increased and can be used as a marker for degranulation (Alter
et al., 2004; Betts et al., 2003). An assay has been developed that measures the increase in
cell surface exposure of LAMP1 over time (Betts et al., 2003). The exposure of LAMP1
to the extracellular environment allows binding of fluorescently-conjugated antibodies that
recognise LAMP1, which enable the identification of cells that degranulated (Figure 1.5)
(Alter et al., 2004). Betts et al. (2003) showed that LAMP1 could be detected on the cell
surface within 30 min of T cell stimulation, and that LAMP1 levels peaked after 4-5 hours
(h). After degranulation, LAMP1 and the antibody bound to it are internalised from the
plasma membrane into an acidic vesicle, as shown by the quenching of some fluorochromes
(Figure 1.5) (Betts et al., 2003).
The level of degranulation was found to correlate to cytokine secretion, loss of intracellular
perforin and target cell lysis (Alter et al., 2004; Betts et al., 2003). Traditional assays, such
as the chromium release assay (Brunner et al., 1968), quantify CTL effector function by
measuring the resulting target cell death. In contrast, the degranulation assay does not give a
direct readout of CTL killing, but gives a direct readout of effector cell activation. As this
was shown to correlate with target cell lysis, it gives an indication of the cytotoxic capability
of CTLs (Betts et al., 2003).
The degranulation assay is currently used for the diagnosis of putative FHL patients
(Bryceson et al., 2012; Chiang et al., 2013). While it can give an insight into which genes
should be sequenced, the assay cannot detect the FHL2 phenotype, as degranulation is not
impaired in perforin deficient cells (Bryceson et al., 2012; Janka and Lehmberg, 2014).
Furthermore, the LAMP1 degranulation assay has been used to isolate tumour reactive CTLs
from patients after vaccination (Rubio et al., 2003). In this thesis, I use the degranulation
assay to screen for regulators of CTL function. The concept of the degranulation assay, as
well as the different in vitro activation stimuli used in this study, are explained in Figure 1.5.






































Fig. 1.5 Principle of the degranulation assay.
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Fig. 1.5 Principle of the degranulation assay. In this thesis I used the degranulation assay
to measure functional activation of primary mouse and human CTL. Mouse CTL were either
derived from OT-I mice or wild-type (WT) mice. A OT-I CTL express a transgenic TCR that
recognises a peptide derived from the ovalbumin (OVA) protein in the context of MHC class I.
EL4 lymphoma cells pulsed with OVA peptide were used as target cells for OT-I CTL. B CTL
derived from WT mice and human CTL were activated with an antibody recognising mouse
or human CD3e , respectively. The mastocytoma cell line P815 expresses Fc receptors on its
surface and can therefore bind to the constant region of antibodies. The variable region of
the aCD3e antibody can then bind to CD3e on the CTL, triggering TCR signalling. In both
experimental set-ups, a fluorescently-conjugated antibody recognising LAMP1 is added to
the cell culture supernatant. Upon exposure of LAMP1 to the plasma membrane through lytic
granule secretion, the aLAMP1 antibody can bind to LAMP1 and remain bound even upon
internalisation of LAMP1. This enables the identification of CTLs that have been activated
by the stimulus.
1.6 Use of CTL for medical purposes
T cells have become of great interest medically due to their successful use for cancer treatment.
The treatment options can be broadly separated into cell-based and antibody-based therapies.
1.6.1 Cell-based therapy
Several different cell-based approaches have been used to treat cancer patients. Initially
tumour-infiltrating lymphocytes that recognise tumour antigens were isolated from patient
samples, expanded in vitro and re-introduced into the patient after lymphodepletion (Rosenberg
et al., 2008). This showed promising results in metastatic melanoma. From patients where
tumour infiltrating lymphocytes could be isolated, this approach was reported to trigger a
response in 50% of the patients. Around 20% of the patients were complete responders, with
complete tumour regression over a 3 year follow up period (Rosenberg et al., 2011).
Since tumour infiltrating lymphocytes can be difficult to obtain, two related approaches
have been developed that use peripheral T cells of the patients and modify them in vitro
to recognise cancer cells. This is achieved through the incorporation of artificial receptors,
either genetically-engineered TCRs or chimeric antigen receptors (CARs), which specifically
recognise cancer antigens (Sadelain, 2016).
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CARs consist of a single-chain variable region of an antibody linked to intracellular
signalling components of the TCR to trigger T cell activation. In recent years, CARs have
been developed further to also include co-stimulatory domains, such as CD28 (Fesnak
et al., 2016; Maher et al., 2002; Sadelain et al., 2013). After genetic modification, the
CAR-expressing T cells are transferred back into the patient. Treating patients suffering
from acute lymphoblastic leukemia with CARs targeting CD19 expressing cells has shown
clinical success, achieving complete remission in 90% of the patients in one study (Maude
et al., 2014). Treatment with CTL containing a genetically-modified TCR showed success in
melanoma treatment (Morgan et al., 2006).
Both the engineered TCR and the CAR approach have advantages and disadvantages.
CARs can recognise any cell surface antigen without the need for it to be presented by an
MHC molecule. Additionally, the choice of different TCR signalling components and co-
stimulatory domains provides flexibility in CAR design (Sadelain et al., 2013). Genetically-
modified TCRs have the advantage of allowing recognition of intracellular peptides and are
therefore able to target a broader range of tumour antigens (Corrigan-Curay et al., 2014).
A big challenge that both approaches face is to identify molecular targets for immunotherapy,
which should ideally be cancer-specific antigens that are not expressed in healthy tissues
(Corrigan-Curay et al., 2014). T cells can identify even very low antigen expression levels
in normal tissues, leading to off-target attacks and adverse effects (Coulie et al., 2014;
Fesnak et al., 2016). Additionally, successful tumour clearance by cell-based therapies often
coincides with other symptoms of hyperactivation of the immune system, such as cytokine
release syndrome, and such side effects require additional treatment (Fesnak et al., 2016).
However, the effects of the cell-based immunotherapy treatment can be long-lasting, resulting
in an improvement of patient survival, likely due to the memory capabilities of the adaptive
immune response (Sharma et al., 2017).
1.6.2 Antibody-based therapy
Antibody-based therapies, also known as immune checkpoint blockage, function by counteracting
T cell inhibition. Inhibitory molecules, such as cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) that binds to B7 ligands and therefore competes with the co-stimulatory molecule
CD28, can inhibit the T cell response (Krummel and Allison, 1995). Blocking CTLA-
4 through the use of antibodies results in enhanced T cell effector function and tumour
clearance (Leach et al., 1996). The CTLA-4 checkpoint inhibitor, ipilimumab, has been
successfully used for treatment of advanced melanoma in patients, and has been shown to
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improve survival (Hodi et al., 2010; Robert et al., 2011). Similarly to cell-based therapies,
some toxicity is also observed with antibody-based therapies due to the enhancement of the
immune response, requiring systemic steroid treatment (Sharma et al., 2017).
Antibodies against another inhibitory receptor, programmed cell death 1 (PD-1), or its
ligand PD-L1, can similarly enhance T cell function, and showed success in clinical trials
(Okazaki et al., 2013; Zou et al., 2016). Pembrolizumab and nivolumab, two antibodies that
recognise PD-1, and atezolimumab, an antibody recognising PD-L1, have been approved for
treatment of a variety of cancer types (Sharma et al., 2017).
Combined treatment with PD-1 and CTLA-4 antibodies has shown even more promise
than individual treatments in melanoma patients (Larkin et al., 2015; Postow et al., 2015;
Wolchok et al., 2013). Additional immune checkpoints, such as lymphocyte activation
gene 3 (LAG-3) and T Cell ITIM Domain (TIGIT), are being explored for checkpoint
blockage therapy (Topalian et al., 2015). This highlights the need to identify further immune
checkpoints that could be potential therapeutic targets. In contrast to cell-based therapies,
the antibody-based approach requires recurrent treatment. Studies that are investigating the
effect of combining checkpoint blockade and cell-based therapies are currently ongoing
(Fesnak et al., 2016).
Interestingly, there are some patients that do not respond to immunotherapy or relapse
after an initial response (Sharma et al., 2017; Sucker et al., 2014). Therefore, a better
understanding of how CTL killing is mediated at a genetic and molecular level is desperately
needed to inform both cell- and antibody-based therapies.
1.7 Techniques used for functional analysis of genes in primary
T cells
Genetic modification of primary cells is a powerful way to study the function of genes and
their products. One common approach to assess the function of genes is to investigate the
phenotypes caused in response to disruption of gene expression. This method of targeting
the gene of interest directly to subsequently investigate the phenotype is generally referred
to as reverse genetics. This is in contrast to forward genetic approaches, which screen for
interesting phenotypes in response to random mutagenesis and only subsequently try to
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identify the particular genetic modification that has been introduced (Doyle et al., 2012).
There are several different ways to disrupt expression of a gene in primary cells. For all
approaches, reagents that modify gene expression have to be delivered to cells in culture. The
delivery methods can be broadly separated into viral and non-viral methods. Viral delivery,
also referred to as transduction, results in stable expression of the delivered material, due
to integration into the host genome. Non-viral methods include lipid-based reagents, such
as lipofectamine, and electroporation, also referred to as nucleofection (Kim and Eberwine,
2010). Depending on the nature of the transfected material, expression after non-viral transfer
can be stable or transient. For example, transposons encoding the gene of interest can result
in stable genetic modification by integration into the host genome. Meanwhile nucleofected
DNA plasmids, synthetic RNA or protein are generally only expressed transiently (Hackett
et al., 2010; Kim and Eberwine, 2010).
With regards to primary T cells, it has been found that both lipid-based reagents and
nucleofection can be toxic (Chicaybam et al., 2013; Ebert et al., 1997). Meanwhile, viral
transduction may trigger an inflammatory reaction and carries the risk of causing detrimental
mutations in the host genome due to random insertion. Additionally, there are restrictions
on the size of a construct that a virus can contain while maintaining infectivity (Kim and
Eberwine, 2010; Ramezani and Hawley, 2002). It is therefore clear that genetic modification
of primary T cells is technically challenging.
One way to circumvent these challenges is by using mouse models, where gene expression
can be deleted permanently, or conditionally using the Cre/loxP or FLP/FRT recombination
systems. Recombination systems allow for conditional KO of genes in certain cell or tissue
types, or at certain time points in the mouse’s life (Bouabe and Okkenhaug, 2013). KO mice
can be generated by incorporating the desired genetic change into the genome of an embryonic
stem cell by homologous recombination. This involves introduction of DNA, e.g. encoding
a selection marker, flanked by sequences homologous to the desired insertion site, thereby
disrupting the sequence of the gene of interest upon incorporation. Modified embryonic
stem cells can be selected for using the selection marker and are subsequently injected
into early-stage mouse embryos, resulting in mice that have the gene of interest knocked
out in tissues derived from the modified embryonic stem cells (Bouabe and Okkenhaug,
2013). Subsequent breeding generates homozygous KO mice, which can be used for in vivo
experiments, or primary cells can be harvested from the mice for in vitro studies.
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While mouse models are a powerful tool to study gene function, manipulation of
gene expression directly in cells can be advantageous as it can yield results more quickly.
Subsequently, I describe two methods that are commonly used to disrupt protein expression
in cells, one technique that functions at the messenger RNA (mRNA) level, small interfering
RNAs (siRNA), and another that functions at the DNA level, clustered regularly interspaced
short palindromic repeats (CRISPR).
siRNAs have been widely used to silence gene expression in mammalian cells, including
primary T cells (Stinchcombe et al., 2015). In this approach, siRNAs form a complex with
the RNA-induced silencing complex (RISC). Functional RISC particles contain a single
stranded siRNA that binds to its complementary mRNA. The RISC complex also contains
an RNase which cleaves the mRNA, leading to post transcriptional gene silencing and
therefore a reduction in protein expression (Meister and Tuschl, 2004). This mechanism of
gene silencing has been used to affect the expression of individual genes as well as gene
expression on a genome-wide scale. However, often only partial protein knockdown is
achieved, and the knockdown will only be maintained while the siRNA is present (Joung
et al., 2017).
In recent years, the discovery of the CRISPR system and its use for gene editing has
revolutionised this field by enabling the creation of KOs in mammalian cells where protein
expression is permanently lost (Hsu et al., 2014). CRISPR has been used to modify the
genome of many species, including human and mouse (Cho et al., 2013; Cong et al., 2013;
Doudna and Charpentier, 2014; Jinek et al., 2013; Li et al., 2013; Mali et al., 2013). The
system uses CRISPR-associated proteins (Cas), such as Cas9, an endonuclease that cuts
DNA and causes double-stranded breaks. Cas9 is guided to a specific region in the genome
by RNAs. In bacteria, the system requires two RNAs to function. Firstly, it requires the
CRISPR RNA (crRNA) which is the reverse complement of the target site in the genome and
binds to the target site by Watson-Crick base pairing. The second RNA that is required is the
trans-activating crRNA (tracrRNA), which forms a duplex with the crRNA and is important
for complex formation with Cas9 (Doudna and Charpentier, 2014). For genome-editing
approaches, the crRNA and tracrRNA duplex has been combined into one molecule to give a
single guide RNA (sgRNA) (Jinek et al., 2012). The target sequence in the genome must
contain a protospacer adjacent motif (PAM) in order for Cas9 to bind and a cut to occur (Jinek
et al., 2012; Sternberg et al., 2014). The PAM sequence therefore limits which sequences
can be cut in the genome. However, the PAM sequence that is recognised varies between
different Cas nucleases (Cong et al., 2013).
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After the Cas9-mediated cut occurred, cell intrinsic DNA repair pathways are triggered
and it is the inaccuracy of the DNA repair mechanisms that result in the desired editing of
the genome (Hsu et al., 2014). Endonuclease cutting leaves behind a double-stranded break
that is repaired by the non-homologous end-joining (NHEJ) or homology-directed repair
(HDR) pathways (Hsu et al., 2014). The error-prone NHEJ is induced in the absence of a
repair template and can introduce insertions or deletions (indels) during repair (Hsu et al.,
2014). Indels may cause frameshift mutations, resulting in gene disruption. Precise genome
editing using HDR is also possible, and provides the opportunity to incorporate a specific
DNA template containing homology sequences to the cut site. However, HDR occurs less
frequently and is therefore more challenging (Hsu et al., 2014; Komor et al., 2017; Ran et al.,
2013).
CRISPR allows to KO individual genes, and therefore allows to examine gene function
in a clean experimental system. Several different technical approaches to use CRISPR for
genome-editing purposes have been developed. Transient expression of CRISPR components
is achieved through the transfection of plasmids or ribonucleoprotein complexes (RNPs),
which contain recombinant Cas9 protein and synthetic crRNA and tracrRNA (Kim et al.,
2014). Stable expression of CRISPR components has been achieved through lentiviral
delivery (Hsu et al., 2014; Shalem et al., 2014; Wang et al., 2014a). The CRISPR approach
has furthermore been scaled up to a genome-wide level using lentiviral sgRNA libraries,
which has given powerful insights into genes that regulate cell viability and resistance to
drugs (Shalem et al., 2014; Wang et al., 2014a).
It is clear that using CRISPR in primary CTL has immense clinical potential, and could
be used to further enhance the immunotherapy approaches outlined in section 1.6. Clinical
trials using CAR T cells in combination with CRISPR-mediated disruption of PD-1 are
currently ongoing (Cornu et al., 2017). Related gene-editing technologies, such as zinc finger
nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have already
been used clinically (Fesnak et al., 2016). ZFNs have been used to KO C-C motif chemokine
receptor 5 (CCR5), a crucial co-receptor for the human immunodeficiency virus (HIV), in
autologous CD4 T cells. Gene-edited CD4 T cells were infused back into patients and this
treatment was found to decrease the abundance of HIV RNA in the peripheral blood (Tebas
et al., 2014). Allogeneic CAR T cells, where TALENs had been used to KO the endogenous
TCR to prevent graft-versus-host disease, were used to treat patients with acute lymphocytic
leukemia (Qasim et al., 2017). In addition to TCR KO, TALENs were used to KO CD52 in the
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therapeutic CAR T cells. This enabled targeting of the patients’ CD52 expressing cancerous
cells using an antibody against CD52, without affecting the transferred CAR T cells. This use
of genetically-modified T cells resulted in a remarkable clinical outcome (Qasim et al., 2017).
Together, these studies demonstrate the great potential of genome editing in primary
human T cells for clinical purposes. Optimisation of the techniques used to deliver the
CRISPR components to primary T cells, as well as a more thorough understanding of the
fundamental biology underlying CTL function, will contribute to the advancement of this
field.
1.8 Aims of this thesis
The work in this thesis aimed to identify regulators of CTL killing through screening
approaches. Engineering the genome of CTLs was explored in order to provide a clean
experimental system to investigate the involvement of individual genes in the CTL killing
process. The currently known regulators of cytotoxic function have largely been identified
using cells derived from patients suffering from immunodeficiency disorders or KO mouse
strains. The hypothesis is that in addition to the proteins outlined in section 1.4.2 and 1.4.3
there are further proteins important for CTL cytotoxic function, perhaps functioning at the
secretion step or further upstream, that remain to be discovered. This thesis aimed to establish
the CRISPR Cas9 technique in primary T cells and to discover regulators of CTL function
through screening using the CRISPR-Cas9 technique and chemical compounds. Furthermore,
the work in this thesis contributes to the goal to perform large-scale screens in primary T
cells in order to understand the molecular mechanisms underlying CTL function at large.
• Aim 1: Develop strategies to use CRISPR-Cas9 in primary mouse CD8 T cells
and establish a robust protocol that generates KO at high efficiency and disrupts
gene expression reproducibly.
In chapter 3, I focus on establishing the CRISPR technology in primary mouse CTL
(mCTL) using RNP complexes, which contained recombinant Cas9 protein, synthetic
crRNAs and tracrRNA. CRISPR-mediated gene editing had not been performed in
primary mouse T cells at the start of this project. I targeted genes whose protein
products are known to be important for CTL killing (Rab27a, Prf1 and Munc13-4)
to confirm that CRISPR generated KOs at an efficiency that allowed detection of a
phenotype in functional assays, such as the degranulation assay.
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• Aim 2: Develop an assay to measure cytotoxic capabilities of CTL at scale. Test
the newly developed method in combination with a CRISPR screen and a compound
library screen to identify regulators of CTL function.
Since one of the aims of this project was to identify regulators of CTL function, an
assay that measures killing as well as degranulation was desirable. The set up of such
an assay is described in chapter 3.
To inform a targeted CRISPR screen, I compared gene expression between naive and
effector CD8 T cells using RNA-sequencing (RNA-seq), described in chapter 4. The
underlying hypothesis was that genes that are highly expressed in activated but not
naive CD8 T cells are likely to be important for effector CTL functions, including
killing capability. I used the readout of this transcriptomic dataset to select a set of
genes for a targeted CRISPR screen. Samples were screened using the combined
degranulation and killing assay, which was set up in chapter 3, in order to identify if
any of these genes regulated CTL function.
In chapter 5 I investigated whether the combined degranulation and killing assay can
also be used in human CTL (hCTL) using samples derived from FHL2 and FHL3
patients. I furthermore tested the scalability of the assay using a compound library that
targeted the NF-kB signalling pathway.
• Aim 3: Establish protocols to use the CRISPR-Cas9 technique in primary human
CD8 T cells.
An alternative CRISPR screening approach to using RNP complexes would be to stably
transduce CTL with a lentivirus encoding Cas9 and sgRNAs. In contrast to the RNP
approach, lentiviral transduction would allow for the incorporation of a fluorescent
marker or an antibiotic resistance gene, which could be used to select edited cells.
As the lifespan of mCTLs is limited to around 10 days in tissue culture, they are not
suitable for a long selection procedure. However, this approach could be applied to






2.1.1 Cell culture conditions and media
The media compositions for all cell types used in this study are listed in Table 2.1. Fetal
bovine serum (FBS) (Labtech) was heat inactivated at 56  C for 30 min before addition
to Roswell Park Memorial Institute (RPMI, Gibco, #21875-034 or Sigma, #R8758) or
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, #41966-029) media. All media
contained antibiotics (penicillin (pen) , streptomycin (strep) ) (Sigma, #P0781) and was
filter sterilised through a 0.22 µm filter. Mouse and human T cell media will subsequently
be referred to by their abbreviations: human T cell media (hTCM) , mouse T cell media
(mTCM).
All centrifugation steps were performed at 200xg for 5-10 min at room temperature
(RT) unless otherwise indicated. Cells were cultured at 37  C and 10% CO2 in a humidified
atmosphere.
2.1.2 Primary mouse T cell culture
Mice
Mice were bred under specific pathogen-free conditions in accordance with UK home office
guidelines. T cells from OT-I mice (Hogquist et al., 1994) (genotype OT-I Rag1tm1Bal on
a C57BL/6 background) express a TCR that specifically recognises amino acids 257-264
(peptide sequence: SIINFEKL) of the chicken OVA protein presented in the context of
H-2Kb MHC class I molecules. This peptide is referred to as ’OVA peptide’ or simply ’OVA’
32 Materials and Methods
Table 2.1 Cell culture media.
Name Composition Source
Human T cell media (hTCM) RPMI 1640 Gibco, #21875-034, Sigma, #R8758
2% (v/v) recombinant IL-2 protein Produced in-house (Ruprecht et al., 2005)
5% (v/v) human serum Sigma, #H6914
2 mM (1% (v/v)) L-glutamine Sigma, #G7513
1 mM (1% (v/v)) sodium pyruvate Gibco, #11360-039
50 µM b -mercaptoethanol Gibco, #31350-010
100 U/ml penicillin, 0.1 mg/ml streptomycin Sigma, #P0781
Mouse T cell media (mTCM) RPMI 1640 Gibco, #21875-034, Sigma, #R8758
20 ng/ml recombinant murine IL-2 Peprotech, #212-12
10 % (v/v) heat-inactivated FBS Labtech
2 mM (1% (v/v)) L-glutamine Sigma, #G7513
1 mM (1% (v/v)) sodium pyruvate Gibco, #11360-039
50 µM b -mercaptoethanol Gibco, #31350-010
100 U/ml penicillin, 0.1 mg/ml streptomycin Sigma, #P0781
Target cell media DMEM Gibco, #41966-029
10 % (v/v) heat-inactivated FBS Labtech
100 U/ml penicillin, 0.1 mg/ml streptomycin Sigma, #P0781
HEK media DMEM Gibco, #41966-029
10 % (v/v) heat-inactivated FBS Labtech
YT media RPMI 1640 Gibco, #21875-034, Sigma, #R8758
2% (v/v) recombinant IL-2 protein Produced in-house (Ruprecht et al., 2005)
10 % (v/v) heat-inactivated FBS Labtech
2 mM (1% (v/v)) L-glutamine Sigma, #G7513
1 mM (1% (v/v)) sodium pyruvate Gibco, #11360-039
50 µM b -mercaptoethanol Gibco, #31350-010
100 U/ml penicillin, 0.1 mg/ml streptomycin Sigma, #P0781
Jurkat media RPMI 1640 Gibco, #21875-034, Sigma, #R8758
10 % (v/v) heat-inactivated FBS Labtech
100 U/ml penicillin, 0.1 mg/ml streptomycin Sigma, #P0781
throughout this thesis. Due to breeding on a Rag1 -/- background, all OT-I T cells express
the same TCR from the double positive stage in T cell development and are CD8-positive.
This system allows uniform stimulation upon addition of OVA peptide in vitro, resulting in
CTL that can kill EL4 target cells loaded with OVA.
C57BL/6N WT mice were obtained through the 3i Consortium (Wellcome Trust Sanger
Institute). Spleens from C57BL/6 Cas9 mice, where Cas9 under the control of the human
EF1a promoter was inserted into the Rosa26 locus (Tzelepis et al., 2016), were kindly
provided by Dr Gabriel Balmus and Dr Kosuke Yusa (Wellcome Trust Sanger Institute).
Spleens from ashen mice (Wilson et al., 2000) were kindly provided by Dr Melina Schuh
(MRC Laboratory for Molecular Biology).
2.1 Cell culture 33
Preparation and stimulation of murine splenocytes
Spleens were manually disrupted using a sterile syringe plunger and resulting splenocytes
were filtered through a 70 µm cell strainer before centrifugation at 200xg for 10 min. For
OT-I splenocytes, each pellet was resuspended in 100 ml mTCM (Table 2.1) containing 10
nM OVA peptide (Anaspec, #AS-60193-5) and cultured at 37  C for 3 days. From day 3
onwards, cells were washed daily and resuspended at roughly 1x106 cells/ml. OT-I cells
were used in functional assays from day 6 - 9 post in vitro stimulation.
To stimulate splenocytes derived from WT, Cas9 or ashen mice, 6 well plates were
coated with 0.5 µg/ml aCD3e (clone Bio500A2, eBioscience, #16-0033-86) and 1 µg/ml
aCD28 (clone 37.51, eBioscience, #16-0281-86) overnight at 4  C. 13.6x106 splenocytes
were seeded per well in 8 ml mTCM on the pre-coated plates. Cells were cultured for 48 h at
37  C and 10% CO2. The resulting stimulated T cells were washed, resuspended at 1x106
cells/ml in fresh mTCM and transferred to uncoated plates. Subsequently, mCTL were split
every 1-2 days and functional assays were performed from day 6 - 9 post in vitro stimulation.
CD8 T cells usually grew out to >80% during expansion, but were purified using the mouse
CD8a T cell isolation kit (Miltenyi Biotec, #130-104-075) in experiments where a pure CD8
population was required.
2.1.3 Primary human T cell culture
Phytohaemagglutinin (PHA)-blasts from FHL patient samples (Table 2.2) were kindly
provided by Professor Stephan Ehl (Medical center, University of Freiburg). T cells derived
from healthy donors (HDs) were obtained from buffycoat (NHS Blood and Transplant Centre).
Peripheral blood mononuclear cells (PBMCs) were isolated from buffycoats by Ficoll-Paque
(GE healthcare, #17-1440-02) gradient centrifugation and washed 5x in RPMI containing 1%
FBS.
Human T cells were stimulated with 1 µg/ml PHA (Sigma, #L1668) and allogeneic
PBMCs derived from buffycoat residue (NHS Blood and Transplant Centre). Allogeneic
PBMCs were isolated as described for HDs, followed by irradiation at 3000 radiation
absorbed dose (rad) of gamma rays prior to addition to human T cells. Cells were cultured
in hTCM (Table 2.1) at 37  C and 10% CO2. Cells were expanded when confluent, roughly
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Table 2.2 Details of mutations in FHL patients. Cells were derived from patients that
presented with FHL2, caused by mutations in PRF1, or FHL3, caused by mutations in
MUNC13-4. Patient mutations are described according to published guidelines (Ogino et al.,
2007). Mutations are indicated as homozygous (hom) if the same mutation is present on both
alleles, heterozygous (het) if only one allele is affected by the mutation and compound het if
both alleles are affected, but the mutations differ on each allele. The abbreviation ’c.’ stands
for coding DNA and is followed by the exact nucleotide mutation at the DNA level (del =
deletion). Intronic locations are numbered with reference to exonic sequences (+1 indicates
that the mutation affects an intron). The abbreviation ’p.’ stands for the protein amino acid
sequence and is followed by the change in amino acids (three letter code) caused by the
mutation (fs = frameshift, X = early stop codon). The affected exons are given in square
brackets.
Patient FHL subtype Mutation
6981 FHL2 hom c.1288G>C; p.Asp430His [Exon 3]
3026 FHL2 compound het c.272C>T; p.Ala91Val [Exon 2] and c.1213C>T; p.Gln405X [Exon 3]
392 FHL2 hom c.1349C>T; p.Thr450Met [Exon 3]
4166 FHL2 c.112G>A; p.Val38Met and c.272C>T; p.Ala91Val [Exon 2 and 3] (het/hom information not provided)
3778 FHL3 hom c.1208C>T; p.Leu403Pro [Exon 14]
1310 FHL3 het c.753(+1) splice site [Exon 9] and c.2346_49del; p.Arg782fsX12 [Exon 24]
4413 FHL3 het c.1389(+1) G>A splice donor site [Exon15] and c.2346_2349del; p.Arg782Ser fsX12 [Exon24]
every 1-3 days until day 14 post in vitro stimulation, at which time the cells usually started
to proliferate less. hCTL were used for functional assays from day 12 - 15 post stimulation
and were re-stimulated as described above roughly every 21 days. The percentage of CD8
and CD4 positive cells was checked on a regular basis by flow cytometry. If necessary, CD8
T cells were purified using the human CD8 T cell isolation kit (Miltenyi Biotec, #130-045-
201). The human CD4 T cell isolation kit (Miltenyi Biotec, #130-045-101) was used to
exclude CD4 cells. For blasticidin concentration response and selection experiments human
T cells were treated with blasticidin (Sigma, #15205) at the concentrations indicated in figure
legends.
2.1.4 Cell line culture
P815 (mouse mastocytoma) cells were used as target cells for human CTL and WT mouse
CTL. P815s express Fc receptors on their cell surface that bind to the constant region
of antibodies. P815s loaded with aCD3e can trigger activation of T cells. EL4 (mouse
lymphoma) cells were used as target cells for OT-I CTL as they can present the OVA peptide
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in the context of H-2Kb MHC class I molecules. Blue fluorescent protein (BFP) P815s and
EL4s, stably expressing Farnesyl-5-TagBFP2 through retroviral transduction were established
in the Griffiths lab (Ritter et al. (2015) and Alex Ritter’s PhD thesis). These target cells are
subsequently referred to as blue EL4 or blue P815s for simplicity. I established red P815s
and EL4s using lentiviral transduction (see section 2.10). All P815 and EL4 cell lines were
cultured in target cell media (Table 2.1) and split 1 in 10 every 2-3 days. For red P815s
and EL4s, the target cell media was supplemented with 1 µg/ml puromycin (Thermo Fisher
Scientific, #A1113803).
Human embryonic kidney (HEK) 293T cells were maintained in target cell media without
antibiotics and split when reaching roughly 80% confluency using trypsin (Sigma, #T3924)
for detachment. The human NK cell line YT was maintained in YT media (Table 2.1) and
the human Jurkat T cell line was maintained in Jurkat media (Table 2.1). YT cells and Jurkat
cells were split 1 in 5 every 2-3 days.
2.2 Nucleofection
2.2.1 Preparation of synthetic RNAs
Synthetic RNAs were obtained as dried pellets from Dharmacon, reconstituted in Tris-EDTA
pH 7.4 (Sigma, #93302) to give stock solutions between 1-10 µg/µl and mixed on an
orbital shaker at 700 rpm for 30 min at RT. Aliquots were stored at  20  C. Details of
all synthetic RNA reagents used are outlined in Table 2.3. siRNA and crRNA sequences
were predesigned by Dharmacon/Horizon Discovery. Only crRNAs targeting exons were
chosen, with preference given to crRNAs targeting different exons in the same gene in order
to increase the possibility of cutting out a large section of the gene.
2.2.2 Nucleofection of primary mouse T cells
mCTLs were nucleofected at day 4-7 post in vitro stimulation. Nucleofections were
performed with the Lonza mouse T cell nucleofection kit (Lonza, #VPA-1006) using the
2b nucleofection machine (Lonza) or the P3 primary cell kit (Lonza, #V4XP-3024) using
the 4D nucleofector (Lonza). Mouse T cell nucleofection media (Lonza, #VZB-1001) was
supplemented with 1% (v/v) medium component A (Lonza, #VZB-1001), 2 mM L-glutamine
(Sigma, #G7513) and 5% (v/v) FBS (Labtech). Before use, 1% (v/v) component B (Lonza,
#VZB-1001) was added and nucleofection media was pre-warmed at 37  C for at least 30 min.
Subsequently, 5x106 cells per condition were centrifuged at 200xg for 5 min. All supernatant
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was removed carefully and pellets were resuspended in 100 µ l nucleofection solution (Lonza)
containing the desired reagents. For siRNA experiments, 5x106 T cells were nucleofected
with 3 µg scramble or Rab27a siRNA (Table 2.3). For CRISPR experiments, 5x106 T
cells were nucleofected with 5 µg per crRNA (3 crRNAs per gene means 15 µg crRNAs
in total), 15 µg tracrRNA and 10 µg Cas9 protein (Takara, #632640), unless otherwise
indicated in figure legends. Nucleofection controls and non-targeting (NT) CRISPR controls
were included in every experiment. Cells resuspended in nucleofection solution containing
all necessary reagents were transferred to nucleofection cuvettes and nucleofected using
program X-001 (2b machine) or program DN-100 (4D machine). Next, each nucleofected
sample, containing 5x106 mCTL, was transferred to 1 ml prewarmed nucleofection media in
1 well of a 12 well plate. Cells were left to recover in the incubator for 3-4 h before splitting
across 3 wells in a 12 well plate and topping up each well with 3 ml mTCM. The following
day, cells were pelleted and resuspended in fresh mTCM at roughly 1x106 cells/ml.
2.2.3 Nucleofection of primary human T cells
Human T cells were stimulated with 5 µg/ml PHA for 3 days prior to nucleofection. The P3
primary cell kit (Lonza, #V4XP-3024) was used for nucleofection with the 4D nucleofector
(Lonza). Prior to nucleofection, hTCM was pre-warmed at 37  C for at least 30 min. 1-
1.5x106 cells were pelleted and resuspended in nucleofection solution containing 2 µg
lifeact-EGFP plasmid or CRISPR reagents. As only 1-1.5x106 cells were nucleofected per
condition, the amount of CRISPR reagents used was scaled down accordingly (e.g. as I used
5 µg per crRNA for 5x106 mouse T cells, I only used 1 µg per crRNA when nucleofecting
1x106 human T cells). Human T cells were nucleofected using program E0-115 on the 4D
nucleofector.
For nucleofection with the Neon transfection system (Thermo Fisher Scientific), human T
cells were washed once in Dulbecco’s Phosphate-Buffered Saline (DPBS) (Gibco, #14190094)
and then resuspended in 110 µl buffer T (Neon transfection system kit, Thermo Fisher
Scientific, #MPK10025) containing the appropriate CRISPR reagents. The reaction conditions
were otherwise identical to the Lonza 4D samples (same number of cells and same amount
of reagent). Cells were transfected using the following settings: 1600V, 10 ms, 3 pulses.
Upon nucleofection with neon or 4D nucleofectors, 1-1.5 million human T cells were
transferred into 500 µl pre-warmed hTCM in one well of a 24 well plate. Cells were left
to recover in the incubator for 2 h before topping up with an additional 500 µl pre-warmed
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hTCM. The next day, cells were pelleted at 200xg for 10 min and resuspended in fresh hTCM.
2.2.4 Nucleofection of Jurkat cells
Jurkat cells were nucleofected using the SE Cell line nucleofection kit (Lonza, #V4XC-1012).
For nucleofections using cuvettes, 1x106 Jurkat cells were pelleted and resuspended in 100 µ l
nucleofection solution containing CRISPR reagents. For nucleofections using 16-well strips,
0.2x106 Jurkat cells were pelleted and resuspended in 20 µ l nucleofection solution containing
CRISPR reagents. In both experimental conditions, Jurkat cells were nucleofected with 2 µg
Cas9 protein, 3 µg tracrRNA, and 1 µg per crRNA (3 crRNAs per gene) targeting CD2 or
the gene encoding b2 microglobulin (B2M) using program CK-116 on the 4D nucleofector.
Cells were transferred into pre-warmed Jurkat media in 24 well plates (1x106 cells samples)
or 96 well plates (0.2x106 cells samples) and left to recover for 2 h before topping up with
pre-warmed Jurkat media.
Table 2.3 Overview of synthetic RNAs (siRNAs, crRNAs and tracrRNA) used in this study.






mouse Thy1 crRNA CR-041986-01-0005
mouse Rab27a crRNA1 CR-060970-01-0005
mouse Rab27a crRNA2 CR-060970-04-0005
mouse Rab27a crRNA3 CR-060970-05-0005
mouse Munc13-4 crRNA1 CM-064384-01-0002
mouse Munc13-4 crRNA2 CM-064384-02-0002
mouse Munc13-4 crRNA3 CM-064384-03-0002
mouse Perforin crRNA1 CM-064701-01-0002
mouse Perforin crRNA2 CM-064701-02-0002
mouse Perforin crRNA3 CM-064701-03-0002
mouse Cav2 crRNA1 CM-063000-01-0002
mouse Cav2 crRNA2 CM-063000-02-0002
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Table 2.3 continued from previous page
Reagent Catalogue number
mouse Cav2 crRNA3 CM-063000-03-0002
mouse Anxa1 crRNA1 CM-040923-01-0002
mouse Anxa1 crRNA2 CM-040923-02-0002
mouse Anxa1 crRNA3 CM-040923-03-0002
mouse Anxa2 crRNA3 CM-061993-01-0002
mouse Anxa2 crRNA3 CM-061993-04-0002
mouse Anxa2 crRNA3 CM-061993-05-0002
mouse Anxa3 crRNA1 CM-046409-01-0002
mouse Anxa3 crRNA2 CM-046409-02-0002
mouse Anxa3 crRNA3 CM-046409-05-0002
mouse Anxa4 crRNA1 CM-057375-02-0002
mouse Anxa4 crRNA2 CM-057375-04-0002
mouse Anxa4 crRNA3 CM-057375-05-0002
mouse Nfil3 crRNA1 CM-063246-01-0002
mouse Nfil3 crRNA2 CM-063246-02-0002
mouse Nfil3 crRNA3 CM-063246-03-0002
mouse Slc7a5 crRNA1 CM-041166-01-0002
mouse Slc7a5 crRNA2 CM-041166-02-0002
mouse Slc7a5 crRNA3 CM-041166-03-0002
mouse Hif1a crRNA1 CM-040638-01-0002
mouse Hif1a crRNA2 CM-040638-03-0002
mouse Hif1a crRNA3 CM-040638-04-0002
mouse Dysf crRNA1 CM-040311-02-0002
mouse Dysf crRNA2 CM-040311-03-0002
mouse Dysf crRNA3 CM-040311-04-0002
mouse Cpne5 crRNA1 CM-053834-01-0002
mouse Cpne5 crRNA2 CM-053834-02-0002
mouse Cpne5 crRNA3 CM-053834-03-0002
mouse Ppfia3 crRNA1 CM-066090-01-0002
mouse Ppfia3 crRNA2 CM-066090-02-0002
mouse Ppfia3 crRNA3 CM-066090-05-0002
mouse Tns2 crRNA1 CM-040926-01-0002
mouse Tns2 crRNA2 CM-040926-02-0002
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Table 2.3 continued from previous page
Reagent Catalogue number
mouse Tns2 crRNA3 CM-040926-03-0002
human CD2 crRNA1 CM-017854-01-0002
human CD2 crRNA2 CM-017854-02-0002
human CD2 crRNA3 CM-017854-05-0002
human B2M crRNA1 CM-004366-01-0002
human B2M crRNA2 CM-004366-02-0002
human B2M crRNA3 CM-004366-03-0002
2.3 Western blotting
2.3.1 Lysate preparation
Cells were counted and pelleted at 200xg for 5 min, resuspended in 1 ml ice-cold DPBS and
pelleted again at 200xg for 5 min at 4  C. Pellets were dried by removing the supernatant,
frozen on dry ice before storage at  80  C or lysed directly at 2-5x107 cells/ml for Western
blotting (WB).
Cytoplasmic lysate preparation
Dried pellets were resuspended in lysis buffer [50 mM Tris(hydroxymethyl)aminomethane
hydrochloride (Tris-HCl) pH 8, 150 mM sodium chloride (NaCl) , 1 mM magnesium
chloride (MgCl2) (all obtained from CIMR media kitchen), 2% Triton X-100 (Sigma,
#T8787) in ultrapure H2O (CIMR media kitchen)]. 1X protease inhibitor cocktail (Roche,
#04693132001) was added just before use. Additionally, 1X PhosSTOP (Roche, #4906845001)
was included in the lysis buffer for lysates used to blot for phosphorylated proteins. After
incubation at 4  C for 30 min, lysates were centrifuged at 18,800 xg for 25 min at 4  C. The
supernatant was transferred into a fresh tube and sample buffer added as outlined in section
2.3.2.
Nuclear lysate preparation
For the detection of the protein Nuclear factor, interleukin 3 regulated (NFIL3), nuclear
proteins were extracted from cell pellets using the NE-PER Nuclear and cytoplasmic
extraction reagents (Thermo Fisher Scientific, #78835). This kit uses 3 buffers, cytoplasmic
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extraction reagent 1 (CER1), cytoplasmic extraction reagent 2 (CER2) and nuclear extraction
reagent (NER). CER1, CER2 and NER were added at a ratio of 200:11:100, as detailed in the
manufacturer’s instructions, to give a final lysate concentration of 5x107 cells/ml. Protease
inhibitors (Roche, #04693132001) were added to CER1 and NER buffers immediately before
use. Cell pellets were resuspended in ice-cold CER1, vortexed for 15 seconds (sec) and
incubated on ice for 10 min. Next, ice-cold CER2 reagent was added, samples were vortexed
for 5 sec and incubated on ice for 1 min prior to centrifugation at 18,800 xg for 5 min at 4  C.
The supernatant, containing cytoplasmic proteins, was transferred to a clean tube. The pellet,
containing nuclear proteins, was resuspended in ice-cold NER, vortexed for 15 sec every
10 min for a total of 40 min. Samples were pelleted at 18,800 xg for 5 min at 4  C and the
supernatant, containing nuclear proteins, was transferred to a clean tube and sample buffer
added as outlined in section 2.3.2.
Whole cell lysate preparation
The following method was used to enable detection of Hypoxia-inducible factor (HIF)-1a
by WB. Four days after nucleofection, control (nuc control and NT CRISPR) mCTL and
mCTL nucleofected with Hif1a CRISPR reagents were transferred to plates coated with
1 µg/ml aCD3e (clone Bio500A2, eBioscience, #16-0033-86). 5x106 mCTL were seeded
per well and the plate was transferred to a hypoxia chamber (Whitley H35 hypoxystation)
kept at 1% O2 and 37  C. After 4 h, samples were collected on ice, centrifuged briefly for
1 min at 200xg and 4  C, washed 1x with ice-cold DPBS containing 1x protease inhibitor
(Roche, #04693132001), and pelleted again. After removing the supernantant, pellets were
resupsended at 5x107 cells/ml in the following lysis buffer, kindly provided by Natalie
Burrows (Patrick Maxwell’s lab, Cambridge Institute for Medical Research): H2O containing
50 mM Tris-HCl pH 7.4, 120 mM NaCl, 5 mM ethylene-Diamine Tetraacetic acid (EDTA),
0.5% nonidet P40 (NP40), 1mM DL-Dithiotheitol (DTT), 1 mM Phenylmethylsulfonyl
fluoride (PMSF), 2 mM sodium orthovanadate (NaOV), 2 mM sodium fluoride (NaF), 20
mM b -glycerol phosphate (BGP), 5 mM sodium pyrophosphate (NaPPi) and 1x protease
inhibitor cocktail (Roche, #04693132001). Each sample was sonicated twice for 2 sec at
an amplitude of 8 using a soniprep 150 plus sonicator (MSE). After 10 min incubation on
ice samples were centrifuged at 16,200xg for 10 min at 4  C. The resulting supernatant was
transferred to a clean tube and sample buffer added as outlined in section 2.3.2.
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Table 2.4 Primary antibodies used for WB. Abbreviations: Rb = Rabbit, Ms = mouse, Rt =
rat, Gt = goat.
Target Species reactivity Clonality Dilution Source
Ms a-Rab27a mouse monoclonal 1 in 100 Abcam, #ab55667
Rb a-Munc13-4 mouse monoclonal clone 1223B 1 in 200 R&D Systems, #MAB89662
Gt a-Munc13-4 human polyclonal 1 in 300 Eversest Biotech, #EB06383
Rt a-Perforin mouse monoclonal clone CB5.4 1 in 500 Enzo life sciences, #ALX-804-057-C100
Ms a-Perforin human monoclonal (supernatant) clone 2D4 1 in 50 (Baetz et al., 1995)
Ms a-Cas9 not applicable monoclonal clone 7A9 1 in 100 Epigentek, #A9000-100
Rb a-Calnexin mouse/human polyclonal 1 in 2000 Sigma, #C4731
Ms a-bactin mouse/human monoclonal clone AC-15 1 in 5000 Sigma, #CA5441
Rb a-NFIL3 mouse monoclonal clone DK580 1 in 500 Cell Signaling Technology, #14312S
Ms a-Hif1a mouse monoclonal clone 241809 1 in 500 R&D Systems, #MAB1536
Rb a-Lamin B1 mouse/human polyclonal 1 in 5000 Abcam, #ab16048
Rb a-p65 (S536) human monoclonal clone 93H1 1 in 500 Cell Signaling Technology, #3033S
Ms a-IkBa human monoclonal clone L35A5 1 in 500 Cell Signaling Technology, #4814S
Rb a-p105/p50 human monoclonal clone D4P4D 1 in 100 Cell Signaling Technology, #13586S
2.3.2 Protein electrophoresis and transfer
Nupage LDS sample buffer (Invitrogen, #NP0007) containing 10% NuPAGE Sample reducing
reagent (Invitrogen, #NP0009) was added to WB lysates at a final concentration of 1X.
Samples were boiled at 95  C for 5 min prior to loading onto pre-cast NuPAGE 4-12% Bis-
Tris gels (Invitrogen, #NP0335) alongside 5 µ l of Precision Plus Protein Kaleidoscope MW
marker (BioRad, #161-0375). Gels were run at 110-130 V for 1-2 h in MES (life technologies,
#NP0002) or MOPS (for high MW proteins, life technologies, #NP0001) sodium dodecyl
sulfate (SDS) running buffer diluted to 1X in distilled H2O. Proteins were transferred to
nitrocellulose membranes (GE Healthcare life sciences, #10600003) in NuPAGE transfer
buffer (life technologies, #NP0006) diluted to 1X in distilled H2O and 10% (v/v) methanol at
RT for 95-100 min at 100 V. Successful transfer was confirmed by staining with ponceau red
(0.1% (w/v) ponceau, 5% (v/v) acetic acid in H2O) for 5 min at RT while shaking, followed
by several washes in H2O to remove the red stain.
2.3.3 Incubation with antibodies and protein detection
Blocking was performed in 1X Tris buffered saline-Tween (TBS-T) (1XTBS + 0.05% (v/v)
Tween-20) containing 5% (w/v) skimmed milk. When blotting for phosphorylated proteins
1X TBS-T (0.05% Tween-20) containing 5% (w/v) BSA was used instead. Blots were
incubated with primary antibodies (Table 2.4) diluted into blocking buffer while rotating
overnight at 4  C. The following day, blots were washed four times for a total of 20 min in
1x TBS-T solution before addition of horseradish peroxidase (HRP) conjugated secondary
antibodies (Table 2.5) diluted into blocking buffer for 1 h at RT. Following four more
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Table 2.5 Secondary antibodies used for WB.
Target Conjugation Dilution Source
Goat a-mouse Peroxidase 1 in 3000 Thermo Fisher Scientific, #32430
Goat a-rabbit Peroxidase 1 in 3000 Thermo Fisher Scientific, #32460
Goat a-rat Peroxidase 1 in 10000 SouthernBiotech, #3030-05
Donkey a-goat Peroxidase 1 in 10000 Jackson ImmunoResearch, #705-035-147
washes, proteins were detected using ECL prime western blotting reagent (GE Healthcare,
#RPN2232) and images were acquired using the ChemiDoc MP imaging system (Bio-Rad).
Band intensities were quantified using the ImageLab4.1 software (Bio-Rad) and samples
were normalised to loading controls and expressed relative to an appropriate experimental
control, as detailed in figure legends.
2.4 Flow cytometry
2.4.1 Cell surface staining
Cells were washed in fluorescence-activated cell sorting (FACS) buffer (DPBS + 1% (v/v)
FBS) and stained with live dead markers (Table 2.6) and fluorescently-conjugated antibodies
(Table 2.7) diluted into FACS buffer for 10-15 min at RT or at 4  C for 30 min. Subsequently,
cells were washed to remove excess antibody and resuspended in FACS buffer for sample
acquisition on LSRFortessa (BD biosciences), Accuri C6 (BD biosciences) or Attune NxT
(Thermo Fisher Scientific) flow cytometers. Data was analysed with FlowJo version 10.4.2
(FlowJo, LLC).
Table 2.6 Live/dead stains used in flow cytometry experiments.
Reagent Dilution Source
Fixable yellow 1 in 1000 Thermo Fisher Scientific, #L34959
Zombie Red 1 in 500 Biolegend, #423110
DAPI 1 in 5000 (1 µg/ml) Thermo Fisher Scientific, #D3571
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Table 2.7 Directly conjugated antibodies used in flow cytometry experiments.
Abbreviations: FITC = Fluorescein isothiocyanate, PE = Phycoerythrin, APC =
Allophycocyanin, BV421 = Brilliant Violet 421, BV711 = Brilliant Violet 711, AF488 =
Alexa Fluor 488.
Antibody specificity and conjugation Clone Isotype Species specificity Dilution Source
B2M-FITC 2M2 mouse IgG1 k human 1 in 400 Biolegend, #316304
CD107a(LAMP1)-PE 1D4B rat IgG2a k mouse 1 in 100 eBioscience, #12-1071-83
CD107a(LAMP1)-PE H4A3 mouse IgG1 k human 1 in 200 eBioscience, #12-1079-42
CD2-FITC RPA-2.10 mouse IgG1 k human 1 in 200 Biolegend, #300206
CD2-PE RPA-2.10 mouse IgG1 k human 1 in 200 Biolegend, #300208
CD4-PE RM4-5 rat IgG2a k mouse 1 in 200 Biolegend, #100511
CD4-PE A161A1 rat IgG2b k human 1 in 200 Biolegend, #357404
CD8-APC 53-6.7 rat IgG2a k mouse 1 in 200 Biolegend, #100712
CD8-BV421 RPA-T8 mouse IgG1 k human 1 in 400 Biolegend, #301036
CD8-BV711 53-6.7 rat IgG2a k mouse 1 in 200 Biolegend, #100747
CD8-BV711 RPA-T8 mouse IgG1 k human 1 in 200 Biolegend, #301044
Thy1.2-APC 53-2.1 rat IgG2a k mouse 1 in 200 BD Biosciences, #561974
Thy1.2-AF488 30-H12 rat IgG2b k mouse 1 in 200 Biolegend, #105316
TNF-PE MAb11 mouse IgG1 k human 1 in 100 BD Biosciences, #554513
2.4.2 Intracellular staining for TNFa detection
Flat bottom 96 well plates were coated with 1 µg/ml aCD3e (clone OKT3, eBioscience, #14-
0037-82) overnight at 4  C. hCTL were treated with drug 19/parthenolide (Medchem express,
#HY-N0141) or dimethyl sulfoxide (DMSO) (Sigma, #D2650) vehicle control overnight
at 8.3 µM. The following day, coated wells were washed with hTCM before addition
of 200,000 hCTL treated with drug 19 or DMSO per well. Golgi stop (BD biosciences,
#554715), containing the protein transport inhibitor monensin, was added at 0.67 µl/ml to
inhibit protein secretion, including the secretion of TNFa . Cells were incubated with and
without the aCD3e stimulus at 37  C. After 4 h, cells were washed in ice-cold DPBS and
stained with ahuman-CD8-BV711 (Table 2.7) and fixable yellow live dead dye (Table 2.6)
for 30 min at 4  C. After washing with FACS buffer, cells were fixed and permeabilised using
100 µl of fixation/permeabilisation solution (BD biosciences, #554715) per well for 20 min
at 4  C. After 2 washes with 1x permeabilisation/wash buffer (BD biosciences, #554715),
samples were incubated with human Fc-block (Miltenyi, #130-059-901) at 4 µl/1x106 cells
for 15 min at RT. Next, mouse ahuman-TNFa-PE (Table 2.7) or mouse IgG1-PE isotype
control (Abcam, #ab81200) were added and incubated for a further 30 min at 4  C. Following
2 washes in 1x permeabilisation/wash buffer, samples were resuspended in FACS buffer for
analysis.
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2.4.3 Cell sorting
Samples were washed with sterile FACS buffer containing 100 U/ml pen, 0.1 mg/ml strep,
and stained with 4’,6-diamidino-2-phenylindole (DAPI) (Table 2.6) to distinguish live cells
from dying cells. P815 and EL4 positive for nuclight red or hCTL positive for Cas9-2A-mCh
were sorted into appropriate media containing 100 U/ml pen, 0.1 mg/ml strep using an
Influx cell sorter (Becton Dickinson). After sorting, cells were pelleted, resuspended in fresh
pen/strep-containing media and transferred to the incubator.
2.5 Assays to measure CTL effector function
In this thesis I used degranulation and killing assays to measure CTL effector function. The
conditions used to trigger an effector response differed according to whether CTLs were
derived from OT-I mice, WT mice or human PBMCs. To measure degranulation and killing
capabilities of OT-I CTL, EL4 target cells were used, which present the OVA peptide in the
context of their H-2Kb MHC class I molecule. EL4s were pulsed with 1 µM OVA peptide for
1 h at 37  C. Subsequently, cells were washed three times into mTCM prior to addition to OT-
I CTL. Unpulsed EL4 that were incubated and washed in parallel served as a negative control.
To trigger a degranulation and killing response in WT mCTL or hCTL I used P815
target cells, which express Fc receptors on their cell surface that are able to bind to the
constant region of antibodies. P815s were loaded with aCD3e (for hCTL: clone UCHT1,
BDPharmingen, #555330; for WT mCTL: clone 145-2C11, eBioscience, #16-0031-86) for
20 min at RT, resulting in a final aCD3e concentration of 0.5 µg/ml for mCTL and 0.25
µg/ml for hCTL upon addition of target cells to CTL.
The conditions outlined above were used throughout. For simplicity, I will refer to hCTL
and mCTL as ’CTL’, to P815 and EL4s as ’targets’ and to OVA peptide and aCD3e as
’stimulus’ for the remainder of section 2.5. In general, two - four technical replicates were
included per condition in every experiment.
2.5.1 Degranulation assay
Both CTL and targets with stimulus were resuspended at 2x106 cells/ml and 200,000 cells
were seeded per well in a round bottom 96 well plate to give an effector-to-target (E:T)
ratio of 1, unless otherwise stated in figure legends. PE-conjugated aCD107a (aLAMP1)
antibody (Table 2.7) was added for the duration of the assay in all wells except staining
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controls. Unstimulated control wells were included for all conditions, which contained CTL
and target cells without stimulus or no target cells at all.
Following incubation at 37  C for 3 h, or the time periods indicated in figure legends,
samples were pelleted at 4  C and washed in ice-cold DPBS. Next, samples were incubated
with fluorescently-conjugated antibodies to stain CD8 and Thy1 cell surface molecules (Table
2.7) and with live/dead markers (Table 2.6) for 30 min on ice. After washing in FACS buffer,
samples were resuspended in FACS buffer before acquisition on Accuri C6 (BD biosciences),
Attune NxT (Thermo Fisher Scientific) or LSRFortessa (BD biosciences) flow cytometers.
Results were analysed with FlowJo version 10.4.2 (FlowJo, LLC). The gating strategy used
for analysis with FlowJo is explained in Figure 3.1. A forward scatter (FSC) and side scatter
(SSC) gate was used to separate the cell population from debris, a second gate was used to
isolate single cells from doublets, a third gate was used to isolate live cells from dead cells, a
fourth gate was used to isolate CD8 cells and a final gate was used to isolate LAMP1-PE
positive cells. Gates were set according to fluorescence minus one controls and experimental
controls (unstimulated CTL).
2.5.2 Combined degranulation and killing assay
For the combined degranulation and killing assay, it was important to use stained target cells
in order to be able to clearly distinguish CTL and targets during analysis steps. Initially,
CFSE-stained target cells were used in this assay. Later on, targets that were permanently
stained blue, as described under section 2.1.4, were used instead. For CFSE staining, target
cells were incubated with 0.25 µM CFSE (Thermo Fisher Scientific, #C34570) for 10 min at
RT in the dark. Following addition of FBS-containing media to quench the dye for 5 min at
RT in the dark cells were washed twice before addition to T cells.
CTL and targets with stimulus were co-cultured at an E:T of 2.5:1 in 96 well round
bottom plates, with 125,000 CTL and 50,000 target cells seeded per well. Controls that
contained CTL and targets without stimulus, CTL on their own or targets on their own were
included in every experiment. After incubation at 37  C for 3 h, samples were pelleted and
washed in ice-cold DPBS. Cells were stained with fluorescently-conjugated aCD8 antibodies
(Table 2.7) and a live dead stain (Table 2.6) for 30 min at 4  C. After washing with FACS
buffer, and just before analysis on the Attune NxT flow cytometer (Thermo Fisher Scientific),
10 µ l 123count ebeads (Invitrogen, #01-1234-42) were added per well. The contents of each
well were mixed thoroughly with a mutlichannel pipette.
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The analysis process for the beads killing assay readout is explained in detail in Figure
3.11 . Gates were set around the beads population and the stained target cell population in
FlowJo version 10.4.2 (FlowJo, LLC). This enabled to count the number of target cells and
beads in each well, and allowed to derive a targets:beads ratio. This ratio was multiplied by
the number of beads known to be present in the 10 µl added to each sample (information
supplied by the manufacturer) in order to determine the total number of target cells remaining
in each well. The number of target cells in wells containing CTL + targets + stimulus, was
compared to the number of target cells in wells containing CTL + targets - stimulus. This
allowed to calculate the percentage of live and dead target cells in each stimulus-containing
well. The degranulation assay readout was analysed as explained in section 2.5.1, with the
exception that beads were gated out in the first gate before FSC/SSC and subsequent gating.
2.5.3 Incucyte killing assay
CTLs were co-cultured with targets stably expressing a red nuclear marker (Essen Bioscience,
#4625, see section 2.10) in ultralow attachment round-bottomed microplates (VWR, #7007).
Cells were mixed at E:T 10:1 or E:T 2.5:1, as indicated in the figure legends. 2000-4000
targets with and without stimulus were plated per well and pelleted at 200xg for 2 min. The
appropriate number of CTL, to give the desired E:T, were carefully added on top in order to
leave the target cell pellet intact. Plates were briefly centrifuged at 200xg for 1 min, then
transferred to an Incucyte S3 live cell analysis system (Essen Bioscience) maintained at 37  C
and 5% CO2. Samples were imaged once an hour using the 4x objective. Target cell death
was detected as loss of red fluorescence and was quantitated using the spheroid quantification
tool (Incucyte S3 software). Results were exported and the percentage of target cell lysis
over time in each well was calculated relative to the first time point measured.
2.5.4 LDH release killing assay
The CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, #G1780) was used to
quantitate the enzyme lactate dehydrogenase (LDH), which is released from the cytoplasm
of cells upon cell death. The released LDH participates in an enzymatic reaction where
a tetrazolium salt is converted into a red formazan product. The amount of cell death is
proportional to the amount of red product formed.
The LDH killing assay was performed in a 96 well round bottom plate in killing assay
media (RPMI - phenol red + 2%FBS + 100 U/ml pen, 0.1 mg/ml Strep). 100,000 CTLs
were seeded per well in one row and serially diluted two fold down the plate. Next, drug
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19/parthenolide (Medchem express, #HY-N0141), or equivalent amount of DMSO vehicle
control, was added at a final concentration of 8.3 µM. Subsequently, 10,000 targets with
stimulus or without stimulus (controls) were added per well, resulting in different E:T ratios
ranging from 10:1 to 1.25:1. Samples were mixed by pipetting, centrifuged at 200xg for 1
min, then incubated for 3 h at 37  C. Lysis buffer (Promega, #G1780) was added to positive
control wells to lyse all cells 45 min before the end of the incubation period. After 3 h,
samples were pelleted at 200 xg for 2 min and 50 µl supernatant was transferred into a
96 well flat bottom plate and mixed with 50 µl substrate mix (Promega, #G1780). After
incubation for 30 min in the dark, absorbance at 490 nm was measured using a spectramax
plate reader (Molecular devices) and Softmax software (Molecular devices). The cell death
readout was determined by subtracting the absorbance of unstimulated (CTL + target) wells
from their stimulated (CTL + targets + stimulus) equivalent, and dividing this number by the
absorbance recorded in positive control wells containing lysis buffer. The percentage lysis
was calculated by multiplying the resulting number by 100.
2.6 RNA preparation and sequencing
10 spleens were collected from 16 week old WT mice (4 males, 6 females) on two different
spleen collection dates. Splenocytes were isolated as described under section 2.1.2. The
mouse CD8a T cell isolation kit (Miltenyi Biotec, #130-104-075) was used to purify CD8
cells. 6x106 purified CD8 cells were pelleted, washed 2x in ice-cold DPBS and frozen at
 80  C (day 0 samples). An aliquot of each sample was used to determine the CD8 and CD4
expression profile by flow cytometric analysis. The remainder of the cells were transferred
onto plates coated with 0.5 µg/ml aCD3e (clone Bio500A2, eBioscience, #16-0033-86)
and 1 µg/ml aCD28 (clone 37.51, eBioscience, #16-0281-86) and cultured as described
under section 2.1.2. On day 7, the CD8 purity of each sample was again confirmed by flow
cytometry. 6x106 cells per sample were pelleted, washed 2x in ice-cold DPBS and frozen at
 80  C (day 7 samples). This resulted in 10 biological replicates for both day 0 and day 7
time points.
RNA was extracted from the cell pellets following the manufacturer’s protocol of the
RNeasy mini kit (Qiagen, #74104). The concentration and quality of the extracted RNA were
determined using a Qubit fluorometer (Thermo Fisher Scientific) and a bioanalyser (Agilent),
respectively. A total of 1 µg of RNA per sample was submitted to the Illumina bespoke team
at the Wellcome Trust Sanger Institute. The Illumina bespoke team prepared stranded 75
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base pairs (bp) paired-end barcoded libraries with oligodT pulldown. For sequencing, all
libraries were pooled across 3 different lanes on an llumina Hiseq platform.
2.7 RNA-seq analysis
The following bioinformatic analyses were performed with Martin Del Castillo Velasco-
Herrera, following a published workflow (Anders et al., 2013): read alignment, fragment
counting, quality control and differential expression analysis of day 7 vs day 0. Reads were
aligned to the mouse reference genome (GRCm38) using STAR, a splice-aware mapper
(Dobin et al., 2013), guided by the ENSEMBL mouse annotation v84. Htseq count (Anders
et al., 2015) was used to count the number of total mapped and uniquely mapped reads. From
this, the percent of uniquely mapped reads was determined. The raw counts were normalised
by calculating the fragments (read pairs) per kilobase per million (FPKM) reads mapped.
Quality control examinations were performed following the DESeq analysis vignette. This
included unsupervised hierarchical clustering of samples and principal component analysis
(PCA).
The DESeq2 Bioconductor package (Anders and Huber, 2010) was used to identify
differentially expressed genes between day 7 and day 0 groups and between males and
females within the day 7 group. The spleen collection date was included as a covariate in the
analysis. P-values were corrected for multiple testing using the Benjamini-Hochberg method,
giving an adjusted p-value (padj). Genes were considered differentially expressed with a
padj <0.01 and a log2(fold change) <-2 or >2.
2.8 Toxicity testing and screening of the NF-kB compound
library
The NF-kB signalling compound library was obtained from MedChem Express (#HY-L014).
Compound toxicity was tested over a range of concentrations in hCTL. First, compounds
were added to 96 well plates at 50 µM in duplicates or triplicates and serial threefold dilutions
were performed down the plate. The appropriate amount of DMSO (Sigma, #D2650) vehicle
control was included on every plate. An equal volume of media containing 125,000 hCTL was
added to every well, which halved the concentration of drug. The final concentration range
was between 25 µM and 0.1 µM. hCTLs were left to incubate with drugs or DMSO overnight.
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The following day the Celltitre96 AQueous One Solution Cell Proliferation Assay
(Promega, #G3580) was used to determine drug toxicity after overnight treatment. This
kit contains an electron coupling reagent (phenazine ethosulfate, PES) and a tetrazolium
compound, which is reduced into a coloured formazan product in metabolically active cells,
meaning the quantity of coloured product detected at 490 nm is proportional to the number
of live cells. 20 µl reagent were added per well and mixed thoroughly. The plates were
incubated for 4 h at 37  C in the dark, then absorbance at 490 nm was recorded using a
spectramax plate reader (Molecular devices) and Softmax software (Molecular devices).
hCTL were treated with compounds for 24 h in total. Concentration response curves were
plotted using Prism software (Graphpad). For every drug, the highest concentration that
did not have toxic effects on hCTLs over a 24 h period was chosen for screening using the
combined degranulation and killing assay (section 2.5.2). Assays were performed in hCTL
at day 13-15 post in vitro stimulation. Treatments with compounds was performed overnight.
In every assay, target cells alone were treated with the compounds in order to test for any
effects of the drugs on target cells.
For follow up of drug 19/parthenolide (Medchem express, #HY-N0141), hCTLs were
treated with 2.075 - 8.3 µM drug 19/parthenolide for time periods indicated in figure legends
followed by analysis using the Incucyte killing assay (section 2.5.3). hCTLs treated with 8.3
µM drug 19/parthenolide were also analysed using the LDH release killing assay (section
2.5.4) and the TNF-expression assay (section 2.4.2).
Additionally, the effect of 8.3 µM drug 19/parthenolide on LAMP1-exposure triggered
by treating hCTLs with 4 µM phorbol 12-myristate 13-acetate (PMA) (Sigma, #P8139)
and 1 µg/ml Ionomycin (Sigma, #IP657) was tested. PMA and Ionomycin were both
prepared in DMSO and controls containing the appropriate amount of DMSO were included
in every experiment. After treatment for 3 h in the presence of ahuman-LAMP1-PE (Table
2.7), cells were stained with ahuman-CD8-BV711 (Table 2.7) and the live/dead marker
Zombie yellow (Table 2.6) for 30 min on ice. After washing in FACS buffer, samples were
resuspended in FACS buffer before acquisition on Attune NxT (Thermo Fisher Scientific) or
LSRFortessa (BD biosciences) flow cytometers. Results were analysed with FlowJo version
10.4.2 (FlowJo, LLC).
To investigate the effect of drug 19/parthenolide on p65 protein levels, hCTLs were treated
with 8.3 µM drug 19/parthenolide, 4 µM PMA and 1 µg/ml Ionomycin or appropriate DMSO
control for 3 h followed by WB lysate preparation (section 2.3.1).
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2.9 Molecular cloning
The Cas9 gene was amplified from the lenti Cas9-Blast vector (Addgene, #52962, see
chapter 6 Figure 6.3 for plasmid map) using a forward primer containing upstream homology
sequences to pHRSIN-mCherry (pHRSIN-mCh) and a XhoI restriction enzyme (RE) site
and one of two different reverse primers. Reverse primer 1 contained a downstream BamHI
RE site and homology region to pHRSIN-mCh. Reverse primer 2 contained a downstream
P2A sequence, as well as the BamHI RE site and homology region to pHRSIN-mCh. The
primer sequences are given in Table 2.8. The PCR mastermix used is given in Table 2.9 and
the PCR conditions in Table 2.10.
Table 2.8 Overview of primers used in this thesis. Primers were acquired from Sigma and
resuspended in nuclease free water to give 100 µM stock solutions.
Purpose Primer Sequence 5’ to 3’




Sequencing Cas9-Blast Cas9-Blast Fwd CCAAAGAGGTGCTGGACG
Cas9-Blast Rev GCTCTTTCAATGAGGGTGGA
Sequencing pHRSIN pHRSIN_SFFV_Fwd TGCTTCTCGCTTCTGTTCG
pHRSIN_WPRE_Rev CCACATAGCGTAAAAGGAGC
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Table 2.9 PCR mastermix composition for Cas9 amplification from the Cas9-Blast
plasmid.
Reagents µl/reaction
10X Pfx reaction mix 5 µl
10 µM Fwd primer 1.5 µl
10 µM Rev primer 1.5 µl
10 ng/µl template DNA 1 µl
Accuprime Pfx DNA polymerase 0.4 µl
MgSO4 1 µl
Nuclease free water 39.6 µl
Agarose gels were prepared by adding the desired amount of agarose (Sigma, #A9539)
to Tris-acetate-EDTA (TAE) buffer (CIMR media kitchen). This mixture was heated in the
microwave to mix and allowed to cool before addition of gel red (Biotium, #41003, final
dilution 1:10,000). PCR products were mixed with Orange loading dye (Thermo Fisher
Scientific, #SM1173) and run alongside O’gene ruler DNA ladder mix (Thermo Fisher
Scientific, #SM1173) on a 0.7% (w/v) agarose gel in 1x TAE buffer (CIMR media kitchen).
5 µg of pHRSIN-mCh plasmid was digested with 1x fast digest green buffer (Thermo Fisher
Scientific, #B72), 1 µl alkaline phosphatase (Sigma, #11097075001), 1 µl XhoI (Thermo
Fisher Scientific, #FD0694), 1 µ l BamHI (Thermo Fisher Scientific, #FD0055) and topped up
to 50 µ l with nuclease free H2O. The digest was performed at 37  C overnight and products
were separated on a 0.7% agarose gel. The expected size of the PCR products were 4220
bp for the Cas9 construct and 4278 bp for the Cas9+P2A construct. The expected size of
pHRSIN digested with XhoI and BamHI was 9665 bp.
Table 2.10 PCR conditions for amplification of Cas9 from the Cas9-Blast plasmid. Cas9
was amplified from the Cas9-Blast plasmid and XhoI and BamHI restriction enzyme sites as
well as homology regions to the pHRSIN plasmid were added.
Step Temperature and time
Cycle 5 times denaturation 95  C for 15 sec
annealing 59  C for 30 sec
elongation 68  C for 4 min 20 sec
Cycle 35 times denaturation 95  C for 15 sec
annealing and elongation 68  C for 4 min 20 sec
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Both PCR products and the digested plasmid were extracted from gels using the QIAquick
gel extraction kit (Qiagen, #28704). 100 ng recipient vector and 2x excess insert were mixed
with the Gibson Assembly mastermix (New England Biolabs, #E2611S) and topped up with
nuclease free H2O to 20 µl per reaction. This mix was kept for 1 h at 50  C on a heatblock,
then transferred to ice for 3 min before addition to NEB 10-beta E.coli (New England Biolabs,
#C3019H).
2 µ l of the gibson product were added to NEB 10-beta E.coli, mixed by flicking 5 times
and allowed to recover for 30 min on ice. Subsequently, E.coli were heatshocked for 30 sec
at 42  C, then placed on ice for 5 min before addition of 950 µl super optimal broth with
catabolite repression (SOC) media. After rotating at 250 rpm for 60 min at 37  C, 100-150
µl of bacteria were streaked out onto Luria-Bertani (LB) agar plates containing 100 µg/ml
ampicillin (CIMR media kitchen), and left to grow at 37  C overnight. 8 individual colonies
were picked per plate (plate 1 = XhoI-Cas9-BamHI plasmid, plate 2 = XhoI-Cas9-2A-BamHI
plasmid) and expanded while shaking at 230 rpm and 37  C for two days in 4 ml ampicillin
containing media (LB media + 100 µg/ml ampicilin). Plasmids were purified using the
QIAprep Spin Miniprep kit (Qiagen, #27106).
A restriction digest was performed with 1x fast digest green buffer (Thermo Fisher
Scientific, #B72), 1 µl XhoI (Thermo Fisher Scientific, #FD0694), 1 µl BamHI (Thermo
Fisher Scientific, #FD0055) and 5 µl of DNA from the miniprep, topped up to 25 µl with
nuclease free H2O. Resulting products were separated on a 0.7% (w/v) agarose gel for size
confirmation. This allowed isolation of colonies that contained intact XhoI and BamHI
RE sites and an insert corresponding to the Cas9 gene in size. Sequencing by Source
BioScience confirmed that Cas9 was correctly inserted. These cultures were expanded to
250 ml, and plasmids were purfied using Qiafilter plasmid maxiprep kit (Qiagen, #12263).
DNA concentration and purity was determined using a DS-11 spectrophotometer (DeNovix).
Primers were designed roughly every 400 bp along the Cas9 gene to be able to sequence it
fully (Table 2.8) and the correct sequence was confirmed by sanger sequencing carried out by
Source BioScience. Plasmid maps of the resulting pHRSIN-Cas9-mCh and pHRSIN-Cas9-
2A-mCh were prepared using snapgene (GSL Biotech).
2.10 Nuclight red lentiviral transduction
The nuclight red lentivirus (Essen bioscience, #4625, #lot611110) encodes a nuclear-
restricted red fluorescent protein (mKate2) and a puromycin resistance gene. P815 and
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blue EL4s were transduced with nuclight red lentivirus at a low multiplicity of infection
(MOI) of 0.07 in the presence of 6 µg/ml protamine sulfate. Cells expressing mKate2 were
isolated by FACS, as explained in section 2.4.3, and subsequently cells were cultured in the
presence of 1 µg/ml puromycin (see section 2.1.4).
2.11 pHRSIN lentiviral production and transduction
The following conditions were used to produce lentivirus with pHRSIN-GFP (for plasmid
map see Appendix A, Figure A.1), pHRSIN-mCh (for plasmid map see chapter 6, Figure 6.3),
pHRSIN-Cas9-mCh (for plasmid map see chapter 6, Figure 6.4) and pHRSIN-Cas9-2A-mCh
(for plasmid map see chapter 6, Figure 6.4) plasmids. The pHRSIN-GFP plasmid was a
gift from Adrian Thrasher (Institute of Child Health). The pHRSIN-mCh plasmid (James
and Vale, 2012) was a gift from John James (MRC Laboratory for Molecular Biology).
pCMVd8.91 (packaging plasmid, for plasmid map see Appendix A, Figure A.2) and pMD-G
(encoding the viral envelope protein VSV-G, for plasmid map see Appendix A, Figure A.3)
plasmids were a gift from Paul Lehner’s lab (Cambridge Institute for Medical Research).
HEK293Ts were seeded in T75 flasks so they reached 70% confluency overnight. The
next day, the following 2 tubes were prepared for each T75: Tube 1 contained 1.5 ml Opti-
MEM (Gibco, #31985-047), 30 µ l 1M HEPES (Gibco, #15630-080) and 42 µ l TransIT 293
reagent (Mirus, #MIR2700). Reagents were mixed and incubated at RT for 5 min. Tube 2
contained 4 µg pCMVd8.91, 4 µg pMD-G and 6 µg of the desired pHRSIN plasmid. The
contents of tube 1 were added dropwise to tube 2 and mixed gently by bubbling air through
a pipette boy held under the liquid for 1 min. After incubation for 15 min at RT, 12 ml
pre-warmed HEK media were added slowly. This mix was added dropwise to HEK293Ts
and cells were transferred to a 37  C incubator. Viral supernatant was collected after 48 h and
72 h. The supernatant was centrifuged at 500xg for 10 min and filtered through a 0.45 µM
pvdf filter to remove cell debris. Next, the viral supernatant was concentrated by incubation
with lenti-X (Takara Clontech, #631232) for 1 h at 4  C at a lenti-X-to-viral supernatant ratio
of 1-to-3 . After centrifugation at 1500xg for 45 min at 4  C, the viral pellet from one T75
was resuspended in 100 µl ice-cold hTCM. This effectively resulted in a 100-120X more
concentrated lentivirus. Concentrated lentivirus was aliquoted and stored at  80  C.
The following conditions were used to transduce cell lines with pHRSIN-Cas9 lentiviruses:
For transduction of P815s, 2x106 P815s were resuspended in target cell media containing
6 µg/ml protamine sulfate (Sigma, #P4020) and 100 µ l concentrated pHRSIN-Cas9-2A-mCh
54 Materials and Methods
or pHRSIN-Cas9-mCh lentivirus. For transduction of YTs, 1x106 cells were resuspended
in YT media containing 6 µg/ml protamine sulfate and 55 µl concentrated pHRSIN-Cas9-
2A-mCh lentivirus. For transduction of Jurkats, 1x106 cells were resuspended in Jurkat
media containing 6 µg/ml protamine sulfate and 45 µ l concentrated pHRSIN-Cas9-2A-mCh
lentivirus.
For transduction of primary human T cells with pHRSIN-GFP or pHRSIN-mCh lentiviruses,
1x106 T cells were resuspended in 300 µ l hTCM containing lentivirus and 6 µg/ml protamine
sulfate or lentiboost (1 in 100 dilution, meaning 8 µg/ml reagent A and 1 mg/ml reagent B,
Sirion Biotech, #SB-P-LV-101-01), as indicated in figure legends. Cells were incubated in
this small volume in one well of a 24 well plate for 4 h at 37  C. After 4 h, wells were topped
up to 2 ml with hTCM containing 1x106 irradiated allogeneic PBMCs and 1 µg/ml PHA.
Before transduction of primary human T cells with pHRSIN-Cas9-2A-mCh lentivirus
the viral titre was determined by transducing Jurkat cells. 0.2x106 Jurkats were infected
with varying volumes of concentrated lentivirus (between 50 µl and 0.05 µl) in a total
volume of 2.5 ml Jurkat media containing 6 µg/ml protamine sulfate. The lentiviral titre
was determined as outlined in Figure 6.7. The number of transduced cells was multiplied
by the percentage of fluorescent cells and the dilution factor. The resulting number was
divided by the transduction volume to give the number of transducing units (TU) per ml.
For transductions, primary human T cells were activated on plates coated with 1 µg/ml
aCD3e (clone OKT3, eBioscience, #14-0037-82) and 2 µg/ml aCD28 (clone CD28.2, BD
Biosciences, #555726). The next day, T cells were transduced with pHRSIN-Cas9-2A-mCh
lentivirus at an MOI of 1.17 in the presence of 6 µg/ml protamine sulfate or lentiboost (1 in
100 dilution, Sirion Biotech, #SB-P-LV-101-01), as an alternative transduction enhancer.
2.12 Cas9-Blast lentiviral production and transduction
The virapower packaging mix (Thermo Fisher Scientific, #K497500) was used for lentiviral
production with the lenti Cas9-Blast plasmid (Addgene, #52962), a gift from Professor Feng
Zhang (Massachusetts Institute of Technology). HEK293T were seeded in T75 flasks so they
reached 70% confluency overnight. The next day, the following 2 tubes were prepared for
each T75: Tube 1 contained 1.5 ml Opti-MEM, 9 µg virapower, 3 µg lenti Cas9-Blast and 12
µ l plus reagent (Thermo Fisher Scientific, #15338100). Tube 2 contained 1.5 ml Opti-MEM
containing 36 µl lipofectamine LTX (Thermo Fisher Scientific, #15338100). Both tubes
were incubated at RT for 5 min, then mixed together and incubated for a further 30 min at
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RT. HEK293T media was removed and replaced with 5 ml Opti-MEM. Subsequently, the
DNA-lipofectamine mix was added to the cells and left overnight. The following day, the
cell culture supernatant was removed and replaced with HEK media. Viral supernatant was
collected after 48 h and 72 h and concentrated using ultracentrifugation (SW-28 swinging-
bucket rotor, Beckmann) at 25,000 rpm for 90 min at 4  C. The resulting viral pellets were
resuspended in 200 µl ice-cold DPBS + 1% FBS per flask, aliquoted and stored at  80  C.
For transduction of primary T cells, 3x106 cells were resuspended in concentrated
lentivirus from one T75 containing 6 µg/ml protamine sulfate. Samples were centrifuged at
754xg for 15 min at 32  C. 1x106 cells were aliquoted per well in a 24 well plate and topped
up to 2 ml with hTCM containing 1x106 irradiated allogeneic PBMC and 1 µg/ml PHA.
Selection with 5 µg/ml Blasticidin was started on day 6 post transduction.
2.13 PCR for Cas9-Blast
DNA was extracted from frozen pellets of HEK293T cells transduced with Cas9-Blast
lentivirus (10,000 cells) or treated with protamine sulfate alone (0.25x106 cells) and from
frozen pellets of hCTL transduced with Cas9-Blast lentivirus (0.45x106 cells) or treated with
protamine sulfate alone (1.3x106 cells). Each pellet was resuspended in 200 µl of DNA
extraction buffer. 1 ml DNA extraction buffer contained 975 µl 10% (w/v) Chelex 100
chelating resin (Bio-Rad, #1421253) diluted into nuclease-free H2O, 10 µ l 10% (v/v) Tween
20 (Sigma, #P1379) and 15 µl proteinase K (Sigma, #P8044). The resulting samples were
incubated at 50  C for 90 min, followed by heating at 95  C for 25 min and then cooled to
RT.
PCR was used to test for the presence of Cas9-Blast in the extracted DNA. PCR was
performed with primers targeting a region between the 3’ end of the Cas9 gene and the
blasticidin resistance gene (Table 2.8), producing a product of 274 bp. PCR was performed
using the mastermix outlined in Table 2.11 and the conditions outlined in Table 2.12. Negative
controls including nuclease-free water instead of DNA were included in the PCR reaction.
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Table 2.11 PCR mastermix for Cas9-Blast PCR. PCR mastermix for amplifying a stretch of
DNA between Cas9 and the Blasticidin resistance gene in the Cas9-Blast plasmid.
Reagents µl/reaction
10X PCR buffer 2.5 µl
50 nM MgCl2 0.75 µl
10 mM dNTP mix 0.5 µl
Fwd primer 0.5 µl
Rev primer 0.5 µl
Platinum taq DNA polymerase 0.1 µl
Template DNA 1 µl
Nuclease free water 18.75 µl
Table 2.12 PCR conditions for Cas9-Blast PCR. PCR conditions to amplify a stretch of DNA
between Cas9 and the Blasticidin resistance gene in the Cas9-Blast plasmid.
Step Temperature and time
initial denaturation 94  C for 2 min
Cycle 35 times denaturation 94  C for 30 sec
annealing 58  C for 30 sec
elongation 72  C for 30 sec
The resulting PCR products were separated on a 1.5% (w/v) agarose gel, prepared as
explained in section 2.9. Gel extraction was performed with the QIAquick gel extraction kit
(Qiagen, #28704) and DNA concentration was determined using a DS-11 spectrophotometer
(DeNovix). Sanger sequencing to confirm the sequence of the PCR product was performed
by Source BioSciences.
2.14 Statistical analysis
Graphs were created and statistical analyses were performed using Prism 7 (GraphPad
Software). The statistical tests used are stated in every figure legend and where relevant
in the text. Statistical analysis was only performed on data obtained from three or more
independent experiments. Paired t-tests were applied for statistical analysis of degranulation
and killing assay results. Samples were paired according to the days that the experiments
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were performed, in order to account for any day-to-day variations. Statistical analysis of
WB results was performed using one sample t-tests. For all other comparisons, unpaired
t-tests with Welch’s correction, which does not assume equal standard deviations (SD),
were performed. For all statistical analyses, differences between samples were considered




technology in primary mouse T cells
3.1 Introduction
Before the advent of CRISPR, gene expression was primarily modulated using siRNAs,
which trigger degradation of mRNA (Dorsett and Tuschl, 2004). The effect of siRNAs is
transient and often results in only partial protein knockdown. In contrast, CRISPR has the
potential to stably and homozygously KO genes, resulting in permanent loss of gene function.
While the siRNA technique was previously established in CTLs (Stinchcombe et al., 2015),
the CRISPR technology was yet to be tested in primary mouse CTLs at the start of this project.
To test whether gene manipulation technologies are working as expected it is desirable to
use target genes where the KO has a known CTL phenotype. Studies of patients suffering
from immunodeficiency diseases have identified several suitable genetic targets. For example,
mutations in RAB27A can cause GS2 in humans (Clark and Griffiths, 2003). This disease
is the consequence of RAB27A deficient CTL not being able to kill target cells due to
a degranulation defect. A study using CTL derived from Rab27a KO mice showed that
while lytic granules polarise towards the immunological synapse, they cannot be secreted
(Stinchcombe et al., 2001a). This indicated that RAB27A is involved in the final stages of
granule secretion. Similarly, mutation of MUNC13-4 causes FHL3 due to a degranulation
defect (Bossi and Griffiths, 2005; Dieckmann et al., 2016; Feldmann et al., 2003). In fact,
RAB27A and MUNC13-4 interact with one another in this process (Neeft et al., 2005).
Perforin is another protein with a well understood function in CTL cytotoxicity. Perforin
defective CTL are unable to kill target cells, causing the immunodeficiency disease FHL2
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(Stepp et al., 1999). These immunodeficiency diseases demonstrate the importance of correct
CTL function.
3.1.1 Chapter aims
• Test the robustness of the degranulation assay and adapt it for screening.
• Manipulate gene expression in primary mouse CTLs using siRNA.
• Optimise the CRISPR-Cas9 technology in primary mouse CTLs.
• Use the CRISPR-Cas9 technology in primary mouse CTLs to target genes where the
KO has a known phenotype in the degranulation assay.
3.2 Results
3.2.1 The effect of Rab27a depletion on CTL degranulation
CTLs derived from the ashen mouse model, where a mutation in Rab27a results in loss of
protein expression, cannot kill target cells as they are unable to release their granule content
(Stinchcombe et al., 2001a; Wilson et al., 2000). CTLs derived from ashen mice were tested
in a degranulation assay, which measures lytic granule secretion by the appearance of the
granule membrane component LAMP1 on the extracellular surface (Figure 3.1). The exposed
extracellular LAMP1 can be bound by a fluorescently-conjugated antibody to allow robust
detection and quantification of the amount of degranulation by flow cytometry. Figure 3.1A
shows the gating strategy typically used in degranulation experiments. The LAMP1 gate was
set so that the signal in the experimental control, which were unstimulated CTLs, was less
than 1%. The percentage of degranulated (LAMP1-PE) positive cells was determined after
45 min, 90 min and 180 min. CTLs derived from homozygous (hom, ash/ash) ashen mice
degranulated significantly less than CTLs derived from heterozygous (het, +/ash) ashen mice
or WT (+/+) mice (Figure 3.1B-D) [45 min (n=2), 90 min (n=2) and 180 min (n=3, p<0.05,
paired t-test)]. RAB27A protein expression in CTLs derived from WT, het and hom ashen
mice was tested by WB, confirming that hom ashen CTL did not express RAB27A protein
(Figure 3.1E).
Due to the robust loss of degranulation observed in ashen CTL, Rab27a provided a





















































































































Fig. 3.1 Degranulation defect in CTL derived from ashen mice.
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Fig. 3.1 Degranulation defect in CTL derived from ashen mice. A Degranulation assays
were analysed using the following gating strategy: initial gate to separate the cell population
from debris, second gate to isolate single cells from doublets, third gate to isolate live cells
from dead cells, fourth gate to isolate CD8-positive cells and a final gate to isolate LAMP1-
PE positive cells. B CTLs were derived from WT (+/+), het (+/ash) or hom (ash/ash) ashen
mice. At day 6-7 after in vitro stimulation CTLs were tested for their ability to degranulate
in response to exposure to aCD3e-loaded P815 target cells. Representative histograms for
CTLs incubated on their own (blue histograms) or mixed at an E:T ratio of 1:1 with aCD3e-
loaded P815 target cells (red histograms) for 45 min, 90 min or 180 min are shown. C
Average degranulation result. During each independent repeat the experiment was performed
at least in technical duplicates, n=2/3 independent experiments, * p<0.05 calculated by
paired t-test. Samples were paired by day of experiment. D One experiment from C that
included CTL from het (+/ash) ashen mice. E Western blot showing RAB27A and calnexin
(loading control) protein expression in cells derived from WT (+/+), hom (ash/ash) and het
(+/ash) ashen mice. WT = wild-type, het = heterozygous, hom = homozygous.
mice could decrease degranulation. Initially, this was attempted using a pool of siRNAs
targeting Rab27a mRNA, as the siRNA technique was already established in the Griffiths lab
(Stinchcombe et al., 2015). CTLs were tested for their ability to degranulate one day after
nucleofection with Rab27a siRNA or scramble control siRNA. Rab27a siRNA nucleofection
significantly decreased degranulation at all time points tested [45 min (n=8, p<0.05, paired
t-test), 90 min (n=8, p<0.001, paired t-test) and 180 min (n=8, p<0.01, paired t-test)] (Figure
3.2A-B). However, the decrease was not as striking as observed with ashen CTL (Figure
3.1). WB showed that RAB27A protein levels were never fully depleted, but reproducibly
decreased, in response to siRNA treatment (Figure 3.2C-D) (n=7, p<0.01, one sample t-test).
As treatment with 3 µg siRNA did not fully deplete RAB27A protein levels after one
day, protein levels were tested 2 and 3 days post nucleofection. However, longer treatment
time did not reduce RAB27A protein further (Figure 3.3A). Additionally, RAB27A protein
levels were not further decreased when the amount of siRNA was doubled (to 6 µg) (Figure
3.3B). In a final attempt to improve the loss of RAB27A protein, CTLs were transfected
with 3 µg siRNA and left to recover for two days before a second transfection with 3 µg
siRNA (Figure 3.3C). However, this ’double hit’ did not deplete RAB27A protein further
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Fig. 3.2 RAB27A knockdown in WT mouse CTLs decreased degranulation.
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Fig. 3.2 RAB27A knockdown in WT mouse CTLs decreased degranulation. A CTLs
were nucleofected with 3 µg scramble siRNA or 3 µg Rab27a siRNA at day 5-7 after in
vitro stimulation. Degranulation assays were performed the following day. Representative
histograms for unstimulated CTL (grey), CTL co-cultured with P815 target cells (blue) and
CTL co-cultured with aCD3e-loaded P815 target cells (red) are shown. Degranulation
was measured by extracellular exposure of LAMP1 after 45 min, 90 min and 180 min.
Degranulation assays were analysed using the following gating strategy: initial gate to
separate the cell population from debris, second gate to isolate single cells from doublets,
third gate to isolate live cells from dead cells, fourth gate to isolate CD8-positive cells and
a final gate to isolate LAMP1-PE positive cells. B Average degranulation result, each
independent experiment was performed at least in technical duplicates. n=8 independent
experiments, *p<0.05, **p<0.01, ***p<0.001 calculated by paired t-test according to the
days the experiments were performed on. C Western blot showing RAB27A and b -actin
(loading control) protein expression one day after scramble or Rab27a siRNA nucleofection
in two independent experiments. D Average RAB27A protein knockdown achieved. In each
repeat the RAB27A protein level was expressed relative to the RAB27A level in the respective
scramble siRNA sample and normalised to calnexin or b -actin loading controls. Bar graphs
show the mean, error bars show the SD, n=7 independent experiments, **P<0.01 calculated
by one sample t-test. exp = experiment.
3.2.2 Optimising the CRISPR technology in primary mouse CTL
Rab27a was established as a good genetic target to test CRISPR, as a decrease in degranulation
could be observed despite only partial protein depletion. However, for the initial set up of
the CRISPR technique in CTL it would be desirable to be able to monitor KO efficiency
at single cell resolution, rather than using a technique like WB, which measures a bulk
population. Therefore, CRISPR was used to target the cell surface protein Thy1.2 (also
known as CD90.2), referred to as Thy1 from now on. Thy1 is a glycosylphosphatidylinositol-
anchored cell surface protein, which is abundantly expressed in mouse T cells (Haeryfar and
Hoskin, 2004; Killeen, 1997). Due to the extracellular expression of Thy1 and the availability
of good antibodies it can be easily monitored at single cell resolution using flow cytometry
(Doench et al., 2014).
CTLs were derived from homozygous Cas9 mice (Tzelepis et al., 2016) and nucleofected
with synthetic crRNAs and tracrRNAs. The concentration of 3 µg used for siRNA experiments

































































































































































































































































































































Fig. 3.3 Optimisation of RAB27A knockdown in WT mouse CTL.
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Fig. 3.3 Optimisation of RAB27A knockdown in WT mouse CTL. A CTLs were
nucleofected with 3 µg scramble siRNA or 3 µg Rab27a siRNA and RAB27A protein
expression was monitored by WB over 3 days, n=1 for each time point. B CTLs were
nucleofected with 6 µg scramble siRNA or 6 µg Rab27a siRNA and RAB27A protein
expression was monitored by WB over 3 days, n=1 for each time point. C CTLs were
nucleofected with 3 µg scramble siRNA or 3 µg Rab27a siRNA . Two days later, the same
cells were nucleofected again with 3 µg scramble siRNA or 3 µg Rab27a siRNA. RAB27A
protein expression was monitored by WB before and after the siRNA double hit, n=1 for each
time point. In all experiments, RAB27A protein levels were normalised to calnexin (loading
control) and expressed relative to the RAB27A level in the respective scramble siRNA sample.
scr si = scramble siRNA, Rab si = Rab27a siRNA.
expression of Thy1 on the cell surface of CD8 T cells was monitored by flow cytometry
over 5 consecutive days (Figure 3.4A). Toxicity was sometimes observed in response to
nucleofecting 10 µg crRNA reagents, as demonstrated by less events recorded in the 10 µg
Thy1 crRNA sample in Figure 3.4A. While almost all samples were 100% positive for Thy1
at day 1 post nucleofection, by day 2 post nucleofection a decrease in the Thy1-positive
population could be observed in the samples nucleofected with Thy1 CRISPR reagents. The
Thy1 levels in samples nucleofected with a non-targeting control crRNA remained unchanged.
The decrease became more prominent at day 3 post nucleofection, and was stably maintained
up until the final time point measured (day 5 post nucleofection). The greatest decrease in
the Thy1 positive population was observed with 10 µg crRNA/tracrRNA (average decrease
of 41.6% at day 5 post nucleofection), closely followed by 5 µg crRNA/tracrRNA (average
decrease of 33.3% at day 5 post nucleofection) and then 3 µg crRNA/tracrRNA (average
decrease of 28.8% at day 5 post nucleofection) (Figure 3.4B). To avoid toxic side effects and
overloading the cells with RNA, while also giving the highest chance of generating KOs, 5
µg crRNA/tracrRNA was chosen as the amount to use in future experiments.
While KO of Thy1 using the approach outlined in Figure 3.4 worked reproducibly, it
depended on the availability of Cas9 homozygous mice. While these experiments were
being conducted, another study was published that used Cas9 protein alongside synthetic
crRNA/tracrRNA (forming RNP complexes) in human T cells (Schumann et al., 2015).
Co-nucleofection of Cas9 protein alongside crRNA and tracrRNA was tested in cells derived
from OT-I mice, which were readily available in the Griffiths lab. OT-I mice express TCRs
that recognise the OVA peptide in the context of H-2Kb MHC class I molecules (Hogquist
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Fig. 3.4 CrRNA and tracrRNA concentration response and time course.
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Fig. 3.4 CrRNA and tracrRNA concentration response and time course. A Cas9 hom CTLs
were nucleofected with the indicated amount of non-targeting or Thy1 crRNA, in addition
to the identical amount of tracrRNA at day 5-7 after in vitro stimulation. Additionally, a
nucleofection control was included, where CTLs were nucleofected but not exposed to any
RNA. Thy1 cell surface protein levels were monitored by flow cytometry over 5 days and
analysed using the following gating strategy: initial gate to seperate cell population from
debris, second gate to isolate single cells from doublets, third gate to isolate live cells
from dead cells, fourth gate to isolate CD8-positive cells and a final gate to determine
the percentage of Thy1 positive cells. The Thy1 gate was set according to the appropriate
nucleofection control for every time point. B Average of Thy1 cell surface expression in CD8
cells over the course of 5 days, n=4 independent experiments for nuc ctrl, 10 µg NT and 10
µg Thy1 samples, n=3 independent experiments for all other samples. Bar graphs show the
mean, error bars the SD, *p<0.05, **p<0.01, ***p<0.001 calculated by unpaired t-test with
Welch’s correction. Nuc ctrl = Nucleofection control, NT = non-targeting.
et al., 1994). OT-I were nucleofected with 5 µg Thy1 crRNA/tracrRNA and varying amounts
of Cas9 protein (Figure 3.5A). As in Figure 3.4 the cell surface expression of Thy1 was
monitored by flow cytometry over 5 consecutive days. Again, a decrease in the Thy1-positive
population could be observed in the samples nucleofected with Thy1 CRISPR reagents, but
not in cells nucleofected with non-targeting control crRNA (Figure 3.5A). This decrease
was stably maintained up until the final time point (day 5 post nucleofection). The greatest
decrease in the Thy1 positive population was observed with 10 µg Cas9 (average decrease of
64.7% at day 5 post nucleofection), followed by 5 µg Cas9 (average decrease of 44.9% at
day 5 post nucleofection) and then 2.5 µg Cas9 (average decrease of 29.5% at day 5 post
nucleofection) (Figure 3.5B). Therefore, 10 µg Cas9 protein was chosen as the amount to
use in future experiments.
To understand why Thy1 KO was more efficient using Cas9 protein than using CTLs
derived from Cas9 homozygous mice, Cas9 protein levels in samples derived from Cas9
hom mice or conditions outlined in Figure 3.5 were investigated. Cas9 levels were much
higher in samples one day after nucleofection with 5 µg or 10 µg of Cas9 protein than in
the samples derived from Cas9 homozygous mice (Figure 3.6A-B). Additionally, I tested
whether using 20 µg Cas9 protein further increases KO efficiency, but this was not the case
(Figure 3.6C). Finally, Cas9 levels were monitored over 3 days post nucleofection of Cas9
protein, demonstrating that the nucleofected Cas9 protein is only present transiently in cells,
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Fig. 3.5 Titration of Cas9 protein for use with synthetic crRNA and tracrRNA.
70 Establishing the CRISPR-Cas9 technology in primary mouse T cells
Fig. 3.5 Titration of Cas9 protein for use with synthetic crRNA and tracrRNA. A OT-I
CTLs were nucleofected with the indicated amount of Cas9 protein in addition to 5 µg
tracrRNA and 5 µg crRNA targeting Thy1 or a non-targeting control crRNA at day 4 after
in vitro stimulation. Additionally, a nucleofection control was included, where CTLs were
nucleofected but not exposed to any RNA or protein. Thy1 cell surface protein levels were
monitored by flow cytometry over 5 days and analysed using the following gating strategy:
initial gate to seperate cell population from debris, second gate to isolate single cells from
doublets, third gate to isolate live cells from dead cells, fourth gate to isolate CD8-positive
cells and a final gate to determine the percentage of Thy1 positive cells. The Thy1 gate was set
according to the appropriate nucleofection control for every time point. B Thy1 cell surface
expression in CD8 cells over the course of 5 days, n=3 independent experiments. Bar graphs
show the mean, error bars the SD, *p<0.05, **p<0.01, ***p<0.001 calculated by unpaired
t-test with Welch’s correction. Nuc ctrl = Nucleofection control, NT = non-targeting.
and all Cas9 protein is lost by day 2 post nucleofection (Figure 3.6D).
3.2.3 Targeting genes that are crucial for CTL killing function by CRISPR
After successfully optimising the CRISPR-Cas9 technology for mouse CTLs by targeting
Thy1, the optimised method was used to target Rab27a, due to the well established effect of
RAB27A loss on degranulation (Figure 3.1), as well as perforin and Munc13-4. To ensure
that the technical aspects of the experiments were working, the Thy1 crRNA was included
as an efficiency control in every experiment and co-nucleofected alongside crRNAs against
the genes of interest. Therefore, each experiment included the following controls: 1) a
nucleofection control, 2) CTLs nucleofected with a non-targeting crRNA, tracrRNA and
Cas9 protein, and 3) CTLs nucleofected with Thy1 targeting CRISPR reagents. Each target
gene was targeted with 3 crRNAs, to increase the chances of a cut, and perhaps even a large
deletion, occurring. To allow time for the protein pool to be turned over, CTLs were tested in
a degranulation and a killing assay four days after nucleofection. Additionally, pellets were
frozen to test protein levels by WB at this time point.
Targeting Rab27a by CRISPR reproducibly resulted in a decrease in degranulation in
comparison to controls (Figure 3.7A-B) (n=5, p<0.05, paired t-test). WB for the RAB27A
protein confirmed that Rab27a CRISPR samples expressed less RAB27A protein than Thy1
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Fig. 3.6 Comparison of stable and transient Cas9 expression. A Representative WB
showing Cas9 protein expression levels in T cells derived from homozygous Cas9 mice
and T cells nucleofected with indicated amounts of Cas9 protein. B Quantification of
WBs showing Cas9 protein expression levels. In each repeat, the Cas9 protein level was
normalised to the b -actin loading control and expressed relative to the Cas9 hom samples.
Bar graphs show the mean, error bars the SD, n=2 independent experiments. C Thy1 protein
cell surface expression one day and four days after CTL nucleofection with the indicated
reagents, n=1. D WB for Cas9 and b -actin (loading control) levels 1, 2 and 3 days after
nucleofection with indicated amounts of Cas9 protein, n=1. Nuc ctrl = Nucleofection control,
NT = non-targeting.
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CTLs ability to kill target cells was determined by an assay that measures death of target
cells stably expressing a red nuclear marker by loss of red fluorescence. There were more
red target cells remaining in wells containing Rab27a CRISPR CTL than in control wells,
meaning that less killing occurred in response to targeting Rab27a by CRISPR (Figure
3.7E-F).
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Fig. 3.7 Decreased degranulation and killing in response to targeting Rab27a using
CRISPR.
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Fig. 3.7 Decreased degranulation and killing in response to targeting Rab27a using
CRISPR. OT-I CTL were nucleofected at day 4 after in vitro stimulation and tested in
functional assays at day 8. A For degranulation assays CTLs were mixed with target cells
at an E:T ratio of 2.5:1. Degranulation was measured by extracellular exposure of LAMP1
after 180 min. The following gating strategy was applied: initial gate to separate the cell
population from debris, second gate to isolate single cells from doublets, third gate to isolate
live cells from dead cells, fourth gate to isolate CD8-positive cells and a final gate to isolate
LAMP1-PE positive cells. Representative histograms for unstimulated CTL co-cultured
with EL4 target cells (blue) and CTL co-cultured with OVA-loaded EL4 target cells (red)
are shown. B Average percentage of LAMP1-PE positive CD8 cells nucleofected with the
indicated reagents in response to 180 min of co-culture with OVA-loaded EL4 target cells,
n=5 independent experiments, *p<0.05, **p<0.01 calculated by paired t-test. Samples
were paired by day of experiment. During each independent repeat the experiment was
performed at least in technical duplicates. Bar graphs show the mean, error bars the SD. C
Representative WB showing RAB27A and b -actin (loading control) protein expression four
days after nucleofection. D Average RAB27A protein levels across 4 independent repeats. In
each repeat, the RAB27A protein level was expressed relative to the nucleofection control
and normalised to calnexin or b -actin loading controls. Bar graphs show the mean, error
bars the SD, *p<0.05 calculated by one sample t-test, ns = not significant. E Incucyte killing
assay showing % lysis of red EL4 target cells. One representative plot for 3 independent
experiments is shown. E:T = 10:1. Each datapoint is an average of 3-4 technical repeats and
the error bars show the SD. F Raw data from Incucyte killing assay showing comparable
levels of red EL4 target cells between treatments at 0 h, but increased levels of red target
cells in Thy1 + Rab27a CRISPR samples after 5 h. Scale bar = 800 µm.
Perforin is another gene that is known to be crucial for CTL killing function. Perforin
protein deficiency in humans causes an immunodeficiency disease (FHL2), and CTL killing
is inhibited in perforin KO mice (Dieckmann et al., 2016; Kägi et al., 1994a; Walsh et al.,
1994). However, while perforin KO should affect the CTLs ability to kill, it should not
decrease their ability to release LAMP1 (Dieckmann et al., 2016). CTLs in which perforin
was targeted by CRISPR did not result in a decrease in degranulation in comparison to the
controls (Figure 3.8A-B). Instead, degranulation was increased in perforin CRISPR samples
(n=4, p<0.05, paired t-test). Meanwhile, the CTLs ability to kill target cells was diminished,
as more red target cells remained in wells containing perforin CRISPR CTL than in control
wells (Figure 3.8E-F). Additionally, WB showed that perforin protein levels were decreased
74 Establishing the CRISPR-Cas9 technology in primary mouse T cells
in perforin CRISPR CTL in comparison to Thy1 CRISPR and nucleofection control samples

























































































































































Fig. 3.8 Targeting Perforin by CRISPR decreased CTL killing, but not degranulation.
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Fig. 3.8 Targeting Perforin by CRISPR decreased CTL killing, but not degranulation. OT-
I CTL were nucleofected at day 4 after in vitro stimulation and tested in functional assays
at day 8. A For degranulation assays CTLs were mixed with target cells at an E:T ratio of
2.5:1. Degranulation was measured by extracellular exposure of LAMP1 after 180 min. The
following gating strategy was applied: initial gate to separate the cell population from debris,
second gate to isolate single cells from doublets, third gate to isolate live cells from dead cells,
fourth gate to isolate CD8-positive cells and a final gate to isolate LAMP1-PE positive cells.
Representative histograms for unstimulated CTL co-cultured with EL4 target cells (blue) and
CTL co-cultured with OVA-loaded EL4 target cells (red) are shown. B Average percentage
of LAMP1-PE positive CD8 cells nucleofected with the indicated reagents in response to
180 min of co-culture with OVA-loaded EL4 target cells. Bar graphs show the mean, error
bars the SD, n=4 independent experiments, *p<0.05 calculated by paired t-test, ns = not
significant. Samples were paired by day of experiment. During each independent repeat the
experiment was performed at least in technical duplicates. C Representative WB showing
Perforin and b -actin (loading control) protein expression four days after nucleofection. D
Average perforin protein levels across 3 independent repeats. In each repeat, the perforin
protein level was expressed relative to the nucleofection control and normalised to calnexin
or b -actin loading controls. Bar graphs show the mean, error bars the SD, ***p<0.001
calculated by one sample t-test. E Incucyte killing assay showing % lysis of red EL4 target
cells. One representative plot for 3 independent experiments is shown. E:T = 10:1. Each
datapoint is an average of 3-4 technical repeats and the error bars show the SD. F Raw
data from Incucyte killing assay showing comparable levels of red EL4 target cells between
treatments at 0 h, but increased levels of red target cells in Thy1 + Perforin CRISPR samples
after 5 h. Scale bar = 800 µm.
MUNC13-4 deficiency causes immunodeficiency in humans (FHL3) and similar phenotypes
in mice (Crozat et al., 2007). Targeting Munc13-4 by CRISPR resulted in a decrease
in degranulation in comparison to controls (Figure 3.9A-B, n=5, p<0.05, paired t-test).
MUNC13-4 protein levels were successfully decreased in response to CRISPR as shown by
WB (n=3, P<0.01, one sample t-test) (Figure 3.9C-D). In addition to decreasing degranulation,
Munc13-4 CRISPR also decreased the ability of CTLs to kill target cells (Figure 3.9E-F).
The data generated in the Rab27a, perforin and Munc13-4 CRISPR experiments was
used to investigate whether Thy1 expression could be used to isolate cells where the CRISPR
had worked. As a crRNA against Thy1 was co-nucleofected in these experiments, I could
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Fig. 3.9 Munc13-4 CRISPR results in decreased degranulation and killing.
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Fig. 3.9 Munc13-4 CRISPR results in decreased degranulation and killing. OT-I CTL
were nucleofected at day 4 after in vitro stimulation and tested in functional assays at
day 8. A For degranulation assays CTLs were mixed with target cells at an E:T ratio of
2.5:1. Degranulation was measured by extracellular exposure of LAMP1 after 180 min. The
following gating strategy was applied: initial gate to separate the cell population from debris,
second gate to isolate single cells from doublets, third gate to isolate live cells from dead
cells, fourth gate to isolate CD8-positive cells and a final gate to isolate LAMP1-PE positive
cells. Representative histograms for unstimulated CTL co-cultured with EL4 target cells
(blue) and CTL co-cultured with OVA-loaded EL4 target cells (red) are shown. B Average
percentage of LAMP1-PE positive CD8 cells nucleofected with the indicated reagents in
response to 180 min of co-culture with OVA-loaded EL4 target cells. Bar graphs show the
mean, error bars the SD, n=3 independent experiments. During each independent repeat the
experiment was performed at least in technical duplicates. C Representative WB showing
MUNC13-4 and calnexin (loading control) protein expression four days after nucleofection.
D Average MUNC13-4 protein levels across 3 independent repeats. In each repeat, the
MUNC13-4 protein level was expressed relative to the nucleofection control and normalised
to calnexin loading controls. Bar graphs show the mean, error bars the SD, ***p<0.01
calculated by one sample t-test, ns = not significant. E Incucyte killing assay showing %
lysis of red EL4 target cells. One representative plot for 3 independent experiments is shown.
E:T = 10:1. Each datapoint is an average of 3-4 technical repeats and the error bars show
the SD. F Raw data from Incucyte killing assay showing comparable levels of red EL4 target
cells between treatments at 0 h, but increased levels of red target cells in Thy1 + Munc13-4
CRISPR samples after 5 h. Scale bar = 800 µm.
gate on Thy1 negative cells during the degranulation assay. This allowed to select cells that 1)
have been nucleofected successfully and 2) have taken up Cas9-RNP complexes. Data from
these assays was analysed using two different gating strategies, outlined in Figure 3.10A,
in order to investigate whether gating on the Thy1-negative population resulted in a more
striking degranulation phenotype in CRISPR samples. Gating on Thy1 negative cells showed
a trend towards further decreasing the percentage of LAMP1-PE positive cells observed in
Munc13-4 and Rab27a CRISPR experiments, in comparison to the results obtained without
gating on Thy1 negative cells. This indicated that gating on Thy1 negative cells could be
used to isolate edited cells to some extent, however this effect was not statistically significant
when tested using a paired t-test (Figure 3.10B).


































































Fig. 3.10 The effect of gating on Thy1 negative cells on degranulation. A Degranulation
assays were analysed using two gating strategies: initial gate to separate the cell population
from debris, second gate to isolate single cells from doublets, third gate to isolate live cells
from dead cells and a fourth gate to isolate CD8-positive cells. This was followed by either
1) a final gate to isolate LAMP1-PE positive cells or 2) a fifth gate to isolate Thy1 negative
cells prior to a sixth gate to isolate LAMP1-PE positive cells. B Average percentage of
LAMP1-PE positive CD8 cells in response to 180 min of co-culture with OVA-loaded EL4
target cells. Each experiment was analysed with gating strategy 1 (blue) and gating strategy 2
(red). The results from both gating strategies were compared using paired t-tests, with sample
pairing by day of experiment, n=3/4 independent experiments. During each independent
repeat the experiment was performed at least in technical duplicates. neg = negative, ns =
not significant.
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While a degranulation defect often overlaps with a killing phenotype, as observed for
Rab27a and Munc13-4 CRISPR samples (Figure 3.7 and 3.9), the perforin CRISPR result
highlighted that some genes implicated in CTL killing could be missed if the degranulation
assay is used as the sole readout in a screen. For example, genes that affect the cytolytic
components of the granules, rather than granule release, could not be detected using the
traditional degranulation assay. Since the aim of this project is to identify genes involved
in CTL killing, an assay that measures killing as well as degranulation would be desirable.
To achieve this, the standard degranulation assay was modified. Firstly, target cells stably
expressing BFP (see chapter 2, section 2.1.4) were used. Secondly, a known amount of
fluorescent cell counting beads was added to each sample just before analysis on the flow
cytometer. Gating on these populations allowed me to determine the number of beads and the
number of blue target cells that were recorded in each sample. This enabled the ratiometric
enumeration of target cells, accounting for any differences in acquisition between samples.
As a result, the percentage of live and dead EL4 target cells in each well could be determined
at the same time as CTL degranulation was measured (Figure 3.11A,B, please see figure
legend for a more detailed description of this calculation).
To test this assay, I used the Rab27a, Munc13-4 and perforin CRISPR samples previously
shown to result in protein loss and a reduced killing phenotype (Figures 3.7, 3.8, 3.9). For
nucleofection control samples, the reduction of EL4 target cells can even be seen by eye when
comparing the EL4 population between CTL+EL4-OVA and CTL+EL4+OVA conditions,
indicating that target cell killing is occurring (Figure 3.11C). In contrast, such a decrease
in the EL4 population cannot be observed for Thy1 + Rab27a CRISPR samples, indicating
that target cell killing is reduced (Figure 3.11C). The bead method enabled quantification of
this difference and allowed me to plot the percentage of target cells killed (Figure 3.11D).
A decrease in target cell killing was observed for Thy1 + Rab27a CRISPR samples (n=3,
p<0.05, paired t-test), Thy1 + Munc13-4 CRISPR samples (n=3, p<0.05, paired t-test) and
Thy1 + perforin CRISPR samples (n=2).





























































































































Sample Count in EL4 gate Count in beads gate EL4:beads ratio *10100 = no. of live EL4 % live % dead
CTL + EL4 - OVA 2132 2540 0.84 8484
CTL + EL4 + OVA 1276 2744 0.47 4747 55.40 44.60
CTL + EL4 -OVA CTL + EL4 +OVA
Fig. 3.11 The combined degranulation and killing assay.
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Fig. 3.11 The combined degranulation and killing assay. A Gating strategy used to
analyse the combined degranulation and killing assay. The fluorescent 123count ebeads can
be separated from cells by size and using different fluorescence channels. One gate is drawn
around the beads (’beads’) to determine the number of beads present in the sample. Another
identical gate is used to select all events except for the beads (’beadsout’), so that the beads
do not interfere with any other fluorescent signal. Within the ’beadsout’ gate, a gate to
separate the cell population from debris is followed by a gate to isolate single cells from
doublets. Next, live cells are isolated from dead cells before gating on CD8 cells to determine
the degranulation readout or blue EL4 target cells to determine the target cell count. B
Example quantification of the killing response using the beads method. The count in the
EL4 gate is divided by the count in the beads gate, giving an EL4:beads ratio. This can be
multiplied by the number of beads added per well (in this example 10,100 beads, information
supplied by the manufacturer for every batch) to calculate the absolute number of live
target cells in the well. Normalising the +OVA sample to its respective -OVA sample allows
determination of the percentage of live target cells remaining in the +OVA sample. This, in
turn, allowed me to deduce the percentage of dead target cells that have been killed by CTLs.
C Representative example of the killing response of CTLs derived from nucleofection control
and Thy1 + Rab27a CRISPR samples. In the nucleofection control sample, a decrease in blue
EL4 target cells from -OVA to +OVA plots can be seen. No decrease in blue EL4 target cells
could be detected between -OVA and + OVA plots from Thy1 + Rab27a CRISPR samples. D
Average killing assay readout for Thy1 + Rab27a CRISPR (n=3 independent experiments),
Thy1 + Munc13-4 CRISPR (n=3 independent experiments) and Thy1 + Perforin CRISPR
(n=2 independent experiments). E:T ratio = 2.5:1, assay duration = 180 min. Bar graphs
show the mean, error bars the SD. Statistical analysis was not performed on Thy1 + Perforin
CRISPR experiments as data was derived from only two independent experiments (see section
2.14). ns = not significant, *p<0.05, **p<0.01, ***p<0.001 as calculated by paired t-test.
Samples were paired by day of experiment to account for day-to-day variations.
3.3 Discussion
Figure 3.1 shows that RAB27A was expressed in CTLs derived from WT and het ashen mice,
but not in hom ashen mice. CTLs derived from hom ashen mice furthermore showed a striking
degranulation defect (Figure 3.1). Using siRNA to knockdown RAB27A protein in CTLs
derived from WT mice resulted in a consistent decrease in degranulation in comparison to the
respective controls. It was not possible to reproduce the striking decrease in degranulation
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observed in CTLs derived from hom ashen mice with siRNA knockdown (Figure 3.2). The
mild siRNA phenotype can be explained by only partial protein knockdown being achieved
(Figure 3.2). The biggest decrease in protein level was achieved with 3 µg siRNA one
day after nucleofection, but this only reduced protein levels by 36% on average (n=7).
Increasing Rab27a siRNA concentration, incubation time or nucleofecting CTLs twice with
siRNA did not decrease RAB27A protein levels further (Figure 3.3). This indicated either
low nucleofection efficiency, or that the siRNA did not work as effectively as expected.
Nonetheless, it is important to note, that even only partial RAB27A protein knockdown still
reproducibly resulted in a decrease in degranulation, making Rab27a a good target for testing
phenotypic effects of CRISPR KO.
The partial protein knockdown observed in response to Rab27a siRNA treatment highlighted
the disadvantage of using a technique like WB for the detection of protein loss, as WB shows
the bulk cell population. Only a small proportion of the cell population may take up the
CRISPR reagents upon nucleofection. Furthermore, even in cells where CRISPR will
introduce cuts in the desired gene, there will be a mixed population of heterozygous and
homozygous KOs. A technique that gives single cell resolution, such as flow cytometry,
allows observation of the effect even if the KO only occurs in a small subset of the entire cell
population.
For ease of detection by flow cytometry, the cell surface protein Thy1 was targeted using
synthetic CRISPR reagents for the initial set up of the CRISPR technique. The best KO
efficiency without toxic side effects was observed with 5 µg crRNA/tracrRNA and 10 µg
Cas9 protein (Figure 3.4 and 3.5). This reproducibly achieved loss of Thy1 surface expression
in over 60% of the cell population (Figure 3.5B), sometimes achieving over 90% KO (Figure
3.6C). Increasing the amount of Cas9 protein beyond 10 µg did not further improve KO
efficiency (Figure 3.6C). Nucleofecting Cas9 protein likely resulted in a higher KO efficiency
than using CTLs from Cas9 hom mice due to the higher Cas9 level in the former samples
(Figure 3.6A-B).
Time course experiments (Figures 3.4 and 3.5) showed that it took 2-3 days for the
CRISPR effect to show, which indicated that this is the amount of time it took for the
CRISPR-induced damage to accumulate and for the Thy1 protein pool to be turned over. As
protein longevity varies greatly, it would be best to wait as long as possible to allow protein
turnover when targeting other genes using CRISPR. However, mouse CTL lifespan in tissue
culture is limited, and they are best used for functional assays around day 7-8 post in vitro
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stimulation. Therefore, CTLs were nucleofected at day 4 post in vitro stimulation and tested
in functional assays at day 8. This optimised CRISPR approach was successfully used to
knock out genes that are known to be crucial for CTL killing function. Targeting Rab27a and
Munc13-4 decreased the degranulation and killing capabilities of CTLs (Figures 3.7 and 3.9).
Targeting perforin affected CTL killing without decreasing degranulation (Figure 3.8).
A downside to any approach involving nucleofection of synthetic RNAs is that there is
no way to select cells that have taken up the reagents. Therefore, the population studied will
always be a mix of WT and genetically modified cells meaning that genes that have subtle
effects upon KO may be overlooked. Because of this it is important to optimise the reagent
concentration in order to maximise the KO efficiency as done in Figure 3.4 to 3.5.
To isolate cells that have been nucleofected successfully in a degranulation assay, others
have co-nucleofected a GFP-plasmid alongside siRNAs (Kabanova et al., 2016). The
underlying assumption is that cells which have taken up the GFP plasmid are also more likely
to have taken up the co-nucleofected reagents. A more accurate approach would be to use
synthetic crRNAs or tracrRNAs fused to a fluorescent marker, as done by Seki and Rutz
(2018). However this fusion may affect the function of the RNA and such products were not
yet available when the experiments outlined in this chapter were performed.
As an alternative approach, a Thy1 crRNA was co-nucleofected alongside the crRNAs
against the gene of interest. The percentage of Thy1 KO could be measured alongside the
percentage of LAMP1-PE positive cells in the degranulation assay. In addition to allowing to
monitor the nucleofection efficiency, targeting Thy1 gave an idea of how well the CRISPR
worked in each experimental condition. A lack of Thy1 KO would indicate a technical
mistake, such as accidentally not adding Cas9 protein. Using the Thy1 readout to select cells
where the CRISPR technique worked, by gating on Thy1 negative cells in the degranulation
assay, did not significantly improve the readout in Rab27a, Munc13-4 or perforin CRISPR
experiments (Figure 3.10).
While it was beneficial to co-nucleofect a Thy1 crRNA in initial experiments to ensure
the CRISPR technique was working robustly, it also raised some concerns. Firstly, targeting
an additional region in the genome could result in unanticipated side effects. Secondly, it
could decrease CRISPR efficiency for the gene of interest by competing for the available
Cas9 and tracrRNA reagents. Thirdly, gating on Thy1 negative cells during the degranulation
assay means that I cannot meaningfully compare the data to the controls that are closest to the
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unmanipulated cells (nucleofection controls and non-targeting CRISPR controls), as these
do not contain a Thy1 negative population. Finally, others have suggested that Thy1 can
affect T cell activation, which could result in unwanted side effects (Haeryfar and Hoskin,
2004; Killeen, 1997). In summary, I therefore concluded that it would be preferable not to
co-nucleofect the Thy1 crRNA alongside crRNAs against other genes from now on.
3.3.1 Development of an assay to measure both degranulation and killing
The degranulation assay is suitable for high throughput screening as it can be performed
in a 96 well format. Picking one time point would maximise the number of samples fitting
on one plate. The 90 min and 180 min time points showed the clearest separation between
scramble and Rab27a siRNA treated samples (Figure 3.2). As the 180 min time point also
showed a clear separation in Incucyte killing assays (Figure 3.7 to 3.9) it was chosen as the
most suitable end point for the degranulation assay in an effort to miniaturise the assay.
The beads assay (Figure 3.11) allowed to determine the percentage of target cells killed
in the same well as the degranulation readout. This was achieved by making two simple
changes to the traditional degranulation assay: 1) the addition of stained target cells and 2)
the addition of a known amount of cell counting beads. This assay will enable to test killing
phenotypes at the same scale as the degranulation assay. To maximise the number of samples
fitting on one plate this assay was limited to one E:T ratio and one time point. Therefore, any
promising hits should be followed up further with additional phenotypic assays.
3.3.2 Summary and evaluation of aims
• Degranulation assay set up and adaptation for a screen.
– The degranulation assay successfully showed a defect in response to RAB27A
and MUNC13-4 depletion. As the 180 min time point showed a clear separation
between experimental samples and controls it was chosen as the only time
point to be used subsequently in order to maximise the number of samples
per degranulation assay. Furthermore, an assay that simultaneously measures
degranulation and killing was developed.
• Manipulate gene expression in primary mouse CTLs using siRNA.
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– RAB27A protein levels were successfully reduced in response to treatment with
Rab27a siRNA, although not to the desired extent. This highlighted the potential
of CRISPR which can stably and homozygously KO genes.
• Optimise the CRISPR-Cas9 technology in primary mouse CTLs.
– The use of synthetic crRNA and tracrRNA reagents as well as Cas9 protein
was optimised through concentration response and time course experiments
targeting the cell surface protein Thy1. Conditions that resulted in reproducible
and efficient KO were successfully established.
• Use the CRISPR-Cas9 technology in primary mouse CTLs to target genes where the
KO has a known phenotype in the degranulation assay.
– Rab27a, perforin and Munc13-4 were successfully targeted by CRISPR in mCTL
as demonstrated by WB, degranulation and killing assays.

Chapter 4
Transcriptome analysis of CD8 T cells to
inform a targeted CRISPR screen
4.1 Introduction
TCR stimulation triggers naive CD8 T cells to differentiate into effector CTL. This causes a
small and quiescent naive cell to undergo rapid clonal expansion, substantially increase in
size and acquire effector functions (de la Roche et al., 2016). The genome will be identical
between a naive CD8 T cell and its corresponding differentiated effector CTL version, but
the genes that are actively expressed will likely differ. In this chapter, RNA-seq was used to
understand what genes are differentially expressed between naive and effector CD8 T cells.
RNA-seq allows measurement of the complete set of transcripts of a cell (Wang et al., 2009)
and therefore allowed me to determine which genes are upregulated in response to activation.
Some of these upregulated genes will be necessary for CTL effector functions, such as target
cell killing. The result of this RNA-seq project formed the basis of a subsequent screen
to investigate how CD8 T cells are regulated at the genetic level. Targeting hits from the
RNA-seq dataset using the CRISPR technology, as optimised in chapter 3, allowed me to
determine whether the upregulated genes affect CTL killing function.
4.1.1 Study design
The experimental approach was to compare the transcriptome of naive CD8 T cells freshly
isolated from spleens of WT mice ("day 0" samples) to the transcriptome of effector CD8
T cells that were activated on aCD3e and aCD28 antibody-coated plates for two days,
followed by 5 days of expansion ("day 7" samples) (Figure 4.1A). This experimental design
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was identical to the standard procedure used to activate WT mouse T cells in vitro. Day 7
was chosen as the end time point as cells are typically used for functional assays, such as
degranulation or killing assays, around this time. At the time that the RNA-seq experiment
was performed the plan was to use T cells derived from Cas9 hom mice for the screen. As
the Cas9 hom mice were on a C57BL/6 background, WT C57BL/6 mice were used for the
RNA-seq study. The study included cells from 10 different mice (4 males and 6 females,
all ⇠16 weeks old). While the main question of interest was what genes are differentially
expressed in day 7 vs day 0 samples, the RNA-seq dataset could additionally be used to
investigate differentially expressed genes between males and females.
4.1.2 Chapter aims
• Determine the differences in gene expression between naive and activated CD8 T cells.
The hypothesis is that there are substantial changes in gene expression between these
two states of CD8 T cells.
• Explore the functional association of the differentially expressed genes using bioinformatic
tools.
• Test the effect of targeting differentially expressed genes by CRISPR in phenotypic
assays (degranulation and killing assays).
• Explore what genes are differentially expressed in CD8 T cells derived from male and
female mice.
4.2 Results
4.2.1 RNA sample preparation and quality control
CD8 T cells were purified from spleens derived from WT mice to ensure that the RNA-
seq data was predominantly derived from CD8 T cells. In order to have a record of the
CD8 purity of each sample, the percentage of CD8 positive cells was determined by flow
cytometry on the same day as freezing cell pellets for RNA extraction. CD8 positive cells
constituted >94.7% of all samples except for one sample where the percentage of CD8s
was slightly lower (Sample 33 day 7: 87.5%) (Figure 4.1B). After RNA extraction with the
RNeasy Mini Kit (Qiagen), the quality of RNA was tested using a Bioanalyser (Agilent).
High quality RNA is critical to ensure successful library preparation for sequencing. The
Bioanalyser determined RNA quality by estimating a RNA integrity number (RIN) (Schroeder
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et al., 2006). The Bioanalyser electrophoretically separated RNA fragments and visualised
their size and distribution via laser-induced fluorescence (see Figure 4.1C and D for a
representative bioanalyser gel and electrophoretic trace). The RIN algorithm takes the entire
electrophoretic trace into account before allocating a score between 1 and 10 to the sample,
with 10 indicating highest quality RNA (Schroeder et al., 2006). Library preparation and
sequencing was performed by the Illumina bespoke team at the Sanger Institute. For library
preparation the Illumina bespoke team required the RNA samples to have a RIN value higher
than 8. All RNA samples in this study had a RIN score between 8.2 and 9.6 (Figure 4.1E).
The Illumina bespoke team performed a stranded library prep with oligodT pulldown. The
20 samples (10 samples for day 0 and 10 samples for day 7) were pooled across 3 paired-end
lanes of an Illumina Hi-Seq and 75 bp reads were sequenced.
CD8 purification Take off stimulus at Day 2 + expand
αCD3 + αCD28 
coated plates








































Fig. 4.1 RNA-seq study design and sample preparation.
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Fig. 4.1 RNA-seq study design and sample preparation. A CD8 T cells were purified from
spleens derived from C57BL/6N WT mice (10 biological replicates, 4 males and 6 females)
across two spleen collection dates. After purification, 6 million cells per sample were frozen
as "day 0" naive cells. The remaining cells were stimulated for two days on 0.5 µg/ml aCD3e
and 1 µg/ml aCD28 coated plates. On day 3 cells were removed from the stimulus, washed
and expanded for a further 5 days. At day 7 post in vitro stimulation 6 million cells per
sample were frozen as "day 7" activated cells. RNA from matched day 0 and day 7 samples
was extracted on the same days. B The percentage of CD8 positive cells was determined
by flow cytometry on the same day as cell pellets were frozen for RNA extraction. C A
representative bioanlayser gel showing the typical banding pattern for a high quality RNA
sample. The two prominent bands correspond to the 28S and 18S ribosomal RNA. D The
bioanalyser electrophoretic trace corresponding to sample 79 day 7 shown in C. The trace
is used to derive the RIN number. E RIN numbers for all samples included in the RNA-seq
experiment as determined by the bioanalyser.
4.2.2 Read mapping, fragment count and quality control
The subsequent bioinformatic analysis steps were performed with Martin Del Castillo
Velasco-Herrera (PhD student in David Adams’ team) following a previously published
workflow (Anders et al., 2013). Reads were aligned to the reference genome (version
GRCm38) using the splice-aware mapper tool STAR (Dobin et al., 2013) guided by version
84 of the Ensembl mouse annotation. Next, the number of read pairs (fragments) that uniquely
aligned to a particular region in the genome were counted using Htseq-count (Anders et al.,
2015). Between 21,786,497 and 49,939,333 reads were mapped per sample, 85.84 - 88.71%
of which mapped uniquely to the reference genome. In order to estimate transcript expression
levels, read counts were normalised by calculating the FPKM (see chapter 2, section 2.7)
(Garber et al., 2011). Pairwise comparisons were performed with the log2-transformed
FPKM values by calculating the pearson correlation coefficient of all possible comparisons.
Hierarchical clustering showed that the samples clustered together according to which group
(i.e. day 0 or day 7) they belonged to (Figure 4.2A), indicating that the gene expression
differs between these two states of cells.
To further identify sources of variance in my dataset a PCA was performed (see chapter 2,
section 2.7). In PCA, data points are projected onto a 2D plane. The x-axis represents the first
principal component (PC1), which explains the greatest variance in the dataset. The y-axis
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Fig. 4.2 RNA-seq quality control.
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Fig. 4.2 RNA-seq quality control. RNA-seq was performed on RNA from CD8 T cells derived
from 10 WT mice (4 males, 6 females) before stimulation and 7 days after stimulation. A
Heatmap comparing samples pairwise in terms of the log2(FPKM) of all protein coding
genes. White indicates a higher pearson correlation coefficient (samples on x and y axis are
similar to one another), blue indicates a lower pearson correlation coefficient (samples on x
and y axis are comparatively different from one another). The hierarchical clustering of the
samples, as shown by the dendrogram, separates the samples by whether they belong to the
day 0 group or the day 7 group. Samples were derived from ⇠16 week old male or female
mice and collected on two different spleen collection dates (SCD, orange = SCD 1, green =
SCD 2) as indicated. B PCA was performed using the top 2000 most variable transcripts
with regularised log transformed expression values for each sample. The percent of the total
variance associated with each principal component is printed on the axis label. Samples
are colour coded according to which group they belong to. C PCA plot where samples are
colour coded according to which group they belong to, as well as which date the spleen was
collected on and whether the spleen was derived from a female or male mouse. The plots
in this figure were prepared with the help of Martin Del Castillo Velasco-Herrera. PC =
principal component. SCD = spleen collection date.
4.2B,C). In agreement with the data in Figure 4.2A, colour coding the samples showed that
the group (i.e. whether a sample belongs to the group day 0 or day 7) is the biggest source of
variance in my dataset. Expanding the colour code to include details such as spleen collection
date and whether the samples were derived from males or females showed that samples also
clustered together due to these factors. This demonstrated that all these factors affected gene
expression, meaning that the spleen collection date should be accounted for in subsequent
analyses.
4.2.3 Comparing gene expression in activated and naive CD8 T cells
The DESeq2 package (Love et al., 2014) was used to identify differentially expressed genes.
DESeq2 tests for differential expression using a negative binomial distribution model (Anders
and Huber, 2010). The spleen collection date was included as a covariate to accommodate
this as a potential confounding factor. P-values were corrected for multiple testing using the
Benjamini-Hochberg correction, giving an adjusted p-value (padj) (see chapter 2, section
2.7). In order to focus on genes with big changes in expression, genes were only considered
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Table 4.1 Top 10 activated differentially expressed genes when comparing day 7 T cells to
day 0 T cells.
Gene Log2(FoldChange) p-value B-H adjusted p-value
Spp1 11.793 0.00E+00 0.00E+00
Lif 10.579 0.00E+00 0.00E+00
Lrrc32 9.477 0.00E+00 0.00E+00
Gzmb 9.103 0.00E+00 0.00E+00
Cdkn1a 9.072 0.00E+00 0.00E+00
Tubb6 8.654 0.00E+00 0.00E+00
Il2ra 7.490 0.00E+00 0.00E+00
Galnt3 7.407 0.00E+00 0.00E+00
Slc16a3 7.397 0.00E+00 0.00E+00
Adam8 7.214 0.00E+00 0.00E+00
to be differentially expressed when the padj was smaller than 0.01 and the log2(fold change)
was larger than 2 (upregulated genes) or smaller than -2 (downregulated genes).
The volcano plot in Figure 4.3A gives an overview of the number of differentially
expressed genes. The fact that there were many significantly up and down regulated genes
upon activation demonstrated how large the effect of activation is on the transcriptome of
CD8 T cells. Genes that are highlighted in blue were detected as differentially expressed
at 1% false discovery rate (FDR) and passed the log2(fold change) cut off. In total, there
were 1803 activated and 2584 repressed significantly differentially expressed genes when
comparing day 7 to day 0. From here on I will focus on the upregulated differentially
expressed genes when comparing day 7 to day 0 samples, as this dataset should include
the genes required for CTL effector functions. The top 10 upregulated genes, as ordered
by the log2(fold change), are shown in Table 4.1. These included Gzmb and Il2ra, which
encode granzyme B and the a-subunit of the high affinity IL2 receptor, respectively. These
two proteins are known to be important for effector CTL function (de la Roche et al., 2016;
Zhang and Bevan, 2011). The complete list of the 1803 upregulated differentially expressed
genes is included digitally on a CD alongside this thesis (Appendix B).
To gain a better overall understanding of what biological pathways are enriched in the
upregulated gene list, I used the Functional Interpretation of Differential Expression Analysis
(FIDEA) server (D’Andrea et al., 2013). FIDEA mapped the genes in my dataset to functional
categories in publicly available databases, such as Gene ontology (GO) (Gene Ontology
Consortium et al., 2012) categories and Kyoto Encyclopaedia of Genes and Genomes (KEGG)
94 Transcriptome analysis of CD8 T cells to inform a targeted CRISPR screen





























Cytokine cytokine receptor interaction
p53 signaling pathway
Steroid biosynthesis
















































































































































small molecule metabolic process









Fig. 4.3 Differential expression analysis between activated and naive CD8 T cells.
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Fig. 4.3 Differential expression analysis between activated and naive CD8 T cells. A
Volcano plot showing the -log10 of the p-value (y-axis) vs the log2 of the fold change of
expression (x-axis) for each gene. Dotted lines indicate the log2(fold change) cut off at
-2 and + 2. The blue colour is used to highlight genes that passed the log2(fold change)
cut off and were detected as differentially expressed at 1% FDR when using the Benjamini-
Hochberg multiple testing adjustment. Some genes encoding members of the granzyme
protein family (Gzmd, Gzme, Gzmf and Gzma) are highlighted on the plot. B Word cloud
derived from FIDEA mapping the significantly upregulated gene set to the KEGG pathway
database. Words are sized according to enrichment using the FIDEA calculated p-value
corrected for multiple testing. C Word cloud derived from FIDEA mapping the significantly
upregulated gene set to the GO database. Words are sized according to enrichment using the
FIDEA calculated p-value corrected for multiple testing. D Annotation cluster derived from
the DAVID functional annotation tool that includes terms related to vesicle fusion, which
could be relevant to CTL function. The heatmap shows the overlap between genes in my
upregulated dataset (y-axis) and genes in the annotation cluster terms (x-axis). Green colour
indicates that a gene is contained within the term, black colour indicates that a gene is not
found in the term. FIDEA = Functional Interpretation of Differential Expression Analysis,
DAVID = Database for Annotation, Visualization and Integrated Discovery, KEGG = Kyoto
Encyclopaedia of Genes and Genomes, GO = Gene ontology.
pathways (Kanehisa et al., 2012). These provide curated gene sets classified according to
participation in common biological processes and can therefore be used to identify enriched
biological themes in large gene lists. The gene sets are largely manually curated based on
available experimental evidence and are therefore limited to published scientific knowledge
(Gene Ontology Consortium et al., 2012). As each database has its own methods for assigning
genes to categories it can be useful to compare the results obtained from separate curations.
The results of the FIDEA analysis using KEGG and GO Slim databases are represented
in word clouds (Figure 4.3B,C). The GO Slim database contains a smaller subset of the
GO terms and is useful for broadly classifying which biological processes a set of genes
is associated with (Gene Ontology Consortium, 2012). The size of the writing for each
functional category in the word clouds corresponds to how enriched the particular category is
in my dataset (D’Andrea et al., 2013). The word clouds particularly showed an enrichment of
genes belonging to the "cell cycle" term of GO Slim and KEGG databases (Figure 4.3B,C).
Other enriched pathways were pathways that are needed to replicate and make bigger cells,
such as DNA replication and metabolism-related pathways (Figure 4.3B,C).
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Using a different functional annotation tool, the Database for Annotation, Visualization
and Integrated Discovery (DAVID) version 6.8 (Huang et al., 2009a,b) for functional
enrichment analysis revealed 192 annotation clusters, representing biological processes,
as enriched in the protein coding genes in my dataset. Annotation clusters group functionally
similar terms together, with each term containing a list of genes associated with the term.
DAVID determined whether these clusters were statistically overrepresented (enriched) in
my dataset of upregulated genes. As for FIDEA, the sources of the functional annotation
are databases such as KEGG and GO. One of the enriched clusters included terms related
to vesicle fusion, which is a key event for CTL killing via the degranulation pathway
(Dieckmann et al., 2016). The heatmap in Figure 4.3D visualises the overlap between
upregulated genes in my dataset and the gene lists in the vesicle fusion annotation cluster.
Ten genes were chosen from this list to target using CRISPR. These genes were Ppfia3,
Anxa1, Anxa2, Anxa3, Anxa4, Tns2, Cav2, Cpne5, Dysf and Unc13a. Additionally, three
other genes, Slc7a5, Hif1a and Nfil3, that were significantly upregulated in my activated
gene list were added as further CRISPR targets. These three genes were previously found to
have interesting phenotypes in CD8 T cells. Lack of SLC7A5 protein was shown to result
in failure of CD8 T cells to differentiate into CTL (Sinclair et al., 2013) and HIF-1a and
NFIL3, also known as E4BP4, depleted CD8 T cells were shown to lack perforin (Rollings
et al., 2018). As these studies used mouse models, it would be interesting to test if these
genes are also crucial for effector functions when only knocked out at day 4 post in vitro
stimulation, as in my experimental set up. An overview of how differentially expressed the
genes chosen for the targeted screen were can be seen in Table 4.2.
4.2.4 Targeted CRISPR screen
The genes of interest were targeted by CRISPR as explained in detail in chapter 3. In short,
at day 4 post in vitro activation CTLs derived from OT-I mice were nucleofected with 3
crRNAs against the genes of interest, in addition to the tracrRNA reagent and Cas9 protein.
Subsequently, CTLs were expanded for four days before measuring their degranulation and
killing ability. As can be seen in Figure 4.4A, no degranulation defect was observed in
response to targeting the genes of interest using CRISPR. Instead, some targets, most notably
Nfil3, showed a trend towards increasing degranulation upon CRISPR treatment (Figure
4.4A). Two genetic targets, Nfil3 and Hif1a , seemed to decrease CTL killing reproducibly
after being targeted by CRISPR (Figure 4.4B).
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Table 4.2 Differentially expressed genes chosen for the targeted CRISPR screen.
Gene Log2(FoldChange) p-value B-H adjusted p-value
Nfil3 5.450 0.00E+00 0.00E+00
Anxa2 4.143 0.00E+00 0.00E+00
Slc7a5 3.591 0.00E+00 0.00E+00
Hif1a 2.446 0.00E+00 0.00E+00
Unc13a 4.223 4.01E-202 1.19E-200
Anxa4 3.115 6.03E-191 1.60E-189
Anxa3 5.661 1.12E-138 1.82E-137
Anxa1 4.261 6.69E-117 8.39E-116
Cav2 5.133 5.14E-40 2.39E-39
Tns2 2.940 2.61E-27 9.64E-27
Cpne5 2.878 1.29E-20 4.16E-20
Ppfia3 2.963 4.34E-14 1.19E-13
















































































































































































































Fig. 4.4 Screening RNA-seq target genes using CRISPR. CTLs were tested for their ability
to degranulate and kill in response to exposure to EL4 target cells loaded with OVA-peptide.
A The degranulation and B the killing readout of the combined degranulation and killing
assays were analysed following the gating strategy and calculations described in chapter 2,
section 2.5.1 and 2.5.2. E:T ratio = 2.5:1, assay duration = 180 min. The bar graphs show
the average of 3 independent experiments, error bars show the SD. During each independent
repeat the experiment was performed in technical duplicates.
Based on the screening results, the effect of Nfil3 and Hif1a CRISPR was investigated
further. This confirmed that Nfil3 CRISPR significantly increased degranulation (n=5, p<0.05,
paired t-test) and decreased killing (n=5, p<0.01, paired t-test) as shown using two different
killing assays (Figure 4.5A-C).


















































































































































































































Fig. 4.5 Targeting Nfil3 by CRISPR resulted in a CTL killing defect.
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Fig. 4.5 Targeting Nfil3 by CRISPR resulted in a CTL killing defect. OT-I CTL were
nucleofected at day 4 after in vitro stimulation and tested in functional assays at day 8.
CTLs were tested for their ability to degranulate and kill in response to exposure to EL4
target cells loaded with OVA-peptide. A The degranulation and B the killing readout of the
combined degranulation and killing assays were analysed following the gating strategy and
calculations described in chapter 2, section 2.5.1 and 2.5.2. E:T ratio = 2.5:1, assay duration
= 180 min. The bar graphs show the average of 5 independent experiments, error bars
show the SD. During each independent repeat the experiment was performed in technical
duplicates, *p<0.05, **p<0.01, ***P<0.001 as calculated by paired t-test. Samples were
paired by day of experiment to account for day-to-day fluctuations. C Incucyte killing assay
readout showing % lysis of red EL4 target cells. One representative plot for 3 independent
experiments is shown. E:T ratio = 10:1 Each datapoint corresponds to the mean ± SD of
3-4 technical repeats. D Representative WB showing NFIL3 and Lamin B1 (loading control)
protein expression four days after nucleofection. E Quantification of the NFIL3 protein level.
In each repeat the NFIL3 protein level was expressed relative to the nucleofection control
and normalised to the loading control, n=3 independent experiments, **p<0.01 calculated
by one-sample t-test. F Representative WB showing perforin and b -actin (loading control)
protein expression four days after nucleofection. G Quantification of the perforin protein
level. In each repeat the perforin protein level was expressed relative to the nucleofection
control and normalised to the loading control, n=3 independent experiments, ns = not
significant, ***p<0.001 calculated by one sample t-test. All bar graphs show the mean ±
SD.
Hif1a CRISPR also significantly decreased the ability of CTLs to kill (n=5, p<0.01,
paired t-test), but only showed a trend towards increasing degranulation (Figure 4.6A-C). To
validate CRISPR efficiency I tested for target protein expression by WB. Decreased NFIL3
protein levels were observed in Nfil3 CRISPR samples (n=3, p<0.01, one sample t-test)
(Figure 4.5D,E). HIF-1a protein could initially not be detected by WB, most likely because
the samples were unstimulated and kept under normoxic conditions (Nakamura et al., 2005).
When stimulated with aCD3e for 4 h in hypoxic conditions (1% O2) HIF-1a could be
detected by WB, and HIF-1a levels were found to be reduced in Hif1a CRISPR samples
(n=1) (Figure 4.6D). Additionally, Hif1a CRISPR samples were shown to have decreased
NFIL3 protein levels (n=2) (Figure 4.6E,F), which was in agreement with a study where
Hif1a was deleted in all Vav-expressing cells using the Cre-lox system in mice (Rollings
et al., 2018).












































































































































































































































Fig. 4.6 Decreased killing in response to targeting Hif1a by CRISPR.
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Fig. 4.6 Decreased killing in response to targeting Hif1a by CRISPR. OT-I CTL were
nucleofected at day 4 after in vitro stimulation and tested in functional assays at day 8. CTLs
were tested for their ability to degranulate and kill in response to exposure to EL4 target cells
loaded with OVA-peptide. A The degranulation and B the killing readout of the combined
degranulation and killing assays were analysed following the gating strategy and calculations
described in chapter 2, section 2.5.1 and 2.5.2. E:T ratio = 2.5:1, assay duration = 180
min. The bar graphs show the average of 5 independent experiments, error bars show the
SD. During each independent repeat the experiment was performed in technical duplicates,
**p<0.01 as calculated by paired t-test. Samples were paired by day of experiment to account
for day-to-day fluctuations. C Incucyte killing assay readout showing % lysis of red EL4
target cells. One representative plot for 3 independent experiments is shown. E:T ratio = 10:1
Each datapoint corresponds to the mean ± SD of 3-4 technical repeats. D WB showing HIF-
1a and b -actin (loading control) protein expression four days after nucleofection of CRISPR
reagents and 4 h after aCD3e stimulation under hypoxic conditions, n=1. E Representative
WB showing NFIL3 and Lamin B1 (loading control) protein expression four days after
nucleofection. F Quantification of the NFIL3 protein level. In each repeat the NFIL3 protein
level was expressed relative to the nucleofection control and normalised to the loading
control, n=2 independent experiments. G Representative WB showing perforin and b -actin
(loading control) protein expression four days after nucleofection. H Quantification of the
perforin protein level. In each repeat the perforin protein level was expressed relative to the
nucleofection control and normalised to the loading control, n=3 independent experiments,
ns = not significant, *p<0.05 calculated by one sample t-test. All bar graphs show the mean
± SD.
The phenotype of increased degranulation and decreased killing was reminiscent of the
phenotype observed upon perforin CRISPR (Figure 3.8). Other studies showed that deleting
components of the HIF-1 complex or NFIL3 in mice resulted in decreased perforin expression
(Finlay et al., 2012; Rollings et al., 2018). I therefore investigated the effect of Hif1a and
Nfil3 CRISPR on perforin protein levels by WB, which confirmed that perforin was decreased
in Hif1a (n=3, p<0.05, one sample t-test) and Nfil3 CRISPR samples (n=3, p<0.001, one
sample t-test) (Figure 4.5F,G and Figure 4.6G,H).
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4.2.5 Comparing gene expression in activated CD8 T cells derived from
males and females
As the PCA plot in Figure 4.2 indicated that some of the variance in my dataset was
due to differences between sexes, I investigated which genes were differentially expressed
between CD8 T cells derived from males and females. For this, I compared male and
female samples derived from the day 7 group and applied the same significance thresholds as
before to identify differentially expressed genes (padj<0.01, log2(fold change) >2 or <-2).
Differentially expressed genes that passed these stringent selection criteria were limited to
Ddx3y, Kdm5d, Eif2s3y and Uty, all of which are located on the Y chromosome according to
the NCBI website (Table 4.3). Not taking into account the stringent log2(fold change) cut-off
revealed 79 significantly up- or down regulated genes (all with padj<0.01). Interestingly, this
gene list included Nfil3, as well as genes that encode several different granzymes (Table 4.3).
Table 4.3 Differentially expressed genes when comparing activated T cells derived from
males to activated T cells derived from females.
Gene Log2(FoldChange) p-value B-H adjusted p-value
Ddx3y 4.231 0.00E+00 0.00E+00
Kdm5d 3.348 0.00E+00 0.00E+00
Eif2s3y 3.081 0.00E+00 0.00E+00
Uty 2.478 1.18E-206 4.07E-203
Eif2s3x -0.649 7.24E-29 2.00E-25
Kdm5c -0.481 2.10E-23 4.81E-20
Kdm6a -0.627 1.85E-22 3.64E-19
Il10 -0.651 1.93E-17 3.32E-14
Pbdc1 -0.477 6.07E-14 9.29E-11
Gm29650 0.333 3.93E-13 5.41E-10
Fosb -0.519 3.29E-11 4.12E-08
Gldc 0.379 8.06E-11 9.25E-08
Esm1 -0.414 5.19E-10 5.49E-07
Eng -0.488 1.24E-09 1.22E-06
Gm5861 -0.471 1.37E-09 1.26E-06
Cdh17 -0.456 1.10E-08 9.46E-06
Gzma -0.377 1.47E-08 1.16E-05
Tcrg-C2 -0.447 1.51E-08 1.16E-05
Maf 0.425 3.14E-08 2.17E-05
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Table 4.3 continued from previous page
Gene Log2(FoldChange) p-value B-H adjusted p-value
Gzmf -0.39 3.13E-08 2.17E-05
5530601H04Rik -0.424 3.69E-08 2.31E-05
Epas1 -0.426 3.59E-08 2.31E-05
Xist -0.211 8.06E-08 4.82E-05
Pkhd1l1 -0.388 1.41E-07 8.11E-05
Gzmc -0.384 2.63E-07 0.000145102
Cyp11a1 -0.248 3.82E-07 0.000202287
Pparg -0.297 4.70E-07 0.000239877
Epsti1 0.282 6.22E-07 0.000295237
Gm8897 -0.373 6.17E-07 0.000295237
Ms4a4c 0.37 8.01E-07 0.000367891
Csgalnact1 -0.304 9.44E-07 0.000406428
Slc16a10 -0.395 9.19E-07 0.000406428
She 0.334 9.76E-07 0.000407425
Batf3 -0.332 1.01E-06 0.000407867
Cxcr6 0.381 1.08E-06 0.000411676
Btla 0.378 1.08E-06 0.000411676
Spry2 -0.385 1.70E-06 0.000632598
Il24 -0.293 2.09E-06 0.000757181
Speer1 -0.337 2.29E-06 0.000809682
Nfil3 -0.299 3.90E-06 0.001343211
Procr -0.266 4.08E-06 0.001369305
Scin -0.307 6.21E-06 0.002035039
Fcgrt 0.271 7.35E-06 0.002355526
Avil -0.353 7.72E-06 0.002416567
Trp53inp1 0.335 8.60E-06 0.002576152
Prss12 0.317 8.56E-06 0.002576152
Map1a 0.324 8.92E-06 0.002613249
Arhgap4 0.212 9.15E-06 0.002625824
Mxd4 0.343 9.63E-06 0.002678748
Mcpt8 -0.27 9.72E-06 0.002678748
Spire1 -0.292 1.21E-05 0.003170046
Gm8890 -0.3 1.22E-05 0.003170046
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Table 4.3 continued from previous page
Gene Log2(FoldChange) p-value B-H adjusted p-value
Atf3 -0.349 1.20E-05 0.003170046
Jdp2 -0.327 1.39E-05 0.0035429
Gm19705 0.341 1.57E-05 0.003862068
Gm8879 -0.299 1.57E-05 0.003862068
Il6ra 0.28 1.72E-05 0.00402067
Loxl2 -0.244 1.71E-05 0.00402067
Gzmg -0.265 1.67E-05 0.00402067
Cd7 0.285 1.90E-05 0.004372669
Trgv2 -0.341 1.95E-05 0.004401909
Il2ra -0.222 2.21E-05 0.004918823
Cxcr3 0.326 2.35E-05 0.005068284
Pisd-ps1 -0.291 2.35E-05 0.005068284
Fkbp11 -0.285 2.43E-05 0.005098991
Lag3 -0.339 2.44E-05 0.005098991
Epdr1 -0.238 2.61E-05 0.005361774
Fcer1g -0.331 2.76E-05 0.005581624
Vipr1 0.297 3.16E-05 0.006255572
Tcrg-C4 -0.327 3.18E-05 0.006255572
Dgka 0.264 3.31E-05 0.006429906
Myo1e -0.314 3.68E-05 0.007031746
Nt5e 0.331 3.84E-05 0.007150566
Plcg2 -0.267 3.81E-05 0.007150566
Nod1 0.292 4.79E-05 0.008801724
Tmem37 0.319 4.98E-05 0.00902281
Slc22a21 -0.247 5.06E-05 0.00905477
Chd3 0.263 5.66E-05 0.009986283
Slc4a7 -0.3 5.73E-05 0.009986283
4.3 Discussion
The RNA-seq study set up was designed to show differences between the transcriptome of
naive CD8 T cells and effector CD8 T cells that were stimulated and kept in culture for 7
days (Figure 4.1A). The heatmap and PCA plots in Figure 4.2 demonstrated that samples
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were mainly separated according to whether the RNA was derived from naive cells (day 0) or
effector cells (day 7), indicating that the gene expression differs between these two states of
cells. The PCA plots further revealed that some variance in the dataset was due to the spleen
collection date and whether samples were derived from males or females (Figure 4.2C). The
former was accounted for during subsequent analysis steps.
Differential expression analysis using the DESeq2 package revealed 1803 differentially
expressed genes where gene expression is upregulated, and 2584 differentially expressed
genes where gene expression is downregulated. Subsequently, I focussed on the 1803
activated differentially expressed genes, as this dataset should include genes that are required
for CTL killing. However, this dataset will additionally also include genes that are required
for other processes in T cell differentiation to cytolytic effectors, such as cell proliferation
and switching glucose metabolism from oxidative phosphorylation to glycolysis to fuel cell
growth (Fox et al., 2005). Using the functional annotation tool FIDEA confirmed that most
of the genes in my activated dataset associated with pathways related to proliferation (e.g.
cell cycle) (Figure 4.3B,C). This was reproducible using two different curations, KEGG and
GO, for the analysis (Figure 4.3B,C).
While I could have taken the approach to target the top upregulated genes in my dataset
(Table 4.1), a more targeted approach to isolate genes that may affect CTL killing was chosen
instead due to the concerns mentioned above. The DAVID functional annotation tool was
used in order to identify annotation clusters of genes related to what is known to be important
for CTL killing function. An annotation cluster was identified that was enriched in my
dataset and contained gene lists associated with vesicle fusion (Figure 4.3D). Vesicle fusion
is known to be important during the degranulation mechanism of CTL killing. 10 genes were
chosen from this list with a focus on genes that had not been studied extensively in CTL.
Additionally, 3 other genes were included that were identified as interesting targets from the
literature (Finlay et al., 2012; Rollings et al., 2018; Sinclair et al., 2013).
The screen was performed in primary mouse CTL derived from OT-I mice as these had
been used successfully with the CRISPR technology (chapter 3) and were readily available in
the Griffiths lab. The results of the RNA-seq study should be applicable to the OT-I system,
as these mice are bred on a C57BL/6 background. T cells derived from OT-I mice express
the OT-I TCR, which specifically recognises the OVA peptide presented by the H-2Kb MHC
class I molecule (Hogquist et al., 1994). Out of the 13 genes that were targeted by CRISPR
(Table 4.2), only Hif1a and Nfil3 showed a reproducible phenotype across three independent
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repeats (Figure 4.4). Due to time constraints, the other 11 genes were not followed up further.
However, I can not conclude that these genes have no effect on CTL degranulation or killing
without validating that the genes were successfully targeted by CRISPR. Since not all of these
genes have commercially available antibodies against their protein, the effect of CRISPR
could instead be confirmed by sequencing the DNA or by looking at the mRNA levels using
qRT-PCR. While these techniques would show if a cut occurred at the DNA level, or if there
is a decrease in mRNA, respectively, neither approach would be guaranteed to reflect the
expression of functional protein.
The killing defect observed in response to Nfil3 and Hif1a CRISPR was confirmed
using two different in vitro killing assays (Figure 4.5B,C and Figure 4.6B,C). Western
blotting confirmed that NFIL3 protein levels were decreased upon Nfil3 CRISPR (Figure
4.5D,E). HIF-1a protein levels were only detectable by WB after samples were stimulated
with aCD3e under hypoxic conditions (Figure 4.6D). Other studies have shown that while
HIF-1a cannot be detected by WB when effector CTL are kept under normoxic conditions,
HIF-1a levels are increased after switching cells to hypoxic conditions and in response
to TCR stimulation (Doedens et al., 2013; Nakamura et al., 2005; Palazon et al., 2017;
Rollings et al., 2018). In agreement with the literature, NFIL3 levels were reduced in Hif1a
CRISPR samples, providing further evidence that the Hif1a gene was successfully targeted
by CRISPR (Figure 4.6E,F). Furthermore, perforin protein levels were decreased in both
Nfil3 and Hif1a CRISPR samples (Figure 4.5F,G and Figure 4.6G,H). This has previously
been observed in a study using the Cre-lox system, with Cre expression under the control
of the vav-promoter, to delete Nfil3 and Hif1a in hematopoietic cells (Rollings et al., 2018).
However, HIF-1 regulation of perforin was found to be indirect, as the perforin promoter
did not contain HIF-1 complex binding sites (Finlay et al., 2012). In future experiments,
it would be interesting to investigate whether the Nfil3 promoter contains HIF-1a binding
sites, to determine whether Nfil3 is directly regulated by HIF-1a . Additionally, it would be
interesting to overexpress NFIL3 in Hif1a KO cells. If this rescues the killing phenotype it
could suggest that the killing defect in Hif1a KO CTLs is mediated via NFIL3.
Although the exact mechanism by which Hif1a and Nfil3 KO lead to a decrease in perforin
is not understood, this explained at least in part why targeting these genes by CRISPR resulted
in a CTL killing defect at the molecular level. In agreement with my findings, other studies
showed that deletion of the HIF-1 complex in CTL resulted in decreased production of other
effector molecules (IFNg , TNFa and granzyme B) as well as reduced tumour cell killing
in vivo (Finlay et al., 2012; Palazon et al., 2017). Meanwhile, increased Hif1a expression,
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achieved through the loss of one of the main negative regulators of the HIF transcription
factors (the von Hippel-Lindau complex), resulted in increased effector function of CTL, as
measured by an increase in the expression of effector molecules, such as granzyme B and
perforin, and in an in vivo cytotoxicity assay (Doedens et al., 2013). Additionally, Nfil3 KO
mice were found to have severely reduced levels of peripheral NK cells and impaired NK
cell cytotoxicity (Gascoyne et al., 2009).
In addition to comparing the transcriptome of effector and naive CD8 T cells, my RNA-
seq dataset also allowed me to compare effector CD8 T cells derived from male and female
mice. Only Y-linked genes passed the log2(fold change)>2 or <-2 and padj<0.01 cut offs
(Table 4.3). This was expected, as females do not have Y chromosomes. Looking at the genes
that were significantly differentially expressed (padj<0.01), but had a smaller effect size
(log2(fold change)>-2 and <2), interestingly identified that CD8 T cells derived from males
had less mRNA encoding several members of the granzyme family, IL2RA and NFIL3 (Table
4.3). It would therefore be interesting to compare expression of NFIL3 protein between
males and females, to see if this transcriptional effect is also present at the protein level.
Furthermore, it could be investigated whether this also translates to a better killing capability
in cells derived from female mice.
In summary, my data, together with published studies, convincingly showed that HIF-1a
and NFIL3 are crucial for CTL killing function. The data in this chapter demonstrated that
loss of NFIL3 and HIF-1a showed an effect even when these genes are only knocked out
in effector CTL. This indicated that the phenotype is not dependent on HIF-1a and NFIL3
being absent during T cell development or effector CTL differentiation. Furthermore, the
RNA-seq dataset revealed interesting differences in expression of mRNAs encoding NFIL3
and several cytotoxic effector molecules between CTLs derived from male and female mice.
4.3.1 Summary and evaluation of aims
• Determine the differences in gene expression between naive and activated CD8 T cells.
The hypothesis is that there are substantial changes in gene expression between these
two states of CD8 T cells.
– Significant differences in gene expression were observed: 1803 significantly
activated differentially expressed genes with padj<0.01 and log2(fold change)>2
were identified using DESeq2.
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• Explore the functional association of the differentially expressed genes using bioinformatic
tools.
– Using FIDEA and DAVID bioinformatic tools identified that upregulated genes in
my dataset predominantly associated with pathways related to cell proliferation,
which was not unexpected as CD8 T cells undergo rapid clonal expansion upon
stimulation.
• Test the effect of targeting differentially expressed genes by CRISPR in phenotypic
assays (degranulation and killing assays).
– Hif1a and Nfil3 were identified as interesting genetic targets that decreased killing
but not the degranulation capability of CTL. Hif1a and Nfil3 have previously been
identified as affecting CD8 T cell cytotoxicity in KO mouse models (Doedens
et al., 2013; Finlay et al., 2012; Rollings et al., 2018). Here I show that loss of
these genes also had an effect on cytotoxicity when expression of these genes is
only lost in differentiated effector CTL in vitro, as opposed to in naive T cells or
during T cell development in vivo. This suggested a more immediate importance
of these genes in CTL killing.
• Explore what genes are differentially expressed in CD8 T cells derived from male and
female mice.
– Highly differentially expressed genes (log2(fold change)>2) were limited to Y-
linked genes when comparing males to females. Interestingly, genes that were
significantly differentially expressed, but that did not pass the stringent log2(fold
change) cut-off, included genes known to be important for CTL function (such as
Gzma and Il2ra), as well as Nfil3.
Chapter 3 and chapter 4 make up the portion of the thesis that focuses on primary mouse T
cells. One of the main conclusions from this aspect of the PhD project is that gene expression
in primary mouse CTLs can be efficiently disrupted using the CRISPR Cas9-RNP approach
as optimised in the last two chapters. Importantly, this approach can be used in cells derived
from any mouse line, regardless of the genetic background. This provides an effective and
versatile tool to study the function of genes in primary mouse T cells.
Additionally, the newly established assay that simultaneously measures degranulation
and killing can be used to identify phenotypes of interest, as demonstrated using an arrayed
CRISPR screen. The readout of the assay was reliable, as comparable results were obtained
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using a separate phenotypic assay, the Incucyte killing assay. In combination with the
optimised CRISPR technology, the assay enables to identify genes important for CTL killing
and/or degranulation.
In hindsight, the experimental design of the RNA-seq study could have been more
targeted to the overall aim of the thesis, which was to identify regulators of CTL killing.
Instead, the RNA-seq study more broadly identified genes that are implicated in CD8 T cell
activation. While some of the genes upregulated in response to activation are necessary for
CTL killing, they are overshadowed by genes important for other biological functions, such
as the proliferation response. A possible alternative approach would have been to incorporate
purified CD4 T cells in the study design. Comparing the transcriptome of activated CD4 and
CD8 T cells would have allowed to filter out genes associated with proliferation in response
to activation, and would have revealed genes relevant for CD8 T cell specific functions.
Nonetheless, the RNA-seq dataset presented in this chapter is a useful resource, as it presents




Screening a compound library that
targets the NF-kB pathway in human T
cells
5.1 Introduction
The assay developed to measure degranulation and killing simultaneously was successfully
used for a small screen in mCTL in chapter 4. The work in this chapter aimed to 1) test
whether this assay also works in hCTL, as a more medically relevant cell type, and 2) to test
the extent to which the combined degranulation and killing assay can be scaled.
In chapter 3, CRISPR was used to target Munc13-4, Rab27a and the gene encoding
perforin (Prf1) in mCTL and the resulting samples were used to validate the newly developed
combined degranulation and killing assay. Since I had not yet set up the CRISPR technology
in hCTL, I instead used cells derived from FHL2 and FHL3 patients to address point 1. FHL2
is caused by mutations in PRF1, and FHL3 is associated with mutations in MUNC13-4. Both
of these genes are crucial for CTL function as demonstrated by data shown in chapter 3 and
the literature (Crozat et al., 2007; Feldmann et al., 2003; Kägi et al., 1994a; Stepp et al., 1999).
To test the scalability of the assay, I used a chemical compound library targeting the
NF-kB signalling pathway obtained from Medchem express. The combined degranulation
and killing assay, performed in a 96 well format, was reasoned to be easily adaptable for
screening dozens of compounds. The NF-kB compound library consisted of 64 drugs, and
allowed me to test the scalability of the combined degranulation and killing assay while
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simultaneously asking whether NF-kB has a direct role in CTL killing.
The canonical NF-kB signalling pathway is known to be activated in response to TCR
recognition of its cognate antigen in the context of MHC class I. TCR signalling and
CD28 co-stimulatory signals trigger activation of PKCq and its recruitment to the IS (Oh
and Ghosh, 2013; Paul and Schaefer, 2013). PKCq has been shown to phosphorylate
CARMA1, and phosphorylated CARMA1 can bind to BCL10 and MALT1 (Schulze-
Luehrmann and Ghosh, 2006; Vallabhapurapu and Karin, 2009). MALT1 and BLC10
are thought to be polyubiquitinated by TRAF6 (Paul and Schaefer, 2013), resulting in
recruitment of the IkB kinase (IKK) complex, consisting of IKKa , IKKb and IKKg , via
the polyubiquitination binding motif of IKKg (Paul and Schaefer, 2013). Subsequently,
IKKg and IKKb are activated by polyubiquitination and phosphorylation, respectively.
Activated IKKb phosphorylates the inhibitor of kB (IkB), which triggers ubiquitination and
degradation of IkB via the 26S proteasome (Paul and Schaefer, 2013; Vallabhapurapu and
Karin, 2009).
The NF-kB family of transcription factors consists of p105/p50 (NFkB1), p100/p52
(NFkB2), p65 (RelA), RelB and c-Rel (Paul and Schaefer, 2013; Vallabhapurapu and
Karin, 2009). They share a Rel homology domain that is important for DNA binding
and dimerisation (Oh and Ghosh, 2013; Vallabhapurapu and Karin, 2009). Under basal
conditions, NF-kB is retained in the cytoplasm as inactive heterodimers or homodimers
bound by the inhibitor of kB. TCR-mediated degradation of IkB, as outlined above, allows
NF-kB dimers to translocate into the nucleus and regulate transcription of their target genes
(Vallabhapurapu and Karin, 2009).
In the nucleus, NF-kB transcription factors bind to promoters that contain kB binding
sites. One crucial NF-kB target gene is the gene encoding IkBa , thereby ensuring a negative
feedback mechanism to terminate NF-kB signalling (Vallabhapurapu and Karin, 2009).
NF-kB is reported to activate expression of over 150 target genes, including cytokines,
chemokines and adhesion molecules (Pahl, 1999). NF-kB target genes are important for T
cell activation, proliferation, differentiation and survival (Schulze-Luehrmann and Ghosh,
2006; Vallabhapurapu and Karin, 2009). It is clear that the NF-kB signalling pathway is
crucial for T cell function, but less is known about its importance for CTL killing specifically.




• Test the combined degranulation and killing assay in hCTL using FHL2 and FHL3
patient samples.
• Investigate the scalability of the assay using a NF-kB compound library.
• Follow up promising hits to elucidate their mechanism of action.
5.2 Results
5.2.1 Testing the combined degranulation and killing assay using patient-
derived CTL
The combined degranulation and killing assay was tested in hCTL using cells derived from
FHL3 patients (carrying mutations in MUNC13-4) and FHL2 patients (carrying mutations in
PRF1). The exact mutations of all patients are outlined in chapter 2, Table 2.2. hCTL derived
from FHL3 patients significantly degranulated less (n=3, p<0.0001, unpaired t-test with
Welch’s correction) and killed target cells less efficiently (n=3, p<0.01, unpaired t-test with
Welch’s correction) than hCTL derived from HDs (Figure 5.1A,B). The killing phenotype was
confirmed for every patient using the Incucyte killing assay (Figure 5.1C-E). In agreement
with the phenotype observed, WB showed that less MUNC13-4 protein was expressed in
patient-derived cells than in cells derived from HDs (Figure 5.1F).
Cells derived from FHL2 patients did not show a defect in degranulation (Figure 5.2A),
but showed a significant decrease in the ability to kill target cells (n=4, p<0.0001, unpaired
t-test with Welch’s correction) (Figure 5.2B). Again, the killing phenotype was confirmed
using the Incucyte killing assay (Figure 5.2C-F). WB for perforin showed that less protein was
expressed in patient-derived cells than in cells derived from HDs (Figure 5.2G). Interestingly,
the perforin antibody recognised two bands in lysates derived from patient 6981 and patient
3026 (Figure 5.2G). These bands were of a higher molecular weight than the banding pattern
produced in samples derived from 5 different HDs. This suggested that while the mutations
in patients 6981 and 3026 did not cause a complete loss of perforin, they still resulted in
impaired protein function. In summary, the patient results demonstrated that the combined
degranulation and killing assay can be used to reliably identify hCTLs with a defect in killing,
degranulation, or both.


























































































































































Fig. 5.1 Decreased degranulation and killing in cells derived from FHL3 patients. A The
degranulation and B killing readout of the combined degranulation and killing assays were
analysed following the gating strategy and calculations described in chapter 2, section 2.5.2.
CTLs were derived from three independent FHL3 patients and compared to CTLs derived
from 6 independent HDs. All samples were purified to isolate CD8 cells. E:T ratio = 2.5:1,
assay duration = 180 min. Each data point is the average of 2-4 technical repeats. **p<0.01,
****p<0.0001 as calculated by unpaired t-test with Welch’s correction. Bar graphs show
the mean ± SD. C Incucyte killing assay showing % lysis of red P815 target cells in the
presence of aCD3 and HD 3 or patient 1310, D HD 2 or patient 4413 and E HD 9 or
patient 3788. E:T = 2.5:1. Each datapoint is an average of 3-4 technical repeats and the
error bars show the SD. F WB showing MUNC13-4 and b -actin (loading control) protein
expression in CTL derived from the indicated HDs and patients. HD = healthy donor, SD =
standard deviation, us = unspecific, FHL = familial hemophagocytic lymphohistiocytosis. *
= potentially non-specific band.
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Fig. 5.2 CTLs derived from FHL2 patients showed a killing defect. A The degranulation
and B killing readout of the combined degranulation and killing assays were analysed
following the gating strategy and calculations described in chapter 2, section 2.5.2. CTLs
were derived from four independent FHL2 patients and compared to CTLs derived from 7
independent HDs. All samples were purified to isolate CD8 cells. E:T ratio = 2.5:1, assay
duration = 180 min. Each data point is the average of 2-4 technical repeats. ****p<0.0001
as calculated by unpaired t-test with Welch’s correction. Bar graphs show the mean ± SD.
C Incucyte killing assay showing % lysis of red P815 target cells in the presence of aCD3
and HD 3 or patient 4166, D HD 4 or patient 6981, E HD 6 or patient 3026 and F HD
3 or patient 392. E:T = 2.5:1. Each datapoint is an average of 3-4 technical repeats and
the error bars show the SD. G WB showing perforin and b -actin (loading control) protein
expression in CTL derived from the indicated HDs and patients. HD = healthy donor, SD =
standard deviation, FHL = familial hemophagocytic lymphohistiocytosis.
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5.2.2 Compound library toxicity testing
So far, the combined degranulation and killing assay had been used to screen just over
a dozen genetic targets (chapter 4). To test the scalability of this assay, I used a drug
library of 64 compounds reported to target the NF-kB signalling pathway. Figure 5.3
shows the composition of this library in terms of molecular targets. Some molecular targets,
such as MALT1, IKK and NF-kB, are direct components of the NF-kB signalling cascade
downstream of the TCR, as outlined in section 5.1. The RIP kinase is also implicated in
activation of the NF-kB signalling pathway (He and Wang, 2018), therefore inhibitors of
RIP kinase should inhibit NF-kB function. In contrast members of the PPAR family have
been shown to inhibit NF-kB (reviewed by Ricote and Glass (2007)). NRF2, regulated by
the protein KEAP1, was shown to inhibit NF-kB, and NF-kB activity is enhanced when
NRF2 levels are decreased (reviewed in Wardyn et al. (2015)).














Fig. 5.3 Overview of molecular targets of the NF-kB signalling compound library.
Piechart showing the molecular targets of the 64 compounds contained in the library obtained
from Medchem express. The library contained activators as well as inhibitors. 2 drugs are
reported to target RIP kinase, 1 drug is reported to target MALT1, 7 drugs target Keap1-Nrf2,
13 drugs target IKK, 15 drugs target NF-kB and 26 drugs target PPAR. This information
was provided by Medchem express.
For simplicity, the drugs were labelled 1-64 according to the order in which they were
supplied. The Celltitre assay (see chapter 2, section 2.8) was used as a toxicity test to
determine whether the drugs were toxic to hCTL after overnight treatment with a range of
concentrations (Figure 5.4). Initially, I tested the sensitivity of the Celltitre assay, in which
absorbance at 490 nm should correspond to the amount of metabolically active cells. I seeded
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a range of hCTL per well and measured the absorbance after 4 h incubation with the Celltitre
reagents. This clearly showed that absorbance decreased as the number of cells decreased
(Figure 5.4A), indicating that this assay could be used to test for toxicity in response to drug
treatment.
The highest concentration to be tested was set to 25 µM. This upper threshold was in
part based on the EC50/IC50 information provided by the supplier of the compound library,
although this information was not available for all 64 compounds. Additionally, using drugs
at a maximum of 25 µM meant that the percentage of DMSO to be added to the vehicle
control could be kept at, or below, 0.25%. The Celltitre assay was used to show that treating
cells with 0.25% DMSO for 24 h did not show toxic effects (Figure 5.4B).
Next, drugs were tested for toxic effects at concentrations between 0.1 µM and 25 µM,
achieved by performing serial three-fold dilutions. Corresponding DMSO controls were
included on every plate. The change in absorbance in response to treatment with drugs
at various concentrations was plotted as a curve (example plots shown in Figure 5.4C-F).
This was used to visually determine the highest concentrations that were not toxic to hCTLs
over a 24 h time period. To give an example, drug 4 only showed toxic effects above a
concentration of 0.9 µM (Figure 5.4C). Therefore 0.9 µM was chosen as the highest non-
toxic concentration for drug 4. For drugs that did not show a toxic effect, such as drug 22, the
highest concentration tested, 25 µM, was chosen as the concentration to use in the functional
assay (Figure 5.4F). The Table C.1 (Appendix C) outlines the highest non-toxic concentration
for all drugs in the library, determined as described above, as well as their official names and
their reported molecular target. The highest non-toxic concentration was the concentration
used for each drug in all further assays.
5.2.3 Compound screen using the combined degranulation and killing
assay
hCTL were treated with the highest non-toxic concentration overnight before functional
testing using the combined degranulation and killing assay. The screen was performed across
seven 96-well plates using cells from the same HD used for toxicity testing at day 13-15 post
in vitro stimulation. Up to 12 samples fit per plate when testing each condition in duplicate.
In addition to the stimulated experimental samples (containing hCTL + P815s + aCD3), I
also included unstimulated controls (hCTL + P815s) as well as hCTL and P815s on their
































































































































































Fig. 5.4 Testing the toxic effect of compounds on hCTL. A The indicated number of cells
were seeded in each well of a 96 well plate and incubated with Celltitre reagent for 4 h.
Absorbance at 490 nm was measured. B Cells were treated with the amount of DMSO
equivalent to treatment with 25 µM drugs. Cell viability after 24 h treatment was compared
to control cells that were not treated with DMSO. The Celltitre reagent was added 4 h before
the end of the 24 h incubation period. Absorbance at 490 nm was measured, n=6 independent
experiments. Bar graphs show the mean ± SD. C-F 125,000 hCTL were seeded per well in a
96 well plate and treated with drugs at the indicated concentrations for approximately 24 h.
Examples for drug 4, 14, 19 and 22 are shown. The assay readout was used to determine the
highest non-toxic concentration for every drug in the library.
own treated with drugs, in order to be able to detect any effects the drugs might have on these
cell types. The degranulation readout from the screen is shown in Figure 5.5 and the killing
readout is shown in Figure 5.6. Drug 37 had to be excluded in the killing assay analysis, as it
appeared to be toxic to P815 target cells over the course of the 3 h assay, therefore affecting
the killing assay result for this sample.
While there were many drugs that seemed to decrease degranulation or killing, there
were no drugs that substantially increased degranulation or killing. Only drugs that reduced
degranulation or killing by more than 50% in comparison to the appropriate DMSO control
were chosen for follow up analysis. Drug 26 was therefore classified as a potential hit
according to the degranulation aspect of the screen (Figure 5.5), and drugs 4, 13, 19, 24, 30
were classified as potential hits according to the killing aspect of the screen (Figure 5.6).
Drug 14 was not classified as a potential hit due to large variability between technical repeats.
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It is likely that some drugs that do have an effect on degranulation or killing did not pass
these stringent cut-off criteria. For example, drug 30 (46% decrease in degranulation) and
drug 4 (48% decrease in degranulation) were close to passing the degranulation threshold,
but encouragingly they were also picked up as potential hits in the killing aspect of the screen.
The aim of this screen was not to identify and characterise every single promising drug, but to
investigate the possibility to use the combined degranulation and killing assay for a mid-size
screen, while focusing on the most promising hits that could be useful to further investigate
the importance of NF-kB in the CTL killing process.
5.2.4 Testing the reproducibility of potential hits
To test whether the effects of drug 4, 13, 19, 24, 26 and 30 in the combined degranulation
and killing assay were reproducible, hCTLs derived from independent HDs were treated
with drugs at the same concentrations previously used (Figure 5.7). Each drug treatment is
connected to its corresponding DMSO control treatment, which was performed simultaneously
on the same cells (Figure 5.7). Not all hits were reproducible, indicating that some hits were
false positives. Additionally, as the screen was performed on cells derived from one HD,
some donor-to-donor variability was expected upon further follow up.
Upon further investigation, drug 24 (n=3) and 13 (n=5) did not significantly affect
degranulation or killing (Figure 5.7B, D). Drug 26 (n=5, p<0.01, paired t-test, mean of
differences = -13.25) and 30 (n=5, p<0.05, paired t-test, mean of differences = -11.35)
significantly decreased degranulation to a small extent, but they did not have a significant
effect on CTL killing (Figure 5.7E,F). The striking killing defect of drug 4 observed in the
screen was not reproducible, however, CTL killing was decreased, at least to a small extent,
in every experiment (n=7, Figure 5.7A). This possibly did not reach statistical significance
due to the variability of the differences between DMSO and drug 4 treatment between repeats.
Drug 19 was the only drug that reproducibly and significantly decreased degranulation (n=7,
p<0.01, paired t-test, mean of differences = -40.41) and killing (n=7, p<0.001, paired t-test,
mean of differences = -42.54) (Figure 5.7C).
The drug with the biggest effect size, drug 19, was investigated further. So far, drug
19 had only been tested with overnight treatment. I used the Incucyte killing assay, which
measures the killing response over time, to test how quickly treatment with drug 19 resulted
in a killing defect. In these assays hCTLs were not pre-treated with drug 19, instead the
compound was only added at the start of the assay. This showed that drug 19 exerted its effect

























































































































































































































































































































































































































Plate 1 Plate 2
Plate 3 Plate 4
Plate 5 Plate 6
Plate 7
Fig. 5.5 Screening identified one drug that reduced degranulation by more than 50%.
Drugs were roughly grouped into plates according to their highest non-toxic concentration.
A control containing the equivalent amount of DMSO to the highest concentration tested was
included on every plate. CD8 cells from one HD were treated with compounds overnight.
The following day, target cells with and without aCD3 were added. E:T ratio = 2.5:1, assay
duration = 180 min. Technical duplicates were prepared for every condition, error bars
represent the SD of technical repeats. Screening was performed in 7 plates across 3 days
(2-3 plates per day). Degranulation assays were analysed following the gating strategy
described in chapter 2, section 2.5.1 and 2.5.2. Drugs were classified as potential hits when
the treatment decreased degranulation by more than 50% in comparison to the appropriate


















































































































































































































































































































































Plate 1 Plate 2
Plate 3 Plate 4
Plate 5 Plate 6
Plate 7
Fig. 5.6 Screening identified five drugs that reduced killing by more than 50%. Drugs
were roughly grouped into plates according to their highest non-toxic concentration. A
control containing the equivalent amount of DMSO to the highest concentration tested was
included on every plate. CD8 cells from one HD were treated with compounds overnight.
The following day, target cells with and without aCD3 were added. E:T ratio = 2.5:1,
assay duration = 180 min. Technical duplicates were prepared for every condition, error
bars represent the SD of technical repeats. Screening was performed in 7 plates across 3
days (2-3 plates per day). Killing assays were analysed following the gating strategy and
calculations described in chapter 2, section 2.5.2. Drugs were classified as potential hits
when the treatment decreased killing by more than 50% in comparison to the appropriate
DMSO control. The dotted line indicates the 50% cut-off on each graph. Drug 37 was
excluded due to toxic effects on P815 target cells. SD = standard deviation.








































































































































































































































































































































Fig. 5.7 Follow up of the effect of promising compounds on degranulation and killing.
Cells derived from independent HDs were treated overnight with drugs identified as potential
hits in the screen. Each treatment is connected to its corresponding DMSO control. Each pair
of data points represents an independent experiment. The combined degranulation and killing
assay was analysed following the gating strategy and calculations described in chapter 2,
section 2.5.2. E:T ratio = 2.5:1, assay duration = 180 min, each data point represents
the average of technical duplicates. The following drugs were tested A drug 4 at 0.9 µM
(n=7 independent experiments), B drug 13 at 8.3 µM (n=5 independent experiments), C
drug 19 at 8.3 µM (n=7 independent experiments), D drug 24 at 0.9 µM (n=3 independent
experiments), E drug 26 at 0.1 µM (n=5 independent experiments) and F drug 30 at 0.9
µM (n=5 independent experiments). *p<0.05, **p<0.01, ***P<0.001, calculated by paired
t-test.
on killing within the first hour (Figure 5.8A). Encouragingly, the killing defect observed with
drug 19 treatment was also titratable in response to a two-fold (Figure 5.8B) and four-fold
(Figure 5.8C) decrease in concentration.
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A third kind of killing assay, the LDH release assay, was used to test the effect of drug
19 treatment when using a variety of E:T ratios (Figure 5.8D). Increasing the amount of
effectors while keeping the amount of target cells constant resulted in an increase in the
percentage of target cells killed over 3 h. The killing observed was significantly reduced in
the presence of drug 19 across three different E:T ratios (n=4, p<0.001 for E:T 10:1, n=4,
p<0.001 for E:T 5:1 and n=4, p<0.01 for E:T 2.5:1, paired t-test), further confirming the
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Fig. 5.8 Drug19 has an immediate effect on CTL killing. Incucyte killing assays showing
the percentage lysis of red P815 target cells over the course of 14 hours in the presence of
aCD3, hCTL and drug 19 or equivalent DMSO vehicle control. One representative plot for
3 independent experiments is shown for using drug 19 at a concentration of A 8.3 µM, B
4.15 µM and C 2.075 µM. E:T = 10:1. Each datapoint is an average of 3 technical repeats
and the error bars show the SD. D LDH release killing assay showing the % lysis of P815
target cells at varying E:T ratios and in the presence of 8.3 µM drug 19 or equivalent DMSO
vehicle control for 3 h, n=4 independent experiments for all E:T except E:T 1.25:1, where
n=2 independent experiments. **p<0.01, ***P<0.001, calculated by paired t-test.
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5.2.5 The effect of drug 19 on NF-kB
Next, I tried to investigate at which point in the NF-kB activation cascade drug 19 intervenes
in NF-kB signalling. Initially I used PMA and ionomycin stimulation in combination with
drug 19 treatment. Studies have shown that PMA and ionomycin can be used to activate NF-
kB in the absence of TCR, aCD3 or aCD28 stimulation (Liu et al., 2016). This treatment
essentially bypasses TCR signalling and triggers degranulation. PMA activates PKCs, while
ionomycin induces calcium release from the endoplasmic reticulum (Liu et al., 2016). I used
PMA and ionomycin stimulation and measured surface exposure of LAMP1 in the presence
and absence of drug 19 treatment. The fact that drug 19 treatment still reduced degranulation
in response to PMA (n=5, p<0.05, paired t-test), ionomycin (n=5, p<0.001, paired t-test)
and combined PMA and ionomycin (n=5, p<0.01, paired t-test) treatment suggested that the
molecular target of drug 19 was not proximal to the TCR, but downstream of the molecular
targets of PMA and ionomycin (Figure 5.9A).
To investigate whether drug 19 affected NF-kB transcription I measured the expression
of the NF-kB target gene TNFa in the presence and absence of aCD3e stimulation (Figure
5.9B). NF-kB p65/p50 heterodimers were shown to be involved in transcriptional activation
of TNFa expression in response to LPS activation in macrophages (Liu et al., 2000). TNFa
can therefore be used as a readout of p65/p50 transcriptional activity. TNFa was not produced
in the absence of aCD3e stimulation, independent of addition of DMSO or drug 19 (Figure
5.9B). Production of TNFa was upregulated in DMSO samples in response to aCD3e
stimulation for 4 h. This upregulation was significantly lowered in the presence of drug 19
(Figure 5.9B, n=3, p<0.01, paired t-test).
Using PMA and ionomycin treatment I investigated whether drug 19 affected phosphorylation
of p65 at Ser536. Levels of phosphorylated p65 were increased in response to PMA and
ionomycin treatment in the DMSO control (Figure 5.9C-D). This upregulation was decreased
with drug 19 treatment (Figure 5.9C-D). Interestingly even basal levels of p65 phosphorylated
at Ser536 seemed slightly lower in response to drug 19 treatment (Figure 5.9C-D). Taken
together, these results suggest that drug 19 acts between PKC (Figure 5.9A) and p65 (Figure

















































































































































Fig. 5.9 Determination of the molecular effect of drug19 on NF-kB. A Surface LAMP1
levels in response to treatment of hCTL with PMA (P), ionomycin (I), or both in the presence
or absence of drug 19 for 3 h. The bar graphs show the average of 5 independent experiments,
error bars show the SD, *p<0.05, **p<0.01, ***p<0.001 calculated by paired t-test. B
TNFa expression in hCTL treated overnight with 8.3 µM drug 19 or DMSO followed by 4 h
stimulation on aCD3-coated plates (stim) or uncoated plates (unstim control) was measured
by intracellular FACS. The bar graphs show the average of 3 independent experiments, error
bars show the SD, **p<0.01 calculated by paired t-test. C Representative WB showing p65
phosphorylated at Ser536 and calnexin (loading control) protein levels 4 h after treatment
with PMA and ionomycin or appropriate DMSO vehicle control in addition to treatment with
8.3 µM drug 19 or DMSO vehicle control. D Average levels of p65 protein phosphorylated
at Ser536 upon PMA and ionomycin treatment in the presence or absence of drug19 in
2 independent repeats. In each repeat p65 protein levels were expressed relative to the
unstimulated control and normalised to calnexin. Bar graphs show the mean ± SD, n=2
independent experiments. P = PMA, I = ionomycin, unstim = unstimulated, stim = stimulated,
ns = not significant, SD = standard deviation.
126 Screening a compound library that targets the NF-kB pathway in human T cells
5.3 Discussion
The combined degranulation and killing assay successfully detected phenotypes in hCTL
derived from FHL2 and FHL3 patients (Figure 5.1A-B). The relatively mild killing phenotype
observed with MUNC13-4 patients in the Incucyte killing assay (Figure 5.1C-E) could
be explained by only partial protein loss in these patients (Figure 5.1F). In patients with
mutations in PRF1 either no perforin protein was detected (patient 4166 and 392) or the
perforin antibody recognised two bands of a higher MW (patient 6981 and 3026) than in
the HDs (Figure 5.2G). Functional assays indicated that the higher MW versions of perforin
were not functional (Figure 5.2A-F). Perforin undergoes various processing steps during
its formation. First a ⇠65 kDa version gets modified by glycans to give a 70 kDa version.
Cleavage of the C-terminus yields the final functional 60 kDa version of perforin (Uellner
et al., 1997). The final processing step did not seem to occur in patients 6981 and 3026,
indicating that the domains affected by their mutations may be important for the C-terminal
cleavage step. Uellner et al. (1997) reported that a mutant version of perforin, where the
C-terminus is truncated, is located in the endoplasmic reticulum, rather than in lytic granules
when expressed in RBL cells. It would therefore be interesting to test the localisation of
perforin in CTL derived from patient 6981 and patient 3026 by immunofluorescence. In
summary, the patient results confirmed that the combined degranulation and killing assay
can be used in hCTL, and shows potential as a diagnostic test for patients suspected to have a
CTL defect.
Next, the combined degranulation and killing assay was used to screen 64 compounds. To
further improve the scalability of the assay, sample fixation to stably maintain the endpoint
could be explored. Additionally it would be interesting to test the assay in a 384-well format,
in order to be able to screen even more samples per plate while reducing the amount of cells
and reagents needed per sample.
The drug screen identified 6 compounds that reduced degranulation or killing by more
than 50% (Figures 5.5 and 5.6). There may be additional compounds in the library that affect
degranulation or killing that were not identified due to using a suboptimal concentration, as
I did not test concentrations above 25 µM. Additionally, the stringent 50% cut-off applied
to the degranulation and killing readouts likely excluded some hits. For example, drug 19
was not picked up as an inhibitor of degranulation in the initial screen, as it did not decrease
degranulation by more than 50% (Figure 5.5). However, drug 19 turned out to significantly
decrease degranulation upon repetition (Figure 5.7). To avoid such false negatives, it would
be preferable to perform screens in triplicates, as done for the genetic screen in chapter 4.
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This would allow the identification of hits with greater certainty, however, the vast amount of
time required to set up these assays limits the scale of such screens without a robot.
The most promising hit, drug 19, significantly reduced degranulation and killing after
overnight treatment (Figure 5.7). A different kind of killing assay, the Incucyte assay,
demonstrated that drug 19 already affected target cell killing within 1 h of treatment (Figure
5.8). Encouragingly, the effect of drug 19 was titratable when reducing the concentration by
two-fold and four-fold, indicating that the effect on killing is mediated by the drug (Figure
5.8). I analysed distinct steps in the NF-kB activation cascade to determine where drug 19
mediated its effect. If the degranulation defect with drug 19 had been rescued with PMA and
ionomycin treatment this would have suggested that drug 19 inhibits signalling proximal to
the TCR. As this was not the case, drug 19 must act downstream of the molecular targets of
PMA and ionomycin (Figure 5.9). TNFa transcription is known to be regulated by p65/p50
heterodimers (Liu et al., 2000). As TNFa production in response to aCD3e stimulation
was decreased in the presence of drug 19 (Figure 5.9), the effect of drug 19 on p65 was
investigated. I found that drug 19 decreased the levels of p65 phosphorylated at Ser536 both
in response to PMA and ionomycin treatment as well as at basal levels (Figure 5.9).
In the literature, parthenolide, the official name for drug 19, has been shown to directly
bind to two components of the NF-kB cascade. It inhibits the ability of p65 to bind to DNA by
alkylating cysteine-38 of p65 (Garcia-Pineres et al., 2001) and it inhibits IKKb by alkylation
of cysteine-179, leading to stabilisation of IkBa and IkBb (Hehner et al., 1999; Kwok
et al., 2001). In addition, other studies have shown that parthenolide also induced HDAC1
depletion (Gopal et al., 2007) and inhibits DNA methyltranferase 1 (Liu et al., 2009). With
the data available in this chapter, I can therefore not be certain that the effect of parthenolide
on CTL killing is due to its inhibition of NF-kB. This highlights a general disadvantage to
using chemical compounds for screening, as they may affect multiple molecular targets, in
contrast to a targeted genetic approach. The striking effect of parthenolide on CTL killing
is nonetheless interesting, but how exactly the effect is mediated remains to be determined.
Specifically targeting p65 by CRISPR or siRNA would help to clarify whether p65 is directly
involved in CTL degranulation and killing. Furthermore, it would be interesting to investigate
which steps in the killing pathway are affected by drug 19 treatment. The degranulation
readout demonstrated that the lytic granule content is not secreted in response to drug 19
treatment. This could be due to a defect in fusion between the granule membrane and plasma
membrane, or due to a block at an earlier step in the CTL killing process. Immunofluorescent
microscopy could be used to determine whether treated CTLs can still form contacts with
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target cells and whether the centrosome and lytic granules still polarise towards the contact
site.
Several other studies have suggested parthenolide as a potential cancer treating drug
(reviewed by Ghantous et al. (2013)). A recent study noted anti-proliferative and pro-
apoptotic effects of parthenolide in glioma cells, and showed that parthenolide inhibits
tumour growth in mice (Yu et al., 2018). For such medical purposes, it is crucial to be aware
of the suppressive effect that parthenolide has on CTL killing.
In its current format, the combined degranulation and killing assay can be used to screen
many dozens of compounds over the course of several days. It is therefore a useful tool to
screen compounds as well as genetic targets. Furthermore, the experiments with patient-
derived CTL demonstrated the potential of the assay as a diagnostic test. Using patient
derived NK cells and CTLs in a simple degranulation assay has already been proposed
as a tool for diagnostic evaluation of patients presenting with FHL symptoms (Bryceson
et al., 2012; Chiang et al., 2013). However, it has been noted that this approach requires
additional monitoring of perforin expression in all clinical samples, as the defect resulting
from mutations in PRF1 cannot be detected using the degranulation assay (Bryceson et al.,
2012). The combined degranulation and killing assay presented in this thesis therefore
provides an advantage over the current gold standard. By cutting out the requirement of
analysing perforin separately the assay reduces time, effort and the amount of patient material
required for diagnosis.
5.3.1 Summary and evaluation of aims
• Test the combined degranulation and killing assay in hCTL using FHL2 and FHL3
patient samples.
– The assay was successfully validated using patient-derived samples. The defects
caused by PRF1 mutations would not have been picked up by the simple degranulation
assay, which is currently being used for diagnostic purposes. The combined assay
that is able to detect both degranulation and killing simultaneously could therefore
have great diagnostic potential.
• Investigate the scalability of the assay using the NF-kB compound library.
– 64 compounds were screened in technical duplicates across 3 days using CD8 T
cells derived from one HD. Out of the drugs tested, 1 drug decreased degranulation
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and 5 drugs decreased killing by more than 50 % in the screen. These promising
hits were followed up using CTL derived from independent HDs. The most
promising compound, drug 19 (parthenolide), reproducibly decreased CTL
degranulation (n=7, p<0.01, paired t-test) and killing (n=7, p<0.001, paired
t-test).
• Follow up promising hits to elucidate their mechanism of action.
– Measuring CTL killing over time revealed that parthenolide reduced CTL killing
within the first hour of treatment. The effect of parthenolide on NF-kB in
primary human T cells was tested at various steps along the NF-kB activation
cascade. Parthenolide treatment was shown to suppress phosphorylation of p65 at
Ser536 and decreased TNFa gene expression in response to aCD3e stimulation,




technology in primary human T cells
6.1 Introduction
As an unbiased approach pooled genome-wide CRISPR screens have lead to many novel
discoveries (Doench, 2017; Shalem et al., 2014; Wang et al., 2014a). In such genome-wide
screens, cell lines are usually transduced with a lentivirus to introduce Cas9 stably into the
cells and a genome-wide sgRNA lentiviral library. Cells containing Cas9 and sgRNAs are
then selected using antibiotics prior to phenotypic screening (Doench, 2017). Cells with the
phenotype of interest are isolated and the sgRNAs that cause the phenotype are determined
by sequencing (Doench, 2017). Performing such a screen in primary T cells would be of
immense interest in order to improve understanding of how the response of T cells to target
antigen is regulated at the genetic level. For example, this could lead to progress in using T
cells to target cancers by immunotherapy.
Several researchers have taken the approach of performing genome-wide screens in
cancer cell lines in order to identify cancer genes that affect T cell killing (Pan et al., 2018;
Patel et al., 2017). These type of screens have identified new immunotherapy targets, or
mechanisms of cancer resistance to immunotherapy. However the findings may be specific to
the cell lines used and may not always reflect complex cancer biology in vivo. Performing
screens in primary T cells could increase the possibility of finding a broadly applicable
strategy for improving T cell mediated killing of tumours.
While pooled genome-wide screens can be performed in immortalised cancer cell lines,
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this approach is more challenging in primary T cells for several reasons. Firstly, pooled
screens usually require large cell numbers (10s of millions) (Doench, 2017). Secondly,
a selection procedure for cells that have incorporated Cas9 and sgRNAs after lentiviral
transduction is required. This can be in the form of antibiotic selection or sorting by FACS.
The selection procedure can take several weeks, and therefore cannot be used on cells with a
limited life span in vitro (Doench, 2017), such as mouse T cells. However, primary human
T cells in theory fit the required criteria. They are able to survive for many months in
tissue culture by regular re-stimulation using PHA and irradiated buffycoat from allogeneic
donors. Through re-stimulation, they can also be expanded to give the desired amount of
cells. Furthermore, any findings in primary human T cells could have immense medical
potential.
An early study trying to use CRISPR in primary human T cells revealed transfection
difficulties when nucleofecting plasmids encoding Cas9 and sgRNAs, leading to low CRISPR
efficiency (Mandal et al., 2014). Nucleofecting human T cells with Cas9-RNPs has been
more successful (Schumann et al., 2015), but this approach only allowed targeting a select
set of genes, rather than unbiased, genome-wide screening.
One option to enable a genome-wide screen would be to produce human T cells that
stably express Cas9. This could be achieved by transducing human T cells with a lentiviral
vector encoding Cas9, however lentiviral vectors containing large inserts (the Cas9 gene is
⇠4000 bp in size) often result in low viral titre (Doench, 2017; Ramezani and Hawley, 2002;
Sanjana et al., 2014). This chapter describes my efforts to test CRISPR in human T cells
and to produce primary human T cells that stably express Cas9 using lentiviral transduction.
Such cells would provide the possibility to generate stable KOs in primary human T cells.
Perhaps such cells could even be used for a genome-wide screen in primary human T cells
using the same approach of a pooled genome-wide lentiviral sgRNA library commonly used
in cell lines.
6.1.1 Chapter aims
• Transduce hCTL with a lentivirus encoding Cas9 as well as antibiotic resistance or a
fluorescent marker to be able to select successfully transduced cells.
• Test nucleofection of hCTL and the transient Cas9-RNP CRISPR approach (optimised
in chapter 3) in primary hCTL.
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• Compare the stable (Cas9 lentivirus) and transient (Cas9-RNP) approaches in terms of
CRISPR efficiency.
6.2 Results
6.2.1 Transduction of hCTL with Cas9-Blast lentivirus
Initially hCTL were transduced with the Cas9-Blast lentivirus (Sanjana et al., 2014), encoding
Cas9 separated by a 2A sequence derived from porcine teschovirus (P2A) from a gene
encoding resistance to the antibiotic blasticidin. Therefore, any cells that express Cas9 upon
transduction could be selected by treatment with blasticidin. In order to be able to select
transduced cells, it was first necessary to establish what concentration of blasticidin killed all
untransduced cells, which can vary greatly between cell types (Doench, 2017). Therefore,
I tested the blasticidin sensitivity of hCTL by exposing them to a variety of blasticidin
concentrations over a time period of 15 days. Blasticidin was renewed every two days and
viability measured by flow cytometry. Changes in cell morphology as detected by forward
scatter/side scatter analysis and staining with DAPI were used as an indicator of whether
cells were alive or dead. 5 µg/ml was determined as the lowest blasticidin concentration that
I tested that killed all hCTL within 15 days of treatment, as live cells were still remaining
after 15 days treatment with 1 µg/ml blasticidin (Figure 6.1). Therefore, 5 µg/ml Blasticidin
was used to select hCTL transduced with the Cas9-Blast lentivirus.
As a control for transduction, hCTL were transduced with a lentivirus encoding just the
fluorescent protein GFP in parallel to transduction with the Cas9-Blast lentivirus. 44.5% of
the cells were successfully transduced with the GFP lentivirus, as visualised by flow cytometry
(Figure 6.2A), confirming that there was no technical problem during the transduction process.
No band corresponding to Cas9 was detected by WB using lysates derived from hCTL
transduced with Cas9-Blast lentivirus, in contrast to lysates from Cas9 hom mice which
served as a positive control for the Cas9 protein (Figure 6.2B). However, Cas9 could be
detected by WB after transduction of HEK293T cells with the Cas9-Blast lentivirus (Figure
6.2C). This indicated low transduction efficiency with this lentivirus in hCTL, but not in
HEK293Ts. PCR was used as a more sensitive technique to show that the Cas9 lentivirus
had successfully integrated in some hCTL (Figure 6.2D). DNA isolated from transduced
HEK293T (positive control) was run alongside DNA from hCTLs on the agarose gel. It is
noteworthy that while DNA was isolated from 450,000 hCTLs for the PCR reaction, the
signal is lower than the signal generated by DNA derived from only 10,000 transduced HEK
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A
B
Fig. 6.1 Blasticidin concentration response. A Human T cells were treated with blasticidin
at the indicated concentrations for 15 days. Blasticidin-containing media was renewed every
2-3 days. Viability was measured by gating on forward scatter (FSC) and side scatter (SSC)
parameters by flow cytometry. The percentage of cells in the FSC/SSC gate was normalised
to the treatment control (no blasticidin treatment) at each time point. B Representative flow
cytometry plots after 15 days of blasticidin treatment showing the change in the FSC/SSC
profile and the DAPI signal within the FSC/SSC gate.
cells. This confirmed that transduction of hCTLs with the Cas9-Blast lentivirus was much
less efficient than transduction of HEK293T with the same lentivirus. Selecting the hCTLs
in blasticidin almost killed transduced and untransduced cells to a comparable level after 6
days of blasticidin treatment (Figure 6.2E). Only a few live cells remained in the transduced
samples, providing further evidence that the transduction efficiency was very low (Figure
6.2E). These live cells were sorted by FACS and single cell dilutions were performed in the
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Fig. 6.2 Transduction of hCTL with Cas9-Blast lentivirus. A GFP expression profile of
untransduced hCTL and hCTL transduced with pHRSIN-GFP lentivirus. B WB showing
Cas9 protein expression in lysates derived from Cas9 hom mice (positive control), but not
in samples transduced with Cas9-Blast lentivirus or any of the negative controls (samples
transduced with a pHRSIN-GFP lentivirus, protamine sulfate (PS) treatment control samples,
or untransduced control samples). C WB showing Cas9 protein expression in lysates derived
from HEKs transduced with Cas9-Blast lentivirus, but not in PS treatment control samples.
D Agarose gel of products from a PCR with primers spanning a 274 bp region between the
3’ end of the Cas9 gene and the blasticidin resistance gene. E Viability of untransduced
hCTL and hCTL transduced with Cas9-Blast lentivirus after 6 days treatment with 5 µg/ml
blasticidin. PS = protamine sulfate, HEK = HEK293T.
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6.2.2 Generation of a lentivirus encoding Cas9 and a fluorescent tag
As an alternative approach to antibiotic selection, Cas9 can be co-expressed with a fluorescent
marker, which allows to detect successfully transduced cells by flow cytometry (Doench,
2017). As hCTL were successfully transduced with the GFP lentivirus (pHRSIN-GFP) used
in Figure 6.2A, the Cas9 gene was cloned into a mCherry fluorescent protein encoding
version of the pHRSIN plasmid (pHRSIN-mCh).
The approach taken to insert Cas9 into the pHRSIN-mCh vector is outlined in Figure
6.3A. I generated two plasmids, in the first plasmid mCherry was immediately downstream
of the Cas9 gene, in the second plasmid the Cas9 gene was linked to mCherry via a sequence
encoding the self-cleaving P2A peptide, shown to have high cleavage efficiency in human
cells (Kim et al., 2011). For simplicity, the P2A sequence is referred to as 2A for the
remainder of this results section.
Primers were designed that amplify the Cas9 gene from the Cas9-Blast lentiviral plasmid
by PCR. The primers included sequences that overlap with the pHRSIN-mCh plasmid,
as well as a XhoI RE site upstream of Cas9 and a BamHI RE site downstream of Cas9.
The resulting PCR products were run on a gel (Figure 6.3B) and purified. The recipient
plasmid (pHRSIN-mCh) was cut with XhoI and BamHI RE, run on a gel and also purified.
The resulting insert and recipient vector fragments were joined by Gibson assembly. After
bacterial transformation and selection on ampicillin plates, 8 colonies were picked per plate
and expanded. After DNA purification, the DNA from the various different colonies was
subjected to a restriction digest with XhoI and BamHI. Running the products of the restriction
digest on a gel allowed for the isolation of colonies that appeared to have the correct insert
as indicated by the excision of a band corresponding to the Cas9 gene in size (⇠4000 bp)
(Figure 6.3C,D). Sanger sequencing carried out by Source Bioscience confirmed the correct
sequence of DNA derived from colonies 1c and 2e, while DNA from colonies 1e and 2h
contained point mutations. The entire Cas9 gene and its flanking regions to the pHRSIN-mCh
vector were sequenced. Figure 6.4 shows plasmid maps for the final pHRSIN-Cas9-mCh and
pHRSIN Cas9-2A-mCh plasmids that were subsequently used for lentivirus production.
As a control to test these lentiviral plasmids, I transduced P815 cells, as this mastocytoma
cell line is more easily transduced than primary human T cells. The mCherry signal was
measured by flow cytometry, and Cas9 protein expression was confirmed by WB (Figure
6.5). While only one band corresponding to Cas9 was observed in the Cas9-mCh lentivirus
































































Fig. 6.3 Cloning Cas9 into the pHRSIN-mCh vector.
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Fig. 6.3 Cloning Cas9 into the pHRSIN-mCh vector. A Schematic showing the plasmid
map for the Cas9-Blast lentivirus (top) that acted as the source to amplify the Cas9 gene
(middle) in order to insert it into the recipient plasmid pHRSIN-mCh (bottom). Location
of the forward primer (Cas9-F) and reverse primers (Cas9-mCh-R and Cas9-2A-mCh-R)
are indicated on the Cas9 gene (middle). Plasmid maps were created with snapgene. B
Agarose gel showing Cas9 amplified from the Cas9-Blast plasmid using primers that add
on a 5’ XhoI restriction enzyme site and a 3’ BamHI restriction enzyme site with (2) or
without (1) the 3’ 2A sequence. These PCR products were cloned into the pHRSIN-mCh
vector digested with XhoI and BamHI restriction enzymes using Gibson assembly. C and D
Agarose gels showing the banding pattern after using XhoI and BamHI restriction enzymes
to digest the DNA derived from ampicillin-resistant clones (a-h) of NEB10beta bacteria
that were transformed with the Gibson assembly products. DNA that showed the expected
banding pattern, cutting out a ⇠4000 bp fragment corresponding to Cas9, were sequenced.
RRE = rev response element, cPPT = central polypurine tract, SFFV = spleen focus forming
virus promoter, EF1al pha = elongation factor 1al pha promoter, Cas9 = CRISPR-associated
protein 9, NLS = nuclear localisation sequence, Flag = flag octapeptide tag, P2A = P2A
self-cleaving peptide, BSD = blasticidin selection marker, WPRE = woodchuck hepatitis
virus post-transcriptional regulatory element, AmpR = ampicillin resistance gene.
samples (Figure 6.5A). These two bands should correspond to two versions of Cas9, one
where the 2A sequence successfully cleaved Cas9 from mCherry, and another where cleavage
was not successful. Therefore, the higher MW band likely corresponded to Cas9 fused to
mCherry, and the lower molecular weight band corresponded to Cas9 where the mCherry tag
was cleaved. While this indicated that the 2A peptide was functional, I would have expected
the 2A cleavage ability to be more efficient. However, to avoid any potential functional effects
of tagging mCherry directly to Cas9, which may block Cas9 activity, the Cas9-2A-mCh
lentivirus was used from now on.
Next, the Cas9-2A-mCh lentivirus was tested on two cell lines that are more closely
related to hCTL than P815s: 1) Jurkat cells, a human T cell line, and 2) YT, a human NK
cell line. Both cell lines were successfully transduced with the lentivirus as shown by the
detection of mCherry signal by flow cytometry and detection of Cas9 by WB (Figure 6.6).
Strikingly, the Cas9 expression was much stronger in the lentivirally transduced samples than
in samples derived from Cas9 hom mice (described in chapter 3) (Figure 6.6B). While only

















Fig. 6.4 Final Cas9-mCh and Cas9-2A-mCh pHRSIN plasmids maps. Two Cas9-
containing pHRSIN-mCh plasmids were produced: A One plasmid with Cas9 directly
fused to mCherry. B A second plasmid where Cas9 and mCherry are separated by a P2A
sequence. Plasmid maps were created with snapgene. RRE = rev response element, cPPT
= central polypurine tract, SFFV = spleen focus forming virus promoter, Cas9 = CRISPR-
associated protein 9, NLS = nuclear localisation sequence, Flag = flag octapeptide tag,
P2A = P2A self-cleaving peptide, WPRE = woodchuck hepatitis virus post-transcriptional
regulatory element, AmpR = ampicillin resistance gene.
that these correspond to the same molecular weight as the lower band in the Cas9-2A-mCh
lentivirus transduced samples (the version of Cas9 where mCherry was cleaved from Cas9).
However, using lentivirus from the same stock did not result in mCherry positive hCTL (data
not shown), again indicating difficulty in transducing this cell type.
6.2.3 Transduction of human T cells with Cas9-2A-mCh lentivirus
Since the Cas9-2A-mCh lentivirus worked on various cell lines, but not on primary hCTL, I
set out to determine the titre of the lentivirus produced. I determined the lentivirus viral titre
on Jurkat cells (Figure 6.7A), as an easy-to-transduce cell type, that will therefore provide an
accurate representation of the viral titre, but is also related to primary human T cells. This
showed that my standard lentiviral production protocol produced Cas9-2A-mCh lentivirus at
a high titre (1.8x107 TU/ml).











































Fig. 6.5 Transduction of P815 cells with Cas9-mCh and Cas9-2A-mCh lentivirus. A WB
showing Cas9 expression after transduction of P815 cells with the Cas9-mCh or Cas9-2A-
mCh lentivirus. B Flow cytometry plots showing the expression of mCherry-positive P815s
after transduction with Cas9-mCh or the Cas9-2A-mCh lentivirus.
Next, I tried to optimise transduction efficiency in primary human CTL. I normally
included protamine sulfate in transduction experiments. Protamine sulfate is a polycationic
polymer that neutralises the charge repulsion between the viral membrane and the plasma
membrane of the cell and has been shown to enhance transduction efficiencies in human T
cells (Cornetta and Anderson, 1989). Another commercially available reagent, the poloxamer
synperonic F108, also known as lentiboost, is known to enhance transduction efficiency via a
different mechanism. Lentiboost interacts with membranes and increases their permeability
(Höfig et al., 2012). A study comparing transduction efficiencies in mouse CD4 and CD8
T cells showed lentiboost performs better than protamine sulfate (Delville et al., 2018).
Encouragingly, comparing transduction efficiencies between samples transduced with the
’empty’ pHRSIN-mCh lentivirus showed that transduction efficiency was higher in the
presence of lentiboost in comparison to protamine sulfate (Figure 6.7B). All of the Cas9-2A-
mCh lentivirus remaining from the viral titration was aliquoted between cells derived from
three different HDs, meaning that these cells were only transduced at a low MOI of 1.17. As
observed with the ’empty’ pHRSIN-mCh lentivirus, transduction with the pHRSIN Cas9-
2A-mCh lentivirus in the presence of lentiboost resulted in a higher transduction efficiency
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Fig. 6.6 Transduction of Jurkat and YT cell lines with Cas9-2A-mCh lentivirus. A Flow
cytometry plots showing the expression of mCherry in YTs and Jurkat cells after transduction
with the Cas9-2A-mCh lentivirus. B WB comparing Cas9 expression in lysates derived from
Cas9 hom mCTL to lysates derived from YTs, Jurkat cells and P815s transduced with the
Cas9-2A-mCh lentivirus.
in comparison to transduction with protamine sulfate (Figure 6.7B,C). While transduction
efficiency was variable in cells from different HDs, up to 17% mCherry-positive cells were
achieved after transduction with Cas-2A-mCh lentivirus in the presence of lentiboost (Figure
6.7D). FACS was used to isolate the mCherry-positive population, however, the cells did
not expand further after sorting. This indicated that in addition to the challenge of low
transduction efficiency with the large Cas9-2A-mCh lentivirus, sorting primary human T
cells provided another hurdle to using the lentiviral CRISPR approach in primary human T
cells.
6.2.4 Nucleofection of primary human T cells
As an alternative approach that does not require sorting, I tested the CRISPR approach
using RNPs, as described in chapter 3, in hCTLs. This approach has been successfully
used by others, mostly in human CD4 T cells (Hultquist et al., 2016; Roth et al., 2018;
Rupp et al., 2017; Schumann et al., 2015). As hCTL had not previously been successfully
nucleofected in our lab, I initially compared the nucleofection efficiency achieved with two
different machines (the neon from ThermoFisher Scientific and the 4D from Lonza). When
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200,000 x 0.385 x 500
2.5 ml
= 1.54x107 TU/ml
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Fig. 6.7 Transduction of human T cells with Cas9-2A-mCh lentivirus. A Determination of
viral titre of the Cas9-2A-mCh lentivirus by transducing Jurkat cells. B mCherry expression
in primary hCTL transduced with pHRSIN-mCh lentivirus using protamine sulfate (PS) or
lentiboost (LB) as transduction enhancers. Bar graphs show the mean ± SD. C mCherry
expression in primary hCTL transduced with pHRSIN-Cas9-2A-mCh lentivirus at MOI of
1.17 using PS or LB as transduction enhancers. The bar graphs show the average of 3
independent experiments, error bars show the SD. D Flow cytometry plots showing mCherry
expression in response to transduction of hCTL derived from the same HD at MOI of 1.17 in
the presence of PS or LB reagents. LB = lentiboost. PS = protamine sulfate.
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nucleofecting a plasmid encoding lifeact-EGFP the nucleofection efficiency achieved with
the two machines was similar, showing an average nucleofection efficiency of 51.38% (neon)
and 56.52% (4D) after one day (Figure 6.8). The fluorescent signal was maintained until day
4 and decreased by day 7 after nucleofection (Figure 6.8).
To test the RNP CRISPR system I used synthetic crRNA reagents targeting the human
CD2 gene, co-nucleofected alongside tracrRNA and Cas9 protein as established for mCTL
in chapter 3. CD2 was targeted as it encodes a cell surface protein that is easily monitored
by flow cytometry. I only used 1-1.5 million cells per nucleofection and scaled down the
CRISPR reagents accordingly (e.g. in chapter 3 I used 5 µg per crRNA when nucleofecting
5 million cells, therefore I used 1 µg per crRNA for 1 million cells). A decrease in CD2
levels could be observed 4 days after nucleofection (Figure 6.9). Strikingly, the percentage
of cells that lost surface expression of CD2 was higher in samples that were nucleofected
with the neon nucleofection system (n=6, p<0.001 at day 4, unpaired t-test with Welch’s
correction). Importantly, the KO was stably maintained until the last time point measured
(one month after nucleofection). This confirmed the great potential of using hCTL over
mCTL to produce stable KOs that are long-lived in tissue culture.
6.2.5 Comparing CRISPR KO efficiency with stable and transient Cas9
expression
Finally, I asked how the stable expression of Cas9 achieved through using the Cas9-2A-
mCh lentivirus compared to the transient nucleofecion of Cas9-RNP complexes in terms
of CRISPR efficiency. Jurkat cells were used that were either untransduced or between
90-100% positive for Cas9-2A-mCh after transduction. While Jurkat cells were nucleofected
with Cas9 protein, tracrRNA and crRNAs targeting CD2, Cas9-2A-mCh-transduced Jurkat
cells were only nucleofected with tracrRNA and crRNAs targeting CD2. The percentage of
CD2 expression at the cell surface was measured at day 5 and day 14 after nucleofection.
Initially, I used the same number of cells and same concentration of reagents previously used
for CD2 CRISPR in human T cells. However, a convincing decrease in CD2 levels was not
observed at day 5 or day 14 post nucleofection (Figure 6.10A). Following the manufacturer’s
protocol, I scaled down the number of cells nucleofected from 1 million (using cuvettes
for nucleofection) to 0.2 million (using 16-well strips for nucleofection) while keeping the
amount of CRISPR reagent the same, thereby increasing the reagent-to-cell ratio. This
showed successful CRISPR-mediated loss of CD2 protein cell surface expression in transient











































Fig. 6.8 Nucleofection of human T cells with lifeact-EGFP. PBMCs were isolated from
buffycoat and activated with 5 µg/ml PHA. At day 3 post activation, 1.5 million cells were
nucleofected with 2 µg lifeact-EGFP plasmid using the Lonza 4D or neon nucleofection
machines. The percentage of cells positive for lifeact-EGFP was determined by flow
cytometry at day 1, 4 and 7 post nucleofection. A Representative flow cytometry plots.
B Average lifeact-EGFP expression measured by flow cytometry at day 1, 4 and 7 post
nucleofection. The bar graphs show the average of 5 independent experiments, error bars


































































































































Fig. 6.9 Targeting CD2 by CRISPR using Cas9-RNP in human T cells. PBMCs were
isolated from buffycoat and stimulated with 5 µg/ml PHA for three days prior to nucleofection.
1-1.5 million cells per condition were nucleofected with Cas9-RNPs targeting CD2. The
Lonza 4D and neon nucleofection machines were tested in parallel. A Representative flow
cytometry plots showing the percentage of cells positive for cell surface CD2 at day 1, 4 and
7 or one month after nucleofection. B Average CD2 cell surface expression measured by flow
cytometry at day 1, 4 and 7 (n=5 independent experiments) and one month post nucleofection
(n=4 independent experiments), *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, unpaired
t-test with Welch’s correction. Bar graphs show the mean ± SD, no nuc = no nucleofection
control.





















































































































































































Fig. 6.10 CRISPR KO efficiency with transient and stable Cas9 expression targeting CD2
in Jurkat cells. A 1 million Jurkat cells were nucleofected with 1 µg per CD2 crRNA (3
crRNAs in total), 3 µg tracrRNA and 2 µg Cas9 protein using the Lonza 4D nucleofection
machine. CD2 cell surface expression was measured by flow cytometry at day 5 and day
14 post nucleofection, n=1. B 0.2 million Jurkat cells were nucleofected with 1 µg per
CD2 crRNA (3 crRNAs in total), 3 µg tracrRNA and 2 µg Cas9 protein using the Lonza 4D
nucleofection machine. CD2 cell surface expression was measured by flow cytometry at day
5 and day 14 post nucleofection. NT samples: n=1, No nuc and CD2 CRISPR samples: n=3
independent experiments, *p<0.05, ***p<0.001, unpaired t-test with Welch’s correction.
Bar graphs show the mean ± SD. C Representative flow cytometry plots showing CD2 cell
surface expression at day 5 post nucleofection. J=Jurkat, JmCh = Jurkat Cas9-2A-mCh, NT
= non-targeting, no nuc = no nucleofection control, ns = not significant.
(n=3, p<0.05 at day 5, unpaired t-test with Welch’s correction) and stable (n=3, p<0.001
at day 5, unpaired t-test with Welch’s correction) Cas9 samples (Figure 6.10B,C). Similar
results were achieved when targeting the gene encoding the cell surface protein B2M (Figure
6.11A,B) (n=3, p<0.01 for transient Cas9, p<0.001 for stable Cas9, unpaired t-test with
Welch’s correction). This confirmed that the Cas9-2A-mCh construct encoded functional
Cas9 protein. For both genetic targets, the sample with stable lentiviral transduction of Cas9
showed a trend towards better CRISPR KO efficiency in comparison to the respective Cas9












































































































Fig. 6.11 CRISPR KO efficiency with transient and stable Cas9 expression targeting B2M
in Jurkat cells. 0.2 million Jurkat cells were nucleofected with 1 µg per B2M crRNA (3
crRNAs in total), 3 µg tracrRNA and 2 µg Cas9 protein using the Lonza 4D nucleofection
machine. B2M cell surface expression was measured by flow cytometry at day 5 and day
14 post nucleofection. A Representative flow cytometry plots showing B2M cell surface
expression at day 5 post nucleofection. B Bar graphs showing the average B2M cell
surface expression at day 5 and day 14 post nucleofection, NT samples: n=1, No nuc and
B2M CRISPR samples: n=3 independent experiments, **p<0.01, ***p<0.001, unpaired
t-test with Welch’s correction. Bar graphs show the mean ± SD. J=Jurkat, JmCh = Jurkat
Cas9-2A-mCh, NT = non-targeting, no nuc = no nucleofection control, ns = not significant.
6.3 Discussion
The blasticidin selection time and concentration required to select for a transduced population
can vary greatly between cell types. Too much antibiotic kills cells including transduced
cells, not enough drug will result in untransduced cells being left in the population (Doench,
2017). 5 µg/ml blasticidin was the lowest concentration that seemed to kill all untransduced
cells, although even 1 µg/ml blasticidin had a stark effect on the FSC/SSC profile of hCTLs
after 15 days of treatment (Figure 6.1). While transduction of hCTL with the Cas9-Blast
lentivirus appeared to be successful by PCR, only few cells survived the treatment with 5
µg/ml blasticidin (Figure 6.2), indicating that this blasticidin concentration may have been
148 Establishing the CRISPR-Cas9 technology in primary human T cells
too high, killing everything including transduced cells. On top of this, low transduction
efficiency, as indicated by the WB and PCR results (Figure 6.2), likely also contributed to the
unsuccessful selection of Cas9-expressing cells. In agreement with my results, a published
study using a lentivirus encoding a puromycin resistance gene alongside Cas9 observed
immense cell death (>90%) upon antibiotic selection (Legut et al., 2018).
In order to be able to visualise transduction efficiency more clearly than by blasticidin
selection, I cloned the Cas9 gene into a lentiviral vector expressing the fluorescent protein
mCherry (Figures 6.3 and 6.4). Two versions of the vector were produced, one where Cas9
was directly fused to mCherry and another where Cas9 and mCherry were separated by a self-
cleaving 2A peptide (Figure 6.4). Using the resulting vector to produce lentivirus resulted
in successful transduction of P815, YT and Jurkat cell lines (Figures 6.5 and 6.6). Due to
concerns that directly fusing Cas9 to mCherry might affect its function the Cas9-2A-mCh
lentivirus was used subsequently.
2A peptides are used to co-express two genes in one mRNA transcript, which are then
cleaved co-translationally (Kim et al., 2011). While 2A peptides have been identified
from several different viruses, a study showed that the P2A peptide, derived from porcine
teschovirus, has the highest cleavage efficiency in human cell lines in comparison to 2A
peptides derived from three other viruses (Kim et al., 2011). However, in this chapter there
was only partial cleavage between Cas9 and mCherry in all cells tested, as shown by two
bands being detected when blotting for Cas9 (Figures 6.5 and 6.6). The lower molecular
weight band likely corresponded to Cas9 cleaved from mCherry and the higher molecular
weight band to Cas9 still fused to mCherry. I would have expected higher cleavage efficiency
of the P2A peptide based on the published data (Kim et al., 2011). This means that the Cas9
pool in the Cas9-2A-mCh transduced samples is a heterogenous population of Cas9 cleaved
from mCherry and Cas9 fused to mCherry. Therefore it was crucial to confirm that this mixed
population of Cas9 is functional as fusion to mCherry could affect its activity. The results
obtained with Cas9-2A-mCh Jurkat cells showed high KO efficiency when targeting B2M
and CD2 using CRISPR (Figures 6.10 and 6.11), indicating that the Cas9-2A-mCh cleaved
and uncleaved products are both functional.
It is known that as vector length increases, viral titre decreased (Ramezani and Hawley,
2002), meaning that viruses containing a large insert, such as Cas9, are likely to have a
relatively low titre (Doench, 2017). Here I managed to produce the Cas9-2A-mCh lentivirus
at a high viral titre (Figure 6.7), however, transduction of human T cells with Cas9-2A-mCh
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lentivirus was still challenging, and much less efficient than transduction of Jurkat, YT or
P815 cell lines. Lentiboost proved to be a better transduction enhancer than protamine sulfate,
yielding 17% transduction efficiency with the Cas9-2A-mCh lentivirus in cells derived from
one HD (Figure 6.7). However, the fluorescence level in the population positive for Cas-2A-
mCh was low, which could indicate a low level of Cas9 expression (Figure 6.7).
A recently published study also reported low transduction efficiency when transducing T
cells with lentivirus encoding Cas9-2A-GFP, obtaining 5% GFP-positive cells (Seki and Rutz,
2018). They noted a low level of GFP fluorescence as well, and concluded that the lentiviral
approach is inefficient (Seki and Rutz, 2018). Notably, I achieved up to 17% transduction
efficiency when using the Cas9-2A-mCh lentivirus at a low MOI of 1.17. It would therefore
be worthwile to try to transduce human T cells at a higher MOI to see if the percentage of
transduced cells could be increased further.
Meanwhile, I successfully used the Cas9-RNP nucleofection approach to target CD2
in human T cells (Figure 6.9). Throughout my PhD project, several studies have been
published using this approach, some have used the 4D nucleofector (Hultquist et al., 2016;
Roth et al., 2018; Rupp et al., 2017) and others the neon nucleofection machine (Gundry
et al., 2016; Schumann et al., 2015). While the two machines seemed similarly efficient
when nucleofecting a DNA plasmid encoding lifeact-EGFP (Figure 6.8), nucleofection with
the neon resulted in higher CD2 KO efficiency (Figure 6.9). This may be due to differences
between the nucleofection solutions or nucleofection pulses used, which can affect cell
permeability and perhaps even Cas9-RNP complex stability. On average, I achieved a
71.88% decrease in CD2 expression when using the neon nucleofection machine, but only a
29.28% decrease in CD2 with the 4D nucleofector at day 4 post nucleofection (n=5, p<0.001,
unpaired t-test with Welch’s correction, Figure 6.9).
Finally, I asked if CRISPR efficiency differed when using transient Cas9 expression
(Cas9-RNP nucleofection approach) or stable Cas9 expression (transduction with Cas9
lentivirus) in Jurkat cells. Surprisingly, the initial attempt to nucleofect Jurkat cells with CD2
CRISPR components was unsuccessful (Figure 6.10). Successful CRISPR-mediated KO of
CD2 and B2M was achieved when scaling down the number of cells used (Figures 6.10 and
6.11), indicating that a higher reagent-to-cell concentration was needed for CRISPR in Jurkat
cells than in hCTL. Jurkat cells may have an abnormal karyotype, and therefore potentially
more than two copies of the CD2 gene, which could explain the requirement for more
CRISPR reagents to cut all alleles. In agreement with this, some published studies indicated
150 Establishing the CRISPR-Cas9 technology in primary human T cells
that Jurkat cells may have a hypotetraploid genome (Cheng and Haas, 1990; Snow and Judd,
1987). Targeting CD2 and B2M in Cas9-2A-mCh-transduced and untransduced Jurkat cells
indicated that the CRISPR efficiency achieved with stable and transient Cas9 expression
was comparable. A non-significant trend towards better KO efficiency was observed with
stable Cas9 expression. However, this may just be due to Cas9 protein being limited by
nucleofection efficiency, while 90-100% of the Cas9-2A-mCh-transduced Jurkat cells were
expressing Cas9 according to mCherry expression measured by flow cytometry.
The Cas9-RNP approach is very useful to target specific genes or perform arrayed screens
(see chapter 4). However, if complete KOs are desired, it might be worth transducing hCTL
with Cas9 lentivirus at a higher MOI and further optimising hCTL survival after sorting in
order to generate hCTL that stably express Cas9. Subsequent transduction with a sgRNA-
containing lentivirus would likely be more efficient due to the smaller insert size, allowing
antibiotic selection and the generation of complete KOs. Stably expressing Cas9-hCTL would
also open the possibility of a genome-wide screen in primary human T cells. Until recently,
genome-wide screens had only been performed in cell lines related to primary T cells, such as
Jurkat and CCRF-CEM cells (Park et al., 2017; Shang et al., 2018). Recently, a group took an
alternative approach where they transduced primary human T cells with a lentiviral sgRNA
library followed by nucleofection of Cas9 protein (Shifrut et al., 2018). The methods and
reagents optimised in this chapter could be used to produce human T cells stably expressing
Cas9. If a Cas9-pure population could be isolated, transduction with a genome-wide sgRNA
lentiviral library would perhaps allow the unbiased pooled genome-wide screening approach
in primary human T cells.
6.3.1 Summary and evaluation of aims
• Transduce hCTL with a lentivirus encoding Cas9 as well as antibiotic resistance or a
fluorescent marker to be able to select successfully transduced cells.
– Initially, hCTL were transduced with a lentivirus encoding Cas9 and antibiotic
resistance to blasticidin. However, blasticidin selection was challenging due
to low transduction efficiency. To obtain a direct readout of the transduction
efficiency, Cas9 was cloned into a lentiviral vector that encodes a fluorescent
marker (pHRSIN-mCh). This lentiviral vector has previously been used to
transduce primary human hematopoietic cells (Demaison et al., 2002). I successfully
used the resulting lentivirus to transduce Jurkat cells, YTs and P815s. Human T
cell transduction proved more challenging due to low transduction efficiency with
6.3 Discussion 151
such a large construct. Using an alternative transduction enhancer to protamine
sulfate, lentiboost, improved transduction efficiency.
• Test nucleofection of hCTL and the transient Cas9-RNP CRISPR approach (optimised
in chapter 3) in primary hCTL.
– I tested two machines commonly used to nucleofect human T cells. At day 4 post
nucleofection, CD2 was knocked out in an average of 71.88% of cells using the
neon machine and 29.28% of cells using the Lonza 4D nucleofection machine.
• Compare the stable (Cas9 lentivirus) and transient (Cas9-RNP) approaches in terms of
CRISPR efficiency.
– Using Jurkat cells I showed that the CRISPR efficiency was comparable when
using stable or transient Cas9. Cells transduced with the Cas9 lentivirus showed a
slight trend towards better KO efficiency when targeting CD2 (averages from day
5: Jurkat: 60.77% KO, Jurkat Cas9-2A-mCh: 86.06% KO) and B2M (averages
from day 5: Jurkat: 83.26% KO, Jurkat Cas9-2A-mCh: 92.05% KO).

Chapter 7
Conclusions and future perspectives
7.1 Summary of findings
Cytotoxic T cells are a crucial component of the adaptive immune system. They are of
great interest for medical therapies as they can kill infected and cancerous cells. They do so
via direct contact to target cells and the focused secretion of lytic granules, also known as
degranulation, which ensures that target cells are killed while leaving surrounding cells intact.
The importance of cytotoxic T cells to maintain a healthy immune system is demonstrated by
the CTL defects observed in patients with life-threatening immunodeficiency diseases (Clark
and Griffiths, 2003; Feldmann et al., 2003; Stepp et al., 1999).
This study aimed to use the CRISPR-Cas9 gene editing technology in a screening setting
to test for genes that regulate CTL killing. In chapter 3, I established the amount of CRISPR-
Cas9-RNP reagents needed to efficiently edit primary mCTL by targeting the abundant cell
surface protein Thy1. Conditions resulting in reproducible and efficient CRISPR-mediated
KO in mCTL were successfully established, in some cases reducing protein expression by
over 90% (Figure 3.6). Targeting Rab27a, a known mediator of cytotoxic T cell function,
using CRISPR-Cas9-RNPs significantly reduced RAB27A protein levels and resulted in a
degranulation and killing phenotype (Figure 3.7). CRISPR-mediated KO of other known
regulators of CTL cytotoxicity, the lytic granule component perforin and MUNC13-4, a part
of the lytic granule fusion machinery, was further used to set up an assay that measures
degranulation and killing simultaneously (Figure 3.11). This flow cytometry-based assay
allowed detection of regulators of T cell killing, while the degranulation readout gave
immediate insight into the underlying molecular mechanism by which the killing is mediated.
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The combined degranulation and killing assay was suitable for screening as it could be
performed in a 96 well format. To identify targets for a screen I performed an RNA-seq
study that compared the transcriptome of naive and effector CD8 T cells (chapter 4). Genes
highly expressed in activated but not naive CD8 T cells are likely to be important for CTL
effector functions, including killing. This gave a large set (1803 genes) of upregulated
differentially expressed genes (Appendix B), which were predominantly associated with
the cell cycle (Figure 4.3). 13 genes, chosen based on functional annotation analysis and
literature research, were targeted by CRISPR and tested in the combined degranulation and
killing assay. Hif1a and Nfil3 were identified as interesting genetic targets where CRISPR-
mediated KO decreased the killing but not the degranulation capability of effector CTL
(Figures 4.5 and 4.6), a phenotype reminiscent of perforin CRISPR samples (Figure 3.8).
This was in line with published studies, which identified that perforin protein expression
was affected by the absence of members of the HIF complex and NFIL3 (Finlay et al., 2012;
Rollings et al., 2018). However, the precise mechanism by which HIF-1a and NFIL3 affect
perforin protein levels remains to be elucidated. Other studies have shown that these genes
are important when lost in naive T cells or during T cell development in vivo (Doedens
et al., 2013; Finlay et al., 2012; Rollings et al., 2018). The data generated in this thesis
demonstrated a direct importance of NFIL3 and HIF-1a in effector CTL to enable killing.
This is likely mediated through their effect on perforin. Furthermore, the RNA-seq dataset
was used to identify genes that are differentially expressed between males and females.
Interestingly this included some genes that are implicated in CTL killing function (such as
Gzma, Il2ra and Nfil3) (Table 4.3). It might therefore be interesting to explore whether there
are differences between the killing capabilities of males and females.
The screen performed in chapter 4 confirmed that the combined degranulation and
killing assay could be used to identify regulators of CTL killing in mCTL. In chapter 5, I
successfully tested this assay in hCTL using cells derived from FHL2 and FHL3 patients.
The traditional degranulation assay is currently used for diagnostic purposes, but cannot
detect defects resulting from perforin mutations (Bryceson et al., 2012). Diagnosis of FHL
therefore requires an additional investigation of perforin protein expression (Bryceson et al.,
2012). The combined degranulation and killing assay would therefore reduce the number of
experiments that need to be performed, making the diagnostic process more efficient. This
highlights the potential of the combined degranulation and killing assay as a diagnostic test.
The scalability of the screen was tested in hCTL using a library containing 64 compounds
that targeted the NF-kB signalling pathway. In this screen for chemical mediators of CTL
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killing, I identified that parthenolide (drug 19) affected CTL killing within 1 h of treatment
(Figure 5.8). Parthenolide was found to affect NF-kB activity via the phosphorylation status
of p65 at Ser536 (Figure 5.9). However, parthenolide has also been reported to affect HDAC1
and DNA methyltransferase 1 (Gopal et al., 2007; Liu et al., 2009), meaning that I could
not conclude that the degranulation and killing defect observed upon CTL treatment with
parthenolide was due to its inhibition of p65. KO of p65 using CRISPR could help to clarify
the role of NF-kB in CTL killing. The drug screen therefore highlighted two important
points. Firstly, that the combined degranulation and killing assay could be used to screen
many dozens of compounds. Secondly, it emphasised the advantage of a CRISPR-based
screen over a drug screen, as the genetic approach provides a cleaner system that is, at least
in theory, not complicated by unanticipated off-target effects.
Finally, I successfully used the CRISPR gene editing technology using the RNP approach
in hCTL (Figure 6.9). I also explored stable Cas9 expression through lentiviral transduction
as an alternative approach to CRISPR in primary human T cells and related cell lines.
This approach could provide an even cleaner system as stable incorporation of antibiotic
resistance cassettes or fluorescent markers would allow selection of cells that contain all
necessary CRISPR reagents. Additionally, this approach has the potential to allow much
larger CRISPR-based screens, as discussed in section 7.4. The difficulties I experienced
with lentiviral transduction of human T cells with Cas9 are in line with observations from
other labs (Legut et al., 2018; Shifrut et al., 2018; Wang et al., 2014b). However, through
careful optimisation of transduction methods I achieved a transduction efficiency of up to
17% (Figure 6.7). Transposon-based stable integration of Cas9 could be explored in parallel
to single cell cloning of the Cas9-2A-mCherry transduced cells in future experiments, in
order to achieve the aim of creating primary human T cells that stably express Cas9.
7.2 Comparison of findings to published studies using CRISPR
in primary T cells
7.2.1 CRISPR in mouse T cells
As this PhD project was ongoing, several papers have been published that use the CRISPR-
Cas9 technique in primary mouse T cells. These can broadly be divided into studies using
primary cells derived from Cas9 expressing mice and studies that use Cas9-RNPs, two
options that were also explored in this thesis. Meanwhile, several studies noted that all-in-one
viral vectors encoding both Cas9 and sgRNAs resulted in low transduction efficiencies, likely
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due to the large size of Cas9, and are not as efficient at generating KOs (Huang et al., 2019;
Seki and Rutz, 2018).
Several Cas9 expressing mice have been generated (Chu et al., 2016b; Platt et al., 2014;
Tzelepis et al., 2016). Chu et al. (2016a) used primary T cells derived from transgenic Cas9
mice and achieved KO of CD44 in around 50% of the cells four days after transduction
with retroviral vectors encoding sgRNAs. Interestingly they showed that their Cas9 mice
expressed more Cas9 in lymphocytes and generate KOs at higher efficiencies than the Cas9
mice generated by Platt et al. (2014).
A paper published after this thesis was submitted used the same transgenic Cas9 mice
(generated by Tzelepis et al. (2016)) that I used for the experiments in Figure 3.4 for genome-
wide CRISPR screens in primary CD4 T cells (Henriksson et al., 2019). They transduced
the Cas9 expressing T cells with a genome-wide retroviral sgRNA library, where each virus
encoded a single sgRNA together with BFP and puromycin resistance. This enabled selection
of cells that stably expressed sgRNAs. In contrast, I transiently nucleofected synthetic
crRNAs and tracrRNAs into primary T cells derived from the transgenic Cas9 mice, a process
which does not allow stable expression or selection of cells that have taken up the reagents.
Using this approach, I achieved an average protein loss of 41.6% in nucleofected cells when
using 10 µg crRNA/tracrRNA (Figure 3.4). In the experimental setup of Henriksson et al.
(2019) all cells should have been expressing a sgRNA and Cas9 after selection procedures.
Therefore, their approach, in contrast to mine, was not limited by nucleofection efficiency or
the stability of synthetic RNAs. Unfortunately, a direct comparison of CRISPR efficiency
between my study and Henriksson et al. (2019) is not possible, because they do not show the
percentage loss of protein expression they achieved in response to CRISPR. In their methods
they state that they used a viral vector encoding BFP, GFP and a sgRNA against GFP to test
Cas9 function. With this approach, Cas9 cutting efficiency can be validated and quantified by
loss of GFP expression in the presence of the GFP-targeting sgRNA. As the results are not
shown it is unclear how efficiently they lose protein expression in their experimental setup.
However, it seems that their CRISPR KO worked to some extent as they observed signs of
altered CD4 T cell differentiation in response to some sgRNAs (Henriksson et al., 2019).
I was able to improve on the CRISPR KO efficiency I achieved with cells derived from
Cas9-expressing mice by using Cas9-RNPs in cells derived from WT mice (64.7% Thy1 KO
achieved with Cas9-RNP (Figure 3.5) in contrast to 33.3% Thy1 KO achieved using the same
concentration of synthetic crRNA/tracrRNA in cells from Cas9-expressing mice (Figure 3.4)).
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Cas9-RNPs have the advantage of allowing gene-editing in primary cells regardless of their
genetic background. Due to its higher efficiency, the Cas9-RNP approach was subsequently
used throughout this thesis.
While Cas9-RNPs have been widely used in primary human T cells, as outlined in the
next section, the first study that used this approach in primary mouse T cells was only
published in 2018 (Seki and Rutz, 2018). Using one guide to target Thy1, Seki and Rutz
(2018) reported 60% loss of Thy1 expression in primary mouse T cells using the Cas9-RNP
approach, which corresponds well to the 64.7% loss of Thy1 expression I achieved with one
guide (Figure 3.5). To further improve CRISPR efficiencies, Seki and Rutz (2018) carefully
optimised a myriad of further experimental parameters. They tested a range of nucleofection
conditions (optimising buffers and pulses), showed that using two or three sgRNAs per gene
rather than one sgRNA per gene resulted in improved KO efficiency and even found that
some commercially available Cas9 proteins lead to higher KO efficiencies than others (Seki
and Rutz, 2018). Using their optimised conditions, Seki and Rutz (2018) achieved 85%-98%
KO across a variety of targets in activated and nonactivated primary human and mouse CD4
and CD8 T cells. Similarly to Seki and Rutz (2018), I routinely used three guides per gene,
resulting in comparable KO efficiencies across many target genes (Rab27a (Figure 3.7),
Perforin (Figure 3.8), Munc13-4 (Figure 3.9), Nfil3 (Figure 4.5), Hif1a (Figure 4.6)). The
study by Seki and Rutz (2018) indicates that there may be potential to improve the KO
efficiency I achieved even further. This could be explore in future experiments, for example
by testing a variety of commercially available Cas9 proteins.
7.2.2 CRISPR in human T cells
Several technical approaches have been pursued to achieve CRISPR-Cas9 mediated gene
editing in primary human T cells. These include nucleofection of DNA plasmids, viral
delivery of CRISPR components and nucleofection of crRNAs and tracrRNAs in combination
with Cas9 protein or Cas9 mRNA.
The first published study that used CRISPR in primary human T cells nucleofected
plasmids encoding Cas9 and sgRNAs (Mandal et al., 2014). Interestingly, they found that a
sgRNA that led to loss of B2M expression in 48% of HEK293T cells only resulted in loss of
B2M expression in less than 5% of primary T cells. Even after targeting the gene with two
guides, they only achieved 18% loss of B2M expression (Mandal et al., 2014), indicating
that their approach to gene-editing in primary T cells was inefficient.
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Further technical difficulties were highlighted by several studies that attempted to use
viral delivery of CRISPR components to primary human T cells. Wang et al. (2014b) tried
to deliver Cas9 and sgRNAs using lentiviral vectors to primary human T cells, but while
they were able to KO CCR5 in a human CD4 T cell line, they stated that attempts to disrupt
CCR5 gene expression in primary human T cells using the same experimental approach were
unsuccessful, although the data is not shown. Similarly, Griffin et al. (2015) tried to deliver
Cas9 and sgRNAs using viral vectors and observed that editing efficiency was lower in
primary CD4 T cells than in related cell lines. More recently, Legut et al. (2018) managed to
transduce primary human T cells with a viral vector encoding Cas9, sgRNA and puromycin
resistance. However, 90% of cells died following selection, indicating that only 10% of the
cells were successfully transduced (Legut et al., 2018). These results correlate well with my
findings in chapter 6, and demonstrate that low transduction efficiency is a key challenge to
stable expression of Cas9 in primary T cells.
The most widely published approach to CRISPR-Cas9 gene editing in primary human T
cells is the Cas9-RNP method. Schumann et al. (2015) achieved ⇠40% loss of cell surface
expression of CXCR4 in primary human T cells in response to nucleofection of in vitro
transcribed crRNA and tracrRNA alongside Cas9 protein. Nucleofection of CRISPR reagents
as RNAs and proteins was found to be less toxic and more efficient at generating KOs than
nucleofection of plasmids (Hendel et al., 2015). Another study using Cas9-RNPs in primary
human T cells achieved 86% loss of CD45 in response to nucleofecting CRISPR reagents
using the neon transfection system (Gundry et al., 2016). These results are comparable to the
efficiencies I obtained when targeting CD2 by CRISPR in primary human T cells, where I
achieved 75.8% KO on average at day 7 post nucleofection when using the neon transfection
system (Figure 6.9). Further studies have successfully used the Cas9-RNP approach to create
more potent CAR T cells, for example by disrupting PD-1 to enhance CAR T cell mediated
killing (Rupp et al., 2017) and by disrupting CD7 to avoid fratricide of CD7 specific CAR T
cells (Gomes-Silva et al., 2017). While not the focus of this thesis, it is also noteworthy that
knock-ins have been achieved using the Cas9-RNP approach (Roth et al., 2018; Schumann
et al., 2015).
Similarly to my approach in chapter 4, where I performed an arrayed screen using Cas9-
RNPs in primary mouse T cells, the Cas9-RNP approach has also been used for an arrayed
screen in primary human T cells. While I targeted 13 genes, Hultquist et al. (2016) targeted
45 genes in order to identify genes that control HIV infection of primary human T cells.
Hultquist et al. (2016) were able to perform an arrayed screen at a larger scale because they
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had access to a 96-well electroporation device. Together, both my study and the paper by
Hultquist et al. (2016) demonstrate the value of the Cas9-RNP technology for the purpose of
small to medium sized arrayed CRISPR screens.
Further to the technical approaches outlined above, nucleofection of Cas9 mRNA, rather
than Cas9 protein, alongside in vitro transcribed RNA has also been used for successful gene
editing in primary human T cells (Ren et al., 2017a). Additionally, the lentiviral delivery
of sgRNAs followed by nucleofection of Cas9 mRNA was shown to result in loss of CD3
expression in 90% of cells, in comparison to 82% KOs achieved with synthetic sgRNA and
Cas9 protein co-nucleofection and 76% KOs achieved with co-nucleofection of synthetic
sgRNAs and Cas9 mRNA (Ren et al., 2017b). Similarly, Shifrut et al. (2018) achieved loss
of CD8 expression in over 80% of cells when using lentiviral delivery of sgRNAs followed
by nucleofection of Cas9 protein. While the KO efficiencies achieved are convincing across
several different technical approaches, the viral delivery of sgRNAs has the additional benefit
of enabling delivery of genome-wide sgRNA libraries, allowing large-scale unbiased screens,
as recently performed by Shifrut et al. (2018).
In summary, the toolbox for disrupting gene expression using CRISPR-Cas9 in primary
human and mouse T cells has been expanding rapidly over the last 5 years as this PhD
project was ongoing. The findings in this thesis correlate well with published findings, and
contribute to knowledge of how to efficiently and robustly disrupt gene expression in primary
T cells. KO efficiencies over 80% have been achieved across many genetic targets, both
in this thesis and in the published literature. Cas9-RNPs or viral expression of sgRNAs in
combination with Cas9 protein/mRNA nucleofection or cells derived from Cas9-expressing
mice have emerged as the most convincing approaches to generate KOs in primary T cells at
high efficiencies.
7.3 Evaluation of the Cas9-RNP approach to CRISPR gene
editing
The results obtained in this thesis indicate that Cas9-RNPs can generate true genetic KOs
in a substantial subset of target cells as measured by WB and flow cytometry (Figures 3.4 -
3.9). Cas9-RNPs generated permanent genetic modifications, which were shown to be stably
maintained, at least until 1 month after nucleofection (Figure 6.9). While some cells treated
with Cas9-RNP appeared to have lost protein expression completely, other cells had only
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partially lost protein expression or not lost it at all. This heterogeneity can be seen clearly
in flow cytometry plots where Thy1 was targeted in mCTL (Figure 3.5) and CD2 or B2M
were targeted in Jurkat cells or hCTL (Figures 6.9, 6.10 and 6.11). The variability of the
fluorescent signal likely correlated to homozygous KOs, heterozygous KOs and unedited
cells. This heterogeneous mix of cells is likely the result of limited transfection efficiency
and variability in DNA repair outcomes. This heterogeneity may create noise in a phenotypic
readout that can conceal the phenotype of genes where KO only has a moderate effect. One
way to limit this noise is to derive clones from the mixed population in order to be able to
identify homozygously edited clones and the precise genetic alteration that occurred.
The benefit of analysing clones was also emphasised by a recently published study, that
showed that CRISPR can result in complex gene rearrangements, such as deletions of many
kilobases, around the cut site (Kosicki et al., 2018). The authors highlighted the need for a
comprehensive analysis of CRISPR edited cells before drawing functional conclusion, let
alone administering the edited cells to patients. Such comprehensive analysis would best be
achieved by cloning cells, followed by performing long-range PCR or sequencing to identify
all genetic changes caused by gene editing (Kosicki et al., 2018).
7.4 The potential to perform large scale screens in primary
human T cells
Secretion of lytic granules is a crucial part of the CTL killing response. Degranulation is
measured by the exposure of LAMP1 on the extracellular surface of CTL. While degranulation
was found to correlate with killing (Betts et al., 2003), it only gives an indirect killing readout.
The combined degranulation and killing assay presented in this thesis measures target cell
death directly, while still including the LAMP1 readout. This allowed me to directly correlate
the target cell lysis and degranulation readouts and gave immediate limited mechanistic
insight. The new assay is therefore an improvement over the traditional degranulation assay.
I showed that this assay can be used to detect genetic defects and compounds that reduce
degranulation and killing. For example, CRISPR-mediated KO of Rab27a (Figure 3.7),
Munc13-4 (Figure 3.9) and parthenolide treatment (Figure 5.7) decreased degranulation and
killing. I also showed that the assay can detect genetic defects that cause an increase in
degranulation while decreasing CTL killing, such as CRISPR-mediated KO of Prf1 (Figure
3.8) and Nfil3 (Figure 4.5). This demonstrated that CTL degranulation does not always
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correlate to cytolytic activity. No genetic targets or chemical compounds tested in this
thesis increased CTL killing, however, the assay should in theory also be able to detect this
phenotype, as long as the percentage of target cells killed throughout the assay duration is
kept below 100% in the control samples.
It would be interesting to scale this assay up to a 384 well format, where less cells and
reagents would be needed per sample. Fixation could be explored in order to stably maintain
the end point of the assay across the plate. Furthermore, the assay could be expanded to
include a cytokine readout, enabling comprehensive analysis of CTL function at scale. Such
an assay would be useful for large-scale arrayed screening approaches of compounds and
genetic targets.
While arrayed screens are potentially powerful, they are limited by the quality of available
datasets and the literature to inform the choice of genetic targets. In order to scale up the
screen even further it would have to be switched from an arrayed to a pooled format. The
pooled format is of particular interest as it would allow a genome-wide screen using a
lentiviral sgRNA library. This would provide an unbiased approach and maximise the
potential of identifying novel regulators of CTL function.
There are three main challenges that I anticipate for a genome-wide screen in primary
hCTL. The first challenge would be to produce primary CTL stably expressing Cas9. As
demonstrated in chapter 6, and acknowledged in the literature, stable expression of Cas9 in
primary human T cells through lentiviral transduction is inefficient (Seki and Rutz, 2018;
Shifrut et al., 2018). A recent study transduced primary human T cells with a genome-wide
sgRNA library and subsequently introduced Cas9 protein through nucleofection (Shifrut
et al., 2018). This approach, however, is limited by nucleofection efficiency, which may
not equal the level of Cas9 expression that would be achieved after stable transduction and
selection procedures. Given that I was able to produce up to 17% Cas9-2A-mCherry positive
hCTL through transduction (Figure 6.7), I would be keen to repeat these experiments and
attempt to clone out individual Cas9-expressing cells.
The second potential hurdle after Cas9 expression will be to select for cells that have
incorporated an sgRNA after transduction with the lentiviral library. This is usually achieved
through antibiotic selection if the sgRNA library contains an antibiotic resistance cassette.
While I had difficulty to select Cas9-expressing cells with blasticidin after transduction with
the Cas9-Blast lentivirus in chapter 6, I would expect that the transduction efficiency with
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the lentiviral sgRNA library would be higher, as the sgRNA construct is smaller than the
Cas9 construct. Higher transduction efficiency would result in better survival upon antibiotic
selection.
Thirdly, pooled screens are dependent on an appropriate flow cytometry based assay to
sort cells with the phenotype of interest. After sorting, samples are sequenced to identify
which sgRNAs were present in the cells with the desired phenotype (Joung et al., 2017).
LAMP1 expression in the degranulation assay could be used as the sorting phenotype.
Similarly to Shang et al. (2018), who sorted Jurkat cells according to increased or decreased
expression of CD69, I could sort cells with low or high LAMP1 signal in response to
stimulation. However, in the degranulation assay I often observed a proportion of cells
that, despite being stimulated, overlapped with the non-degranulating control in terms of the
LAMP1 signal (e.g. see Figure 3.7). These cells likely did not degranulate as they did not
encounter a target cell throughout the assay. This indicated that further optimisation of the
E:T ratio and assay duration would be necessary to minimise the background noise in the
degranulation assay.
Additional technical difficulties can be anticipated. Genome-wide screens require sorting
of tens of millions of cells, which takes many hours (Doench, 2017). The effect of this sorting
time on cell viability and aLAMP1-PE antibody signal needs to be taken into account. How
will cell viability be affected if they are kept at room temperature for a prolonged period of
time during sorting? Would the aLAMP1-PE antibody still be bound, and how would its
brightness be affected over time? These factors have the potential to create further noise in
the degranulation assay. Splitting the assay over several days, as done in chapter 5 for the
drug screen, would address some of these concerns.
In addition to the technical difficulties identified, the biological caveat that a killing
phenotype does not always overlap with a degranulation phenotype, as outlined in section 7.1,
needs to be taken into account. In summary, the degranulation assay would be an immensely
interesting readout for a genome-wide screen, but requires careful planning and further
optimisation.
7.5 Conclusions
In conclusion, the techniques established and optimised in this thesis will be of value to
research into the fundamental biology underlying the CTL killing mechanism. Detailed
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analysis of individual gene targets as well as larger screens are possible. Additionally, the
combined degranulation and killing assay could potentially be valuable as a diagnostic tool
to identify immunodeficiency disorders. Efficient CRISPR-Cas9 gene editing in primary
human CTL is furthermore of great interest for medical purposes, including cell-based
immunotherapies. While better techniques are required to modify T cells, we also need to
improve the understanding of fundamental T cell biology to inform future therapies. The
methods developed here can be used to discover, study the mechanism of and validate genetic
targets for T cell therapies.
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Fig. A.2 pCMVd8.91 packaging plasmid used for lentivirus production.
pMD-G
6.01 kb
Fig. A.3 pMD-G VSV-G envelope plasmid used for lentivirus production.
Appendix B
Differentially expressed genes in effector
and naive CD8 T cells
As outlined in chapter 4, 1803 significantly activated differentially expressed genes with
padj<0.01 and log2(fold change)>2 were identified when comparing the transcriptome of
effector (day 7 post activation) and naive (day 0) CD8 T cells. The full list of all 1803 genes
is included digitally on a CD.

Appendix C
NF-kB signalling compound library
toxicity test
Table C.1 NF-kB signalling compound library toxicity test. The NF-kB signalling
compound library was acquired from MedChem express. Drugs were labelled according to
their position in the rack (position 1 - 64). The information given in this table was obtained
from Medchem express, except for the highest non-toxic concentrations (HNTC), which were
determined using the Celltitre96 AQueous One Solution Cell Proliferation Assay (Promega)
as described in chapter 5.
Drug # Official name Molecular target HNTC
1 Sodium Salicylate Autophagy, NF-kB 25 µM
2 LY2409881 IKK 25 µM
3 Dimethyl fumarate Keap1-Nrf2 25 µM
4 Bardoxolone Keap1-Nrf2 0.9 µM
5 IKK 16 IKK 0.9 µM
6 Pyrrolidinedithiocarbamate (ammonium) NF-kB 8.3 µM
7 BMS-345541 (free base) IKK 0.9 µM
8 MRT67307 Autophagy, IKK 0.9 µM
9 Wy-14643 PPAR 25 µM
10 Didox NF-kB 25 µM
11 Cyclo(his-pro) NF-kB 25 µM
12 Pioglitazone (hydrochloride) PPAR 25 µM
13 MLN120B IKK 8.3 µM
14 MI 2 (MALT1 inhibitor) MALT1 0.9 µM
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Drug Official name Target HNTC
15 GW1929 PPAR 8.3 µM
16 T0070907 PPAR, RAD51 8.3 µM
17 Adjudin NF-kB 25 µM
18 L-165041 PPAR 25 µM
19 Parthenolide Autophagy, 8.3 µM
DNA Methyltransferase
HDAC, NF-kB
20 Andrographolide NF-kB 8.3 µM
21 Stachydrine NF-kB 25 µM
22 Tomatidine Akt, ERK, NF-kB 25 µM
23 PS-1145 IKK 0.1 µM
24 BMS-345541 IKK 0.9 µM
25 Fenofibrate Autophagy, PPAR 2.8 µM
Cytochrome P450
26 TPCA-1 IKK 0.1 µM
27 Benzafibrate PPAR 8.3 µM
28 ACHP (Hydrochloride) IKK 8.3 µM
29 BAY 11-7082 Autophagy, Deubiquitinase, 8.3 µM
NF-kB
30 Bardoxolone (methyl) Autophagy, Keap1-Nrf2 0.9 µM
31 IMD-0354 IKK 0.3 µM
32 SC-514 IKK 0.9 µM
33 Retinoic acid PPAR, RAR/RXR 0.9 µM
34 BAY 11-7085 NF-kB 0.3 µM
35 GSK0660 PPAR 8.3 µM
36 GW 501516 Autophagy, PPAR 8.3 µM
37 QNZ NF-kB 8.3 µM
38 BMS-687453 PPAR 8.3 µM
39 RTA-408 Keap1-Nrf2, NF-kB 0.1 µM
40 GSK583 RIP kinase 0.1 µM
41 Ezetimibe Autophagy, Keap1-Nrf2 8.3 µM
42 GSK3787 PPAR 8.3 µM
43 DG172 (dihydrochloride) PPAR 0.9 µM
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44 Amlexanox IKK 8.3 µM
45 JSH-23 NF-kB 2.8 µM
46 Resveratrol Autophagy, IKK 2.8 µM
47 Rosiglitazone Autophagy, PPAR, 8.3 µM
TRP Channel
48 Balaglitazone PPAR 0.9 µM
49 Clofibrate PPAR 8.3 µM
50 Daidzein PPAR 8.3 µM
51 GW0742 PPAR 8.3 µM
52 FH535 PPAR, Wnt, b -catenin 0.9 µM
53 Ciprofibrate PPAR 8.3 µM
54 Gemfibrozil PPAR 8.3 µM
55 Curcumin Autophagy, Keap1-Nrf2 2.8 µM
56 Polydatin Autophagy, NF-kB 0.3 µM
57 GW9662 PPAR 0.3 µM
58 Elafibranor PPAR 0.9 µM
59 Necrostatin-1 Autophagy, RIP kinase 0.3 µM
60 Rosiglitazone (maleate) Autophagy, PPAR 8.3 µM
61 NK-252 Keap1-Nrf2 0.9 µM
62 Lipoic acid NF-kB 8.3 µM
63 JW74 PPAR, Wnt 2.8 µM
64 Troglitazone Autophagy, PPAR 8.3 µM

